<HTML><HEAD><TITLE>Gene Ontology Results</TITLE></HEAD><BODY>
<H1>Gene Ontology Enrichment Results</H1>
<A HREF="homerResults.html">Homer <i>de novo</i> Motif Enrichment Results</A><BR/>
<A HREF="knownResults.html">Known Motif Enrichment Results</A><BR/>
<H4>Text file version of complete results (i.e. open with Excel)
<UL>
<LI><A HREF="biological_process.txt">biological process</A>: Functional groupings of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="molecular_function.txt">molecular function</A>: Mechanistic actions of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="cellular_component.txt">cellular component</A>: Protein localization (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="chromosome.txt">chromosome location</A>: Genes with similar chromosome localization (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="kegg.txt">KEGG pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.genome.jp/kegg/pathway.html">KEGG</A>)</LI>
<LI><A HREF="interactions.txt">protein interactions</A>: "Proteins interacting with a common protein (BIND, EcoCyc, HPRD)" (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="interpro.txt">interpro domains</A>: Proteins with similar domains and features (<A HREF="http://www.ebi.ac.uk/interpro/">Interpro</A>)</LI>
<LI><A HREF="pfam.txt">pfam domains</A>: Proteins with similar domains and features (<A HREF="http://www.sanger.ac.uk/Software/Pfam/">Pfam</A>)</LI>
<LI><A HREF="smart.txt">smart domains</A>: Proteins with similar domains and features (<A HREF="http://smart.embl-heidelberg.de/">SMART</A>)</LI>
<LI><A HREF="gene3d.txt">gene3d domains</A>: Proteins with similar domains and features (<A HREF="http://cathwww.biochem.ucl.ac.uk:8080/Gene3D">Gene3D</A>)</LI>
<LI><A HREF="prosite.txt">prosite domains</A>: Proteins with similar domains and features (<A HREF="http://ca.expasy.org/prosite/">Prosite</A>)</LI>
<LI><A HREF="prints.txt">prints domains</A>: Proteins with similar domains and features (<A HREF="http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/">PRINTS</A>)</LI>
<LI><A HREF="msigdb.txt">MSigDB lists</A>: "Genes sets for pathways, factor/miRNA target predictions, expression patterns, etc." (<A HREF="http://www.broadinstitute.org/gsea/msigdb/index.jsp">MSigDB</A>)</LI>
<LI><A HREF="biocyc.txt">BIOCYC pathways</A>: Groups of proteins in the same pathways (<A HREF="http://biocyc.org/">BIOCYC</A>)</LI>
<LI><A HREF="cosmic.txt">COSMIC cancer mutations</A>: Genes mutated in similar cancers (<A HREF="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">COSMIC</A>)</LI>
<LI><A HREF="gwas.txt">GWAS genes</A>: Genes mutated in similar diseases (<A HREF="http://www.genome.gov/26525384">GWAS Catalog</A>)</LI>
<LI><A HREF="lipidmaps.txt">Lipid Maps pathways</A>: Groups of proteins in the same lipid pathways (<A HREF="http://www.ncbi.nlm.nih.gov/biosystems/">Lipid Maps/Biosystems</A>)</LI>
<LI><A HREF="pathwayInteractionDB.txt">Pathway Interaction DB</A>: Groups of proteins in the same pathways (<A HREF="http://pid.nci.nih.gov/">Pathway Interaction Database</A>)</LI>
<LI><A HREF="reactome.txt">REACTOME pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.reactome.org/PathwayBrowser/">REACTOME</A>)</LI>
<LI><A HREF="smpdb.txt">SMPDB pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.smpdb.ca/">SMPDB</A>)</LI>
<LI><A HREF="wikipathways.txt">WikiPathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage">Wikipathways</A>)</LI>
</UL>
<H2>Enriched Categories</H2>
<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<TR><TD>2.625e-11</TD><TD>-24.36</TD><TD>BENPORATH_EED_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_EED_TARGETS</TD><TD>997</TD><TD>18</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,PAPPA,MTSS1,PCDH17,BMPR1B,SPAG6,GABRB2,PAX9,ALX1,NPTX2,HEY1,ZIC1,ZIC4,IL7,EYA4,GPC5,GRIA2,RNF128</TD></TR>
<TR><TD>5.079e-09</TD><TD>-19.10</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>1045</TD><TD>16</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,GABRB2,SPAG6,PCDH17,PAX9,SATB2,CXCL14,PAPPA,EPHA3,GRIA2,RNF128,GPC5,EYA4,IL7,ZIC1,ZIC4</TD></TR>
<TR><TD>4.373e-08</TD><TD>-16.95</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>610</TD><TD>12</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,GPC5,RNF128,PAX9,PCDH17,SPAG6,GRIA2,IL7,PAPPA,CXCL14,ZIC1,ZIC4</TD></TR>
<TR><TD>1.144e-07</TD><TD>-15.98</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>963</TD><TD>14</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,ALX1,GPC5,PAX9,RNF128,PCDH17,SPAG6,GRIA2,IL7,PCDH11X,PAPPA,CXCL14,ZIC4,ZIC1</TD></TR>
<TR><TD>1.940e-07</TD><TD>-15.46</TD><TD>AACTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACTTT_UNKNOWN</TD><TD>1745</TD><TD>18</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,ZFHX4,NPTX2,PEX5L,MTSS1,STAC,SLC6A15,LSR,CPEB2,RNF128,PLAG1,FST,KYNU,ZIC4,ZIC1,MEIS2,PCDH11X,EYA4</TD></TR>
<TR><TD>2.031e-07</TD><TD>-15.41</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>1009</TD><TD>14</TD><TD>17275</TD><TD>46</TD>
<TD>FST,EPHA3,NPTX2,GPC5,CDKN2A,PLAG1,PCDH17,SATB2,IL7,EYA4,CXCL14,STAC,PAPPA,ZIC1</TD></TR>
<TR><TD>7.040e-07</TD><TD>-14.17</TD><TD>PBX1_02</TD><TD>MSigDB lists</TD><TD>PBX1_02</TD><TD>119</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,MEIS2,MTSS1,RNF128,IL7</TD></TR>
<TR><TD>9.946e-07</TD><TD>-13.82</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>3694</TD><TD>25</TD><TD>17255</TD><TD>46</TD>
<TD>SPAG6,PAPPA,MTSS1,CLDN1,CRB1,PCDH11X,PEX5L,PLEKHM3,SLC6A15,FST,IL7,KYNU,CDKN2A,GALNT13,STAC,ALX1,GPC5,EPHA3,PCDH17,ZIC4,SATB2,MEIS2,RNF128,GRIA2,ZFHX4</TD></TR>
<TR><TD>1.787e-06</TD><TD>-13.24</TD><TD>PAX4_02</TD><TD>MSigDB lists</TD><TD>PAX4_02</TD><TD>221</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,ZFHX4,MEIS2,ZIC4,GABRB2,ZIC1,KYNU</TD></TR>
<TR><TD>3.912e-06</TD><TD>-12.45</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7347</TD><TD>35</TD><TD>17255</TD><TD>46</TD>
<TD>EDA2R,CPEB2,MTSS1,PAPPA,IL7,KYNU,STAC,PEX5L,SLC6A15,PLEKHM3,DCDC2,EPHA3,GPC5,GRIA2,NPTX2,ZIC1,RNF128,MEIS2,PAX9,SAA2,CRB1,PCDH11X,SPAG6,LSR,GALNT13,GABRB2,CDKN2A,ALX1,ZIC4,RBM11,SATB2,PCDH17,EYA4,ZFHX4,PCDH20</TD></TR>
<TR><TD>8.848e-06</TD><TD>-11.64</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_24H_UP</TD><TD>MSigDB lists</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_24H_UP</TD><TD>184</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,HEY1,ENPP5,SLC6A15,DCDC2,PCDH17</TD></TR>
<TR><TD>1.492e-05</TD><TD>-11.11</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>4254</TD><TD>25</TD><TD>17255</TD><TD>46</TD>
<TD>GRIA2,ZFHX4,RNF128,MEIS2,ZIC4,SATB2,GPC5,EPHA3,PCDH17,FST,IL7,GALNT13,KYNU,CDKN2A,ALX1,STAC,PEX5L,SLC6A15,PLEKHM3,MTSS1,CLDN1,CRB1,PCDH11X,SPAG6,PAPPA</TD></TR>
<TR><TD>1.825e-05</TD><TD>-10.91</TD><TD>ACTGTGA_MIR27A_MIR27B</TD><TD>MSigDB lists</TD><TD>ACTGTGA_MIR27A_MIR27B</TD><TD>439</TD><TD>8</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,PAPPA,SATB2,EYA4,PCDH17,ZFHX4,PLAG1,NPTX2</TD></TR>
<TR><TD>1.985e-05</TD><TD>-10.83</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>2154</TD><TD>17</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,PCDH11X,CRB1,PAPPA,IL7,CDKN2A,GALNT13,KYNU,STAC,DCDC2,SATB2,GPC5,EPHA3,PCDH17,BMPR1B,GRIA2,ZFHX4</TD></TR>
<TR><TD>1.985e-05</TD><TD>-10.83</TD><TD>Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>Burkitt_lymphoma</TD><TD>2154</TD><TD>17</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,GRIA2,BMPR1B,PCDH17,EPHA3,GPC5,SATB2,DCDC2,STAC,CDKN2A,KYNU,GALNT13,IL7,PAPPA,CRB1,PCDH11X,MTSS1</TD></TR>
<TR><TD>2.143e-05</TD><TD>-10.75</TD><TD>CIZ_01</TD><TD>MSigDB lists</TD><TD>CIZ_01</TD><TD>215</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,MEIS2,PAPPA,PLAG1,PCDH11X</TD></TR>
<TR><TD>3.595e-05</TD><TD>-10.23</TD><TD>stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>969</TD><TD>11</TD><TD>17255</TD><TD>46</TD>
<TD>SLC6A15,CDKN2A,ZFHX4,STAC,PAPPA,GPC5,MTSS1,CRB1,SATB2,ZIC4,DCDC2</TD></TR>
<TR><TD>3.595e-05</TD><TD>-10.23</TD><TD>mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>COSMIC cancer mutations</TD><TD>mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>969</TD><TD>11</TD><TD>17255</TD><TD>46</TD>
<TD>PAPPA,GPC5,MTSS1,CRB1,SATB2,ZIC4,DCDC2,SLC6A15,CDKN2A,ZFHX4,STAC</TD></TR>
<TR><TD>3.620e-05</TD><TD>-10.23</TD><TD>astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>astrocytoma_Grade_III</TD><TD>1567</TD><TD>14</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC4,MTSS1,PCDH11X,CRB1,EPHA3,GPC5,PAPPA,GALNT13,CDKN2A,KYNU,ALX1,ZFHX4,PEX5L,PLEKHM3</TD></TR>
<TR><TD>4.307e-05</TD><TD>-10.05</TD><TD>human chr8q21.13</TD><TD>chromosome location</TD><TD>human chr8q21.13</TD><TD>37</TD><TD>3</TD><TD>26169</TD><TD>48</TD>
<TD>HEY1,ZFHX4,IL7</TD></TR>
<TR><TD>4.990e-05</TD><TD>-9.91</TD><TD>AP1_Q2</TD><TD>MSigDB lists</TD><TD>AP1_Q2</TD><TD>250</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,ZIC1,ZIC4,PAX9,RNF128,MEIS2</TD></TR>
<TR><TD>6.478e-05</TD><TD>-9.64</TD><TD>Znf_ZIC</TD><TD>interpro domains</TD><TD>IPR041643</TD><TD>5</TD><TD>2</TD><TD>18616</TD><TD>48</TD>
<TD>ZIC4,ZIC1</TD></TR>
<TR><TD>6.808e-05</TD><TD>-9.59</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>1442</TD><TD>13</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,ALX1,KYNU,GALNT13,CDKN2A,PEX5L,PLEKHM3,CRB1,PCDH11X,MTSS1,GPC5,EPHA3,PAPPA</TD></TR>
<TR><TD>6.815e-05</TD><TD>-9.59</TD><TD>zf_ZIC</TD><TD>pfam domains</TD><TD>PF18366</TD><TD>5</TD><TD>2</TD><TD>17385</TD><TD>46</TD>
<TD>ZIC1,ZIC4</TD></TR>
<TR><TD>6.887e-05</TD><TD>-9.58</TD><TD>tryptophan catabolic process to kynurenine</TD><TD>biological process</TD><TD>GO:0019441</TD><TD>5</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>7.689e-05</TD><TD>-9.47</TD><TD>CATGTAA_MIR496</TD><TD>MSigDB lists</TD><TD>CATGTAA_MIR496</TD><TD>166</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,SATB2,MEIS2,GRIA2,ZIC1</TD></TR>
<TR><TD>7.820e-05</TD><TD>-9.46</TD><TD>oesophagus-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma</TD><TD>4348</TD><TD>24</TD><TD>17255</TD><TD>46</TD>
<TD>AZGP1,CRB1,PCDH11X,PLAG1,ALX1,STAC,GALNT13,CDKN2A,KYNU,LSR,PEX5L,SATB2,DCDC2,ZIC4,PCDH17,EPHA3,ZFHX4,NPTX2,EYA4,GRIA2,PCDH20,RNF128,ZIC1,IDO2</TD></TR>
<TR><TD>8.558e-05</TD><TD>-9.37</TD><TD>TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P</TD><TD>MSigDB lists</TD><TD>TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P</TD><TD>546</TD><TD>8</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,GRIA2,PCDH17,PLAG1,PCDH20,MEIS2,STAC,SATB2</TD></TR>
<TR><TD>1.017e-04</TD><TD>-9.19</TD><TD>oesophagus-lower_third-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-lower_third-carcinoma-adenocarcinoma</TD><TD>6408</TD><TD>30</TD><TD>17255</TD><TD>46</TD>
<TD>STAC,ALX1,GALNT13,CDKN2A,GABRB2,LSR,SLC6A15,PEX5L,AZGP1,PCDH11X,CRB1,CLDN1,MTSS1,CPEB2,PAPPA,ENPP5,ZFHX4,EYA4,GRIA2,PCDH20,RNF128,MEIS2,SATB2,RBM11,ZIC4,DCDC2,HEY1,PCDH17,GPC5,EPHA3</TD></TR>
<TR><TD>1.031e-04</TD><TD>-9.18</TD><TD>'de novo' NAD biosynthetic process</TD><TD>biological process</TD><TD>GO:0034627</TD><TD>6</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.031e-04</TD><TD>-9.18</TD><TD>'de novo' NAD biosynthetic process from tryptophan</TD><TD>biological process</TD><TD>GO:0034354</TD><TD>6</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.070e-04</TD><TD>-9.14</TD><TD>RNA polymerase II regulatory region sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000977</TD><TD>783</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>PLAG1,MEIS2,ALX1,ZFHX4,SATB2,ZIC4,ZIC1,HEY1,PAX9</TD></TR>
<TR><TD>1.121e-04</TD><TD>-9.10</TD><TD>lung-left_upper_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-left_upper_lobe-carcinoma-adenocarcinoma</TD><TD>567</TD><TD>8</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC1,SLC6A15,PLEKHM3,CDKN2A,ZFHX4,PAPPA,ZIC4,PCDH11X</TD></TR>
<TR><TD>1.122e-04</TD><TD>-9.10</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>1970</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC4,PCDH11X,SATB2,ENPP5,EPHA3,PAPPA,PLAG1,BMPR1B,GRIA2,PLCH1,ZFHX4,CDKN2A,NPTX2,SLC6A15,PAX9</TD></TR>
<TR><TD>1.134e-04</TD><TD>-9.08</TD><TD>RNA polymerase II regulatory region DNA binding</TD><TD>molecular function</TD><TD>GO:0001012</TD><TD>789</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>ZIC4,ZIC1,HEY1,PAX9,MEIS2,PLAG1,ALX1,ZFHX4,SATB2</TD></TR>
<TR><TD>1.135e-04</TD><TD>-9.08</TD><TD>developmental process</TD><TD>biological process</TD><TD>GO:0032502</TD><TD>5697</TD><TD>28</TD><TD>18054</TD><TD>48</TD>
<TD>CXCL14,CRB1,FST,DCDC2,CLDN1,EYA4,PLAG1,MEIS2,NPTX2,SATB2,PLEKHM3,MTSS1,EDA2R,RBM11,ALX1,ZIC1,KYNU,PAX9,SPAG6,LSR,HEY1,GABRB2,ZIC4,IL7,BMPR1B,EPHA3,PCDH17,CDKN2A</TD></TR>
<TR><TD>1.135e-04</TD><TD>-9.08</TD><TD>larynx</TD><TD>COSMIC cancer mutations</TD><TD>larynx</TD><TD>1972</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,CDKN2A,NPTX2,PLCH1,GRIA2,PAX9,SLC6A15,PCDH11X,SATB2,ZIC4,PAPPA,BMPR1B,PLAG1,ENPP5,EPHA3</TD></TR>
<TR><TD>1.148e-04</TD><TD>-9.07</TD><TD>diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_adenocarcinoma</TD><TD>4447</TD><TD>24</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,EYA4,GRIA2,PAX9,PCDH20,MEIS2,ZIC1,SATB2,ZIC4,DCDC2,PCDH17,EPHA3,STAC,ALX1,GALNT13,CDKN2A,LSR,FST,PEX5L,CRB1,PCDH11X,CLDN1,PAPPA,SPAG6</TD></TR>
<TR><TD>1.148e-04</TD><TD>-9.07</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>4447</TD><TD>24</TD><TD>17255</TD><TD>46</TD>
<TD>PEX5L,LSR,FST,STAC,ALX1,CDKN2A,GALNT13,SPAG6,PAPPA,CRB1,PCDH11X,CLDN1,ZIC1,PAX9,PCDH20,MEIS2,EYA4,GRIA2,ZFHX4,PCDH17,EPHA3,ZIC4,DCDC2,SATB2</TD></TR>
<TR><TD>1.149e-04</TD><TD>-9.07</TD><TD>left_upper_lobe</TD><TD>COSMIC cancer mutations</TD><TD>left_upper_lobe</TD><TD>569</TD><TD>8</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH11X,ZIC4,PAPPA,CDKN2A,ZFHX4,SLC6A15,PLEKHM3,ZIC1</TD></TR>
<TR><TD>1.276e-04</TD><TD>-8.97</TD><TD>oesophagus-lower_third-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-lower_third-carcinoma-squamous_cell_carcinoma</TD><TD>3577</TD><TD>21</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,GRIA2,EYA4,MEIS2,PCDH20,IDO2,ZIC1,SATB2,ZIC4,GPC5,EPHA3,PCDH17,GALNT13,CDKN2A,PEX5L,AZGP1,PCDH11X,EDA2R,PAPPA,ENPP5,SPAG6</TD></TR>
<TR><TD>1.324e-04</TD><TD>-8.93</TD><TD>GO_GLYCOPROTEIN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_GLYCOPROTEIN_BINDING</TD><TD>98</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,GPC5,AZGP1,FST</TD></TR>
<TR><TD>1.452e-04</TD><TD>-8.84</TD><TD>ATACTGT_MIR144</TD><TD>MSigDB lists</TD><TD>ATACTGT_MIR144</TD><TD>190</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,CPEB2,ZIC4,PAPPA,PLAG1</TD></TR>
<TR><TD>1.503e-04</TD><TD>-8.80</TD><TD>ONDER_CDH1_TARGETS_2_DN</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_DN</TD><TD>440</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,FST,LSR,CLDN1,STAC,MTSS1,RNF128</TD></TR>
<TR><TD>1.710e-04</TD><TD>-8.67</TD><TD>transcription regulatory region sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000976</TD><TD>833</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>ZFHX4,ALX1,PLAG1,MEIS2,SATB2,ZIC4,PAX9,ZIC1,HEY1</TD></TR>
<TR><TD>1.728e-04</TD><TD>-8.66</TD><TD>FXR_Q3</TD><TD>MSigDB lists</TD><TD>FXR_Q3</TD><TD>105</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>1.844e-04</TD><TD>-8.60</TD><TD>OCT1_02</TD><TD>MSigDB lists</TD><TD>OCT1_02</TD><TD>200</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,CXCL14,PLAG1,NPTX2</TD></TR>
<TR><TD>1.855e-04</TD><TD>-8.59</TD><TD>lower_third</TD><TD>COSMIC cancer mutations</TD><TD>lower_third</TD><TD>8105</TD><TD>34</TD><TD>17255</TD><TD>46</TD>
<TD>LSR,CDKN2A,GABRB2,GALNT13,ALX1,CLDN1,CRB1,PCDH11X,SPAG6,EYA4,ZFHX4,PCDH20,ZIC4,RBM11,SATB2,PCDH17,HEY1,STAC,PEX5L,SLC6A15,EDA2R,CPEB2,MTSS1,AZGP1,ENPP5,PAPPA,GRIA2,IDO2,ZIC1,RNF128,MEIS2,DCDC2,GPC5,EPHA3</TD></TR>
<TR><TD>1.886e-04</TD><TD>-8.58</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_B</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_B</TD><TD>42</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,ZIC1,CDKN2A</TD></TR>
<TR><TD>1.927e-04</TD><TD>-8.55</TD><TD>bone-chondrosarcoma-conventional</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-conventional</TD><TD>8</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>2.164e-04</TD><TD>-8.44</TD><TD>FAC1_01</TD><TD>MSigDB lists</TD><TD>FAC1_01</TD><TD>207</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,HEY1,PAPPA,ZIC4,ZIC1</TD></TR>
<TR><TD>2.213e-04</TD><TD>-8.42</TD><TD>TAATAAT_MIR126</TD><TD>MSigDB lists</TD><TD>TAATAAT_MIR126</TD><TD>208</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,ZFHX4,GRIA2,ZIC1,ZIC4</TD></TR>
<TR><TD>2.417e-04</TD><TD>-8.33</TD><TD>autonomic_ganglia-neuroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-neuroblastoma</TD><TD>4032</TD><TD>22</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC1,RNF128,GRIA2,PLCH1,ZFHX4,NPTX2,EPHA3,DCDC2,ZIC4,RBM11,LSR,FST,KYNU,GABRB2,GALNT13,CDKN2A,PAPPA,PLAG1,CPEB2,AZGP1,PCDH11X,CRB1</TD></TR>
<TR><TD>2.426e-04</TD><TD>-8.32</TD><TD>neuroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>neuroblastoma</TD><TD>4033</TD><TD>22</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC1,RNF128,PLCH1,GRIA2,NPTX2,ZFHX4,EPHA3,ZIC4,DCDC2,RBM11,FST,LSR,GABRB2,GALNT13,KYNU,CDKN2A,PLAG1,PAPPA,CPEB2,CRB1,PCDH11X,AZGP1</TD></TR>
<TR><TD>2.451e-04</TD><TD>-8.31</TD><TD>GSE6259_FLT3L_INDUCED_DEC205_POS_DC_VS_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE6259_FLT3L_INDUCED_DEC205_POS_DC_VS_CD4_TCELL_DN</TD><TD>115</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,SLC6A15,PAPPA,RBM11</TD></TR>
<TR><TD>2.468e-04</TD><TD>-8.31</TD><TD>REACTOME_TRYPTOPHAN_CATABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_TRYPTOPHAN_CATABOLISM</TD><TD>9</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>2.473e-04</TD><TD>-8.30</TD><TD>bone-chondrosarcoma-mesenchymal</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-mesenchymal</TD><TD>9</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>2.562e-04</TD><TD>-8.27</TD><TD>TEAD2 (TEA domain transcription factor 2)</TD><TD>protein interactions</TD><TD>8463</TD><TD>115</TD><TD>4</TD><TD>17456</TD><TD>47</TD>
<TD>ZFHX4,SAA2,SATB2,CDKN2A</TD></TR>
<TR><TD>2.645e-04</TD><TD>-8.24</TD><TD>sequence-specific double-stranded DNA binding</TD><TD>molecular function</TD><TD>GO:1990837</TD><TD>883</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>ZIC1,HEY1,PAX9,ZIC4,SATB2,MEIS2,PLAG1,ZFHX4,ALX1</TD></TR>
<TR><TD>2.696e-04</TD><TD>-8.22</TD><TD>GO_ORGAN_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_ORGAN_MORPHOGENESIS</TD><TD>822</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,SATB2,IL7,PLAG1,BMPR1B,PAX9,HEY1,ALX1,CRB1</TD></TR>
<TR><TD>2.745e-04</TD><TD>-8.20</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm</TD><TD>7461</TD><TD>32</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,BMPR1B,GPC5,EPHA3,NPTX2,PLCH1,MEIS2,RNF128,PAX9,ZIC1,MTSS1,AZGP1,PAPPA,KYNU,STAC,IL7,SLC6A15,PLEKHM3,PEX5L,RBM11,SATB2,PCDH17,ZFHX4,PCDH20,CLDN1,CRB1,PCDH11X,SPAG6,CDKN2A,GALNT13,ALX1,LSR</TD></TR>
<TR><TD>2.758e-04</TD><TD>-8.20</TD><TD>autonomic_ganglia</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia</TD><TD>4067</TD><TD>22</TD><TD>17255</TD><TD>46</TD>
<TD>EPHA3,ZIC4,DCDC2,RBM11,ZIC1,RNF128,GRIA2,PLCH1,NPTX2,ZFHX4,PLAG1,PAPPA,CPEB2,PCDH11X,AZGP1,CRB1,FST,LSR,KYNU,CDKN2A,GALNT13,GABRB2</TD></TR>
<TR><TD>2.868e-04</TD><TD>-8.16</TD><TD>HNF6_Q6</TD><TD>MSigDB lists</TD><TD>HNF6_Q6</TD><TD>220</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,PCDH17,PAX9,PLAG1</TD></TR>
<TR><TD>2.868e-04</TD><TD>-8.16</TD><TD>TCF4_Q5</TD><TD>MSigDB lists</TD><TD>TCF4_Q5</TD><TD>220</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,GABRB2,ENPP5,FST</TD></TR>
<TR><TD>2.952e-04</TD><TD>-8.13</TD><TD>cellular developmental process</TD><TD>biological process</TD><TD>GO:0048869</TD><TD>3769</TD><TD>21</TD><TD>18054</TD><TD>48</TD>
<TD>CRB1,FST,CLDN1,DCDC2,PLAG1,EDA2R,MTSS1,PLEKHM3,NPTX2,SATB2,RBM11,ALX1,SPAG6,LSR,ZIC1,HEY1,IL7,GABRB2,BMPR1B,EPHA3,CDKN2A</TD></TR>
<TR><TD>2.991e-04</TD><TD>-8.11</TD><TD>FOXO4_01</TD><TD>MSigDB lists</TD><TD>FOXO4_01</TD><TD>222</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,FST,CRB1,PLAG1,MEIS2</TD></TR>
<TR><TD>3.053e-04</TD><TD>-8.09</TD><TD>AP3_Q6</TD><TD>MSigDB lists</TD><TD>AP3_Q6</TD><TD>223</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,PAPPA,RBM11,PLAG1,CXCL14</TD></TR>
<TR><TD>3.073e-04</TD><TD>-8.09</TD><TD>tryptophan catabolic process</TD><TD>biological process</TD><TD>GO:0006569</TD><TD>10</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.073e-04</TD><TD>-8.09</TD><TD>indole-containing compound catabolic process</TD><TD>biological process</TD><TD>GO:0042436</TD><TD>10</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.073e-04</TD><TD>-8.09</TD><TD>indolalkylamine catabolic process</TD><TD>biological process</TD><TD>GO:0046218</TD><TD>10</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.078e-04</TD><TD>-8.09</TD><TD>tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-5651</TD><TD>7</TD><TD>2</TD><TD>902</TD><TD>4</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.087e-04</TD><TD>-8.08</TD><TD>mesenchymal</TD><TD>COSMIC cancer mutations</TD><TD>mesenchymal</TD><TD>10</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>3.087e-04</TD><TD>-8.08</TD><TD>bone-chondrosarcoma-dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-dedifferentiated</TD><TD>10</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>3.219e-04</TD><TD>-8.04</TD><TD>follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>follicular_lymphoma</TD><TD>1239</TD><TD>11</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,CDKN2A,GABRB2,GALNT13,GRIA2,PAPPA,SPAG6,GPC5,SATB2,PCDH11X,ZIC4</TD></TR>
<TR><TD>3.297e-04</TD><TD>-8.02</TD><TD>anatomical structure development</TD><TD>biological process</TD><TD>GO:0048856</TD><TD>5354</TD><TD>26</TD><TD>18054</TD><TD>48</TD>
<TD>PLEKHM3,MTSS1,EDA2R,NPTX2,SATB2,RBM11,ALX1,CRB1,FST,CXCL14,EYA4,CLDN1,DCDC2,PLAG1,MEIS2,ZIC4,IL7,GABRB2,BMPR1B,PCDH17,EPHA3,SPAG6,LSR,ZIC1,PAX9,HEY1</TD></TR>
<TR><TD>3.519e-04</TD><TD>-7.95</TD><TD>FOXM1_01</TD><TD>MSigDB lists</TD><TD>FOXM1_01</TD><TD>230</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,MEIS2,MTSS1,PCDH17,PLAG1</TD></TR>
<TR><TD>3.590e-04</TD><TD>-7.93</TD><TD>GATA4_Q3</TD><TD>MSigDB lists</TD><TD>GATA4_Q3</TD><TD>231</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,MEIS2,ZIC4,ZIC1,FST</TD></TR>
<TR><TD>3.675e-04</TD><TD>-7.91</TD><TD>Tryptophan catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-71240</TD><TD>13</TD><TD>2</TD><TD>10287</TD><TD>23</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.749e-04</TD><TD>-7.89</TD><TD>kynurenine metabolic process</TD><TD>biological process</TD><TD>GO:0070189</TD><TD>11</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.757e-04</TD><TD>-7.89</TD><TD>GO_TRYPTOPHAN_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_TRYPTOPHAN_METABOLIC_PROCESS</TD><TD>11</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.878e-04</TD><TD>-7.86</TD><TD>SMID_BREAST_CANCER_LUMINAL_B_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_LUMINAL_B_DN</TD><TD>514</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,ZIC1,PLCH1,SLC6A15,KYNU,CLDN1,NPTX2</TD></TR>
<TR><TD>3.884e-04</TD><TD>-7.85</TD><TD>TST1_01</TD><TD>MSigDB lists</TD><TD>TST1_01</TD><TD>235</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,ZIC4,ZIC1,PCDH17,HEY1</TD></TR>
<TR><TD>4.027e-04</TD><TD>-7.82</TD><TD>AACWWCAANK_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACWWCAANK_UNKNOWN</TD><TD>131</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,GABRB2,PCDH17,ZFHX4</TD></TR>
<TR><TD>4.098e-04</TD><TD>-7.80</TD><TD>tryptophan degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_TRYPTOPHAN-DEGRADATION-1</TD><TD>8</TD><TD>2</TD><TD>902</TD><TD>4</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>4.116e-04</TD><TD>-7.80</TD><TD>TCF11_01</TD><TD>MSigDB lists</TD><TD>TCF11_01</TD><TD>238</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,SATB2,ZFHX4,RNF128,ZIC4</TD></TR>
<TR><TD>4.148e-04</TD><TD>-7.79</TD><TD>right_lower_lobe</TD><TD>COSMIC cancer mutations</TD><TD>right_lower_lobe</TD><TD>5798</TD><TD>27</TD><TD>17255</TD><TD>46</TD>
<TD>PEX5L,SLC6A15,FST,CXCL14,ALX1,GABRB2,KYNU,GALNT13,SPAG6,ENPP5,PAPPA,PLAG1,PCDH11X,CRB1,MTSS1,ZIC1,IDO2,PCDH20,MEIS2,EYA4,ZFHX4,NPTX2,PCDH17,GPC5,EPHA3,ZIC4,SATB2</TD></TR>
<TR><TD>4.148e-04</TD><TD>-7.79</TD><TD>lung-right_lower_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right_lower_lobe-carcinoma-adenocarcinoma</TD><TD>5798</TD><TD>27</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC1,IDO2,PCDH20,MEIS2,EYA4,ZFHX4,NPTX2,PCDH17,EPHA3,GPC5,ZIC4,SATB2,PEX5L,SLC6A15,FST,CXCL14,ALX1,GABRB2,KYNU,GALNT13,ENPP5,SPAG6,PAPPA,PLAG1,CRB1,PCDH11X,MTSS1</TD></TR>
<TR><TD>4.192e-04</TD><TD>-7.78</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3583</TD><TD>20</TD><TD>17255</TD><TD>46</TD>
<TD>SLC6A15,ALX1,KYNU,CDKN2A,GABRB2,GALNT13,PAPPA,PCDH11X,CRB1,CLDN1,PCDH20,MEIS2,EYA4,GRIA2,ZFHX4,PCDH17,EPHA3,GPC5,BMPR1B,SATB2</TD></TR>
<TR><TD>4.192e-04</TD><TD>-7.78</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3583</TD><TD>20</TD><TD>17255</TD><TD>46</TD>
<TD>EYA4,GRIA2,ZFHX4,PCDH20,MEIS2,SATB2,PCDH17,EPHA3,GPC5,BMPR1B,ALX1,CDKN2A,KYNU,GABRB2,GALNT13,SLC6A15,CRB1,PCDH11X,CLDN1,PAPPA</TD></TR>
<TR><TD>4.196e-04</TD><TD>-7.78</TD><TD>ZID_01</TD><TD>MSigDB lists</TD><TD>ZID_01</TD><TD>239</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PAPPA,MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>4.325e-04</TD><TD>-7.75</TD><TD>lung-carcinoma-small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-small_cell_carcinoma</TD><TD>10086</TD><TD>38</TD><TD>17255</TD><TD>46</TD>
<TD>GRIA2,PLCH1,PAX9,RNF128,MEIS2,ZIC1,DCDC2,BMPR1B,EPHA3,GPC5,STAC,CXCL14,KYNU,FST,IL7,PLEKHM3,PEX5L,MTSS1,EDA2R,PAPPA,PLAG1,ZFHX4,EYA4,PCDH20,SATB2,RBM11,ZIC4,HEY1,PCDH17,ALX1,GALNT13,CDKN2A,LSR,CRB1,PCDH11X,SCGB3A2,CLDN1,SPAG6</TD></TR>
<TR><TD>4.385e-04</TD><TD>-7.73</TD><TD>small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_cell_carcinoma</TD><TD>10091</TD><TD>38</TD><TD>17255</TD><TD>46</TD>
<TD>SPAG6,CLDN1,PCDH11X,SCGB3A2,CRB1,GALNT13,CDKN2A,ALX1,LSR,HEY1,PCDH17,RBM11,SATB2,ZIC4,PCDH20,ZFHX4,EYA4,PLAG1,PAPPA,MTSS1,EDA2R,PLEKHM3,PEX5L,KYNU,STAC,CXCL14,IL7,FST,BMPR1B,GPC5,EPHA3,DCDC2,MEIS2,RNF128,PAX9,ZIC1,GRIA2,PLCH1</TD></TR>
<TR><TD>4.458e-04</TD><TD>-7.72</TD><TD>upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma</TD><TD>1508</TD><TD>12</TD><TD>17255</TD><TD>46</TD>
<TD>CRB1,GPC5,EPHA3,PCDH17,PLCH1,CDKN2A,ZFHX4,PEX5L,ZIC1,PLEKHM3,PAX9,PCDH20</TD></TR>
<TR><TD>4.491e-04</TD><TD>-7.71</TD><TD>tryptophan metabolic process</TD><TD>biological process</TD><TD>GO:0006568</TD><TD>12</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>4.500e-04</TD><TD>-7.71</TD><TD>transcription regulatory region DNA binding</TD><TD>molecular function</TD><TD>GO:0044212</TD><TD>949</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>SATB2,ALX1,ZFHX4,PLAG1,MEIS2,PAX9,ZIC1,HEY1,ZIC4</TD></TR>
<TR><TD>4.501e-04</TD><TD>-7.71</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_UP</TD><TD>MSigDB lists</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_UP</TD><TD>12</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,FST</TD></TR>
<TR><TD>4.526e-04</TD><TD>-7.70</TD><TD>GATA_C</TD><TD>MSigDB lists</TD><TD>GATA_C</TD><TD>243</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,ZIC1,ZIC4,IL7,PCDH11X</TD></TR>
<TR><TD>4.535e-04</TD><TD>-7.70</TD><TD>regulatory region nucleic acid binding</TD><TD>molecular function</TD><TD>GO:0001067</TD><TD>950</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>PLAG1,MEIS2,ZFHX4,ALX1,SATB2,ZIC4,HEY1,ZIC1,PAX9</TD></TR>
<TR><TD>4.642e-04</TD><TD>-7.68</TD><TD>angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>angiosarcoma</TD><TD>2238</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>MEIS2,PCDH20,ZIC1,CDKN2A,KYNU,GALNT13,EYA4,PAPPA,GPC5,EPHA3,PCDH17,PCDH11X,SATB2,EDA2R,DCDC2</TD></TR>
<TR><TD>4.642e-04</TD><TD>-7.68</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>2238</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>PAPPA,PCDH17,EPHA3,GPC5,PCDH11X,SATB2,DCDC2,EDA2R,PCDH20,MEIS2,ZIC1,GALNT13,CDKN2A,KYNU,EYA4</TD></TR>
<TR><TD>4.868e-04</TD><TD>-7.63</TD><TD>lung-right_upper_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right_upper_lobe-carcinoma-adenocarcinoma</TD><TD>10584</TD><TD>39</TD><TD>17255</TD><TD>46</TD>
<TD>CRB1,PCDH11X,CLDN1,SPAG6,ALX1,GABRB2,CDKN2A,GALNT13,SATB2,ZIC4,PCDH17,ZFHX4,EYA4,PCDH20,AZGP1,MTSS1,CPEB2,EDA2R,PAPPA,PLAG1,STAC,KYNU,IL7,FST,SLC6A15,PLEKHM3,PEX5L,BMPR1B,EPHA3,GPC5,NPTX2,GRIA2,PLCH1,SAA2,PAX9,MEIS2,RNF128,ZIC1,IDO2</TD></TR>
<TR><TD>4.868e-04</TD><TD>-7.63</TD><TD>right_upper_lobe</TD><TD>COSMIC cancer mutations</TD><TD>right_upper_lobe</TD><TD>10584</TD><TD>39</TD><TD>17255</TD><TD>46</TD>
<TD>SPAG6,CRB1,PCDH11X,CLDN1,ALX1,CDKN2A,GALNT13,GABRB2,PCDH17,ZIC4,SATB2,PCDH20,EYA4,ZFHX4,PAPPA,PLAG1,CPEB2,EDA2R,AZGP1,MTSS1,PEX5L,PLEKHM3,SLC6A15,IL7,FST,STAC,KYNU,GPC5,EPHA3,BMPR1B,ZIC1,IDO2,SAA2,PAX9,RNF128,MEIS2,GRIA2,PLCH1,NPTX2</TD></TR>
<TR><TD>5.058e-04</TD><TD>-7.59</TD><TD>AFP1_Q6</TD><TD>MSigDB lists</TD><TD>AFP1_Q6</TD><TD>249</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ZIC1,ZIC4,ZFHX4,MEIS2</TD></TR>
<TR><TD>5.087e-04</TD><TD>-7.58</TD><TD>blood_vessel</TD><TD>COSMIC cancer mutations</TD><TD>blood_vessel</TD><TD>2257</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,GALNT13,KYNU,EYA4,PCDH20,MEIS2,ZIC1,PCDH11X,SATB2,DCDC2,EDA2R,PAPPA,PCDH17,GPC5,EPHA3</TD></TR>
<TR><TD>5.522e-04</TD><TD>-7.50</TD><TD>human chr3q24</TD><TD>chromosome location</TD><TD>human chr3q24</TD><TD>19</TD><TD>2</TD><TD>26169</TD><TD>48</TD>
<TD>ZIC1,ZIC4</TD></TR>
<TR><TD>5.561e-04</TD><TD>-7.49</TD><TD>double-stranded DNA binding</TD><TD>molecular function</TD><TD>GO:0003690</TD><TD>977</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>ZIC4,HEY1,ZIC1,PAX9,PLAG1,MEIS2,ALX1,ZFHX4,SATB2</TD></TR>
<TR><TD>5.589e-04</TD><TD>-7.49</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>1546</TD><TD>12</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,PCDH11X,SATB2,CRB1,GPC5,PCDH17,PAPPA,GALNT13,ZFHX4,PEX5L,MEIS2,RNF128</TD></TR>
<TR><TD>5.589e-04</TD><TD>-7.49</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>1546</TD><TD>12</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,GALNT13,PEX5L,RNF128,MEIS2,SATB2,CRB1,PCDH11X,MTSS1,PCDH17,GPC5,PAPPA</TD></TR>
<TR><TD>5.637e-04</TD><TD>-7.48</TD><TD>cell-cell adhesion via plasma-membrane adhesion molecules</TD><TD>biological process</TD><TD>GO:0098742</TD><TD>255</TD><TD>5</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH17,CLDN1,PCDH20,CRB1,PCDH11X</TD></TR>
<TR><TD>5.925e-04</TD><TD>-7.43</TD><TD>intestinal_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>intestinal_adenocarcinoma</TD><TD>7350</TD><TD>31</TD><TD>17255</TD><TD>46</TD>
<TD>EPHA3,PCDH17,DCDC2,ZIC4,RBM11,SATB2,MEIS2,RNF128,PAX9,PCDH20,PLCH1,GRIA2,EYA4,NPTX2,ZFHX4,ENPP5,PLAG1,PAPPA,EDA2R,MTSS1,CRB1,AZGP1,PCDH11X,PEX5L,SLC6A15,FST,LSR,GALNT13,GABRB2,CDKN2A,ALX1</TD></TR>
<TR><TD>5.925e-04</TD><TD>-7.43</TD><TD>stomach-carcinoma-intestinal_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-intestinal_adenocarcinoma</TD><TD>7350</TD><TD>31</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,CRB1,AZGP1,PCDH11X,EDA2R,PLAG1,PAPPA,ENPP5,CDKN2A,GALNT13,GABRB2,ALX1,FST,LSR,SLC6A15,PEX5L,RBM11,SATB2,ZIC4,DCDC2,EPHA3,PCDH17,NPTX2,ZFHX4,GRIA2,PLCH1,EYA4,RNF128,MEIS2,PCDH20,PAX9</TD></TR>
<TR><TD>5.979e-04</TD><TD>-7.42</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>6620</TD><TD>29</TD><TD>17255</TD><TD>46</TD>
<TD>EPHA3,GPC5,PCDH17,BMPR1B,HEY1,ZIC4,RBM11,ZIC1,MEIS2,PCDH20,PLCH1,GRIA2,EYA4,ZFHX4,SPAG6,PLAG1,PAPPA,EDA2R,PCDH11X,AZGP1,CRB1,PEX5L,FST,IL7,LSR,GALNT13,CDKN2A,GABRB2,ALX1</TD></TR>
<TR><TD>6.099e-04</TD><TD>-7.40</TD><TD>CTTTGA_LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGA_LEF1_Q2</TD><TD>1122</TD><TD>10</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,KYNU,FST,GABRB2,PLAG1,GPC5,ENPP5,MEIS2,ZIC4,ZIC1</TD></TR>
<TR><TD>6.099e-04</TD><TD>-7.40</TD><TD>CAGGTG_E12_Q6</TD><TD>MSigDB lists</TD><TD>CAGGTG_E12_Q6</TD><TD>2298</TD><TD>15</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,FST,PCDH17,BMPR1B,RNF128,PAX9,PLAG1,ENPP5,IL7,EYA4,LSR,ZIC4,MEIS2,MTSS1,CXCL14</TD></TR>
<TR><TD>6.199e-04</TD><TD>-7.39</TD><TD>conventional</TD><TD>COSMIC cancer mutations</TD><TD>conventional</TD><TD>14</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>6.240e-04</TD><TD>-7.38</TD><TD>cell differentiation</TD><TD>biological process</TD><TD>GO:0030154</TD><TD>3675</TD><TD>20</TD><TD>18054</TD><TD>48</TD>
<TD>SPAG6,LSR,ZIC1,HEY1,IL7,GABRB2,BMPR1B,EPHA3,FST,CRB1,CLDN1,DCDC2,PLAG1,PLEKHM3,MTSS1,EDA2R,NPTX2,SATB2,RBM11,ALX1</TD></TR>
<TR><TD>6.242e-04</TD><TD>-7.38</TD><TD>humerus</TD><TD>COSMIC cancer mutations</TD><TD>humerus</TD><TD>556</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,KYNU,MTSS1,CDKN2A,PCDH11X,ZFHX4,EYA4</TD></TR>
<TR><TD>6.400e-04</TD><TD>-7.35</TD><TD>TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497</TD><TD>MSigDB lists</TD><TD>TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497</TD><TD>559</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,CPEB2,PCDH17,ZIC1,PAPPA,PLAG1,SATB2</TD></TR>
<TR><TD>6.537e-04</TD><TD>-7.33</TD><TD>WTGAAAT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WTGAAAT_UNKNOWN</TD><TD>561</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,FST,ZFHX4,PAX9,ZIC1,ZIC4,PAPPA</TD></TR>
<TR><TD>6.742e-04</TD><TD>-7.30</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>7396</TD><TD>31</TD><TD>17255</TD><TD>46</TD>
<TD>PAPPA,SPAG6,CRB1,AZGP1,PCDH11X,SCGB3A2,MTSS1,CLDN1,PLEKHM3,SLC6A15,PEX5L,CXCL14,STAC,GABRB2,KYNU,GALNT13,LSR,IL7,BMPR1B,PCDH17,GPC5,EPHA3,SATB2,DCDC2,PAX9,MEIS2,RNF128,ZIC1,ZFHX4,NPTX2,GRIA2</TD></TR>
<TR><TD>6.881e-04</TD><TD>-7.28</TD><TD>GTGACTT_MIR224</TD><TD>MSigDB lists</TD><TD>GTGACTT_MIR224</TD><TD>151</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,CPEB2,PLAG1,EYA4</TD></TR>
<TR><TD>6.939e-04</TD><TD>-7.27</TD><TD>TGATTTRY_GFI1_01</TD><TD>MSigDB lists</TD><TD>TGATTTRY_GFI1_01</TD><TD>267</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,MEIS2,ZFHX4,ZIC1,ZIC4</TD></TR>
<TR><TD>7.002e-04</TD><TD>-7.26</TD><TD>DNA-binding transcription activator activity, RNA polymerase II-specific</TD><TD>molecular function</TD><TD>GO:0001228</TD><TD>438</TD><TD>6</TD><TD>17306</TD><TD>43</TD>
<TD>MEIS2,PLAG1,ALX1,SATB2,ZIC1,PAX9</TD></TR>
<TR><TD>7.047e-04</TD><TD>-7.26</TD><TD>CTTTGTA_MIR524</TD><TD>MSigDB lists</TD><TD>CTTTGTA_MIR524</TD><TD>408</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,GRIA2,CPEB2,ZIC1,PCDH17,MTSS1</TD></TR>
<TR><TD>7.086e-04</TD><TD>-7.25</TD><TD>DNA-binding transcription activator activity</TD><TD>molecular function</TD><TD>GO:0001216</TD><TD>439</TD><TD>6</TD><TD>17306</TD><TD>43</TD>
<TD>SATB2,ZIC1,PAX9,MEIS2,PLAG1,ALX1</TD></TR>
<TR><TD>7.125e-04</TD><TD>-7.25</TD><TD>FARMER_BREAST_CANCER_CLUSTER_3</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_CLUSTER_3</TD><TD>15</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,KYNU</TD></TR>
<TR><TD>7.434e-04</TD><TD>-7.20</TD><TD>human chr12q21.31</TD><TD>chromosome location</TD><TD>human chr12q21.31</TD><TD>22</TD><TD>2</TD><TD>26169</TD><TD>48</TD>
<TD>SLC6A15,ALX1</TD></TR>
<TR><TD>7.651e-04</TD><TD>-7.18</TD><TD>multicellular organism development</TD><TD>biological process</TD><TD>GO:0007275</TD><TD>4967</TD><TD>24</TD><TD>18054</TD><TD>48</TD>
<TD>DCDC2,CLDN1,EYA4,PLAG1,MEIS2,CXCL14,FST,CRB1,ALX1,SATB2,NPTX2,EDA2R,MTSS1,RBM11,ZIC1,PAX9,LSR,HEY1,BMPR1B,EPHA3,PCDH17,GABRB2,ZIC4,IL7</TD></TR>
<TR><TD>7.669e-04</TD><TD>-7.17</TD><TD>DURAND_STROMA_S_UP</TD><TD>MSigDB lists</TD><TD>DURAND_STROMA_S_UP</TD><TD>273</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,CLDN1,PAPPA,GALNT13,PAX9</TD></TR>
<TR><TD>7.961e-04</TD><TD>-7.14</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>157</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ZFHX4,FST,SLC6A15</TD></TR>
<TR><TD>7.994e-04</TD><TD>-7.13</TD><TD>animal organ morphogenesis</TD><TD>biological process</TD><TD>GO:0009887</TD><TD>953</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,ALX1,SATB2,IL7,PAX9,ZIC1,PLAG1,HEY1,CRB1</TD></TR>
<TR><TD>8.013e-04</TD><TD>-7.13</TD><TD>NAD de novo biosynthesis</TD><TD>BIOCYC pathways</TD><TD>HUMAN_NADSYN-PWY</TD><TD>11</TD><TD>2</TD><TD>902</TD><TD>4</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>8.013e-04</TD><TD>-7.13</TD><TD>L-kynurenine degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6309</TD><TD>11</TD><TD>2</TD><TD>902</TD><TD>4</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>8.129e-04</TD><TD>-7.11</TD><TD>GO_INDOLALKYLAMINE_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_INDOLALKYLAMINE_METABOLIC_PROCESS</TD><TD>16</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>8.537e-04</TD><TD>-7.07</TD><TD>CTCAAGA_MIR526B</TD><TD>MSigDB lists</TD><TD>CTCAAGA_MIR526B</TD><TD>70</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,PCDH17,ZFHX4</TD></TR>
<TR><TD>8.786e-04</TD><TD>-7.04</TD><TD>GO_POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>967</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,PAX9,CDKN2A,PLAG1,HEY1,ALX1,ZIC1,MEIS2,SATB2</TD></TR>
<TR><TD>8.871e-04</TD><TD>-7.03</TD><TD>GTGCCAA_MIR96</TD><TD>MSigDB lists</TD><TD>GTGCCAA_MIR96</TD><TD>282</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,EPHA3,PAPPA,MTSS1,ZFHX4</TD></TR>
<TR><TD>9.156e-04</TD><TD>-7.00</TD><TD>EVI1_05</TD><TD>MSigDB lists</TD><TD>EVI1_05</TD><TD>163</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,IL7,MEIS2,PLAG1</TD></TR>
<TR><TD>9.177e-04</TD><TD>-6.99</TD><TD>indolalkylamine metabolic process</TD><TD>biological process</TD><TD>GO:0006586</TD><TD>17</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>9.187e-04</TD><TD>-6.99</TD><TD>Homeobox-like_sf</TD><TD>interpro domains</TD><TD>IPR009057</TD><TD>293</TD><TD>5</TD><TD>18616</TD><TD>48</TD>
<TD>MEIS2,ALX1,SATB2,PAX9,ZFHX4</TD></TR>
<TR><TD>9.197e-04</TD><TD>-6.99</TD><TD>MAHADEVAN_IMATINIB_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>MAHADEVAN_IMATINIB_RESISTANCE_UP</TD><TD>17</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,CXCL14</TD></TR>
<TR><TD>9.367e-04</TD><TD>-6.97</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY15_POST_POLARIZATION_UP</TD><TD>MSigDB lists</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY15_POST_POLARIZATION_UP</TD><TD>164</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,PLAG1,KYNU,SATB2</TD></TR>
<TR><TD>9.367e-04</TD><TD>-6.97</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>MSigDB lists</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>164</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,MTSS1,PCDH11X,CRB1</TD></TR>
<TR><TD>9.395e-04</TD><TD>-6.97</TD><TD>pseudomyxoma_peritonei</TD><TD>COSMIC cancer mutations</TD><TD>pseudomyxoma_peritonei</TD><TD>596</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH17,MEIS2,EDA2R,EYA4,CDKN2A,STAC,ZFHX4</TD></TR>
<TR><TD>9.395e-04</TD><TD>-6.97</TD><TD>peritoneum-appendix-other-pseudomyxoma_peritonei</TD><TD>COSMIC cancer mutations</TD><TD>peritoneum-appendix-other-pseudomyxoma_peritonei</TD><TD>596</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH17,MEIS2,EYA4,EDA2R,STAC,ZFHX4,CDKN2A</TD></TR>
<TR><TD>9.488e-04</TD><TD>-6.96</TD><TD>appendix</TD><TD>COSMIC cancer mutations</TD><TD>appendix</TD><TD>597</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,STAC,ZFHX4,EDA2R,EYA4,MEIS2,PCDH17</TD></TR>
<TR><TD>9.538e-04</TD><TD>-6.96</TD><TD>carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>carcinoid-endocrine_tumour</TD><TD>7903</TD><TD>32</TD><TD>17255</TD><TD>46</TD>
<TD>NPTX2,GRIA2,PAX9,RNF128,MEIS2,ZIC1,DCDC2,BMPR1B,GPC5,EPHA3,STAC,CXCL14,KYNU,IL7,PLEKHM3,SLC6A15,PEX5L,AZGP1,MTSS1,PAPPA,ZFHX4,SATB2,PCDH17,GALNT13,CDKN2A,GABRB2,LSR,SCGB3A2,CRB1,PCDH11X,CLDN1,SPAG6</TD></TR>
<TR><TD>9.581e-04</TD><TD>-6.95</TD><TD>peritoneum</TD><TD>COSMIC cancer mutations</TD><TD>peritoneum</TD><TD>598</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>MEIS2,PCDH17,CDKN2A,ZFHX4,STAC,EDA2R,EYA4</TD></TR>
<TR><TD>9.596e-04</TD><TD>-6.95</TD><TD>plasma membrane part</TD><TD>cellular component</TD><TD>GO:0044459</TD><TD>2794</TD><TD>16</TD><TD>18985</TD><TD>48</TD>
<TD>PCDH20,PCDH11X,GABRB2,STAC,NPTX2,AZGP1,PCDH17,GRIA2,EPHA3,EDA2R,CRB1,ARHGAP45,GPC5,BMPR1B,SLC6A15,CLDN1</TD></TR>
<TR><TD>9.778e-04</TD><TD>-6.93</TD><TD>cerebellum</TD><TD>COSMIC cancer mutations</TD><TD>cerebellum</TD><TD>783</TD><TD>8</TD><TD>17255</TD><TD>46</TD>
<TD>MEIS2,STAC,CDKN2A,EYA4,SPAG6,EPHA3,GPC5,PCDH11X</TD></TR>
<TR><TD>9.805e-04</TD><TD>-6.93</TD><TD>metal ion binding</TD><TD>molecular function</TD><TD>GO:0046872</TD><TD>4137</TD><TD>20</TD><TD>17306</TD><TD>43</TD>
<TD>PCDH20,BMPR1B,PLEKHM3,ZFHX4,PCDH17,PCDH11X,PLAG1,ENPP5,EYA4,PAPPA,ZIC1,ZIC4,NPTX2,IDO2,CRB1,RNF128,GALNT13,ARHGAP45,STAC,PLCH1</TD></TR>
<TR><TD>1.005e-03</TD><TD>-6.90</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN</TD><TD>MSigDB lists</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN</TD><TD>290</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,FST,NPTX2,EPHA3,CLDN1</TD></TR>
<TR><TD>1.033e-03</TD><TD>-6.88</TD><TD>chr3q24</TD><TD>MSigDB lists</TD><TD>chr3q24</TD><TD>18</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4</TD></TR>
<TR><TD>1.033e-03</TD><TD>-6.88</TD><TD>GO_HEPARAN_SULFATE_PROTEOGLYCAN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_HEPARAN_SULFATE_PROTEOGLYCAN_BINDING</TD><TD>18</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GPC5,FST</TD></TR>
<TR><TD>1.047e-03</TD><TD>-6.86</TD><TD>DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN</TD><TD>MSigDB lists</TD><TD>DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN</TD><TD>169</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,PLAG1,ZFHX4,ZIC1</TD></TR>
<TR><TD>1.069e-03</TD><TD>-6.84</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN</TD><TD>294</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,CDKN2A,NPTX2,CLDN1,KYNU</TD></TR>
<TR><TD>1.126e-03</TD><TD>-6.79</TD><TD>GHANDHI_BYSTANDER_IRRADIATION_UP</TD><TD>MSigDB lists</TD><TD>GHANDHI_BYSTANDER_IRRADIATION_UP</TD><TD>77</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,KYNU,RNF128</TD></TR>
<TR><TD>1.131e-03</TD><TD>-6.78</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>1001</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,SPAG6,SATB2,PCDH11X,CDKN2A,GABRB2,GALNT13,ZFHX4,GRIA2</TD></TR>
<TR><TD>1.152e-03</TD><TD>-6.77</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_CATABOLIC_PROCESS</TD><TD>19</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.164e-03</TD><TD>-6.76</TD><TD>FOXJ2 (forkhead box J2)</TD><TD>protein interactions</TD><TD>55810</TD><TD>77</TD><TD>3</TD><TD>17456</TD><TD>47</TD>
<TD>ZFHX4,EYA4,SATB2</TD></TR>
<TR><TD>1.204e-03</TD><TD>-6.72</TD><TD>TTGCCAA_MIR182</TD><TD>MSigDB lists</TD><TD>TTGCCAA_MIR182</TD><TD>302</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PLCH1,MEIS2,MTSS1,PCDH17,SATB2</TD></TR>
<TR><TD>1.213e-03</TD><TD>-6.71</TD><TD>RYAAAKNNNNNNTTGW_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RYAAAKNNNNNNTTGW_UNKNOWN</TD><TD>79</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,PLAG1</TD></TR>
<TR><TD>1.234e-03</TD><TD>-6.70</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>3882</TD><TD>20</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,SATB2,RBM11,PCDH17,GPC5,EPHA3,BMPR1B,GRIA2,ZFHX4,PAX9,MEIS2,CPEB2,CRB1,PCDH11X,PAPPA,IL7,GALNT13,CDKN2A,KYNU,PEX5L</TD></TR>
<TR><TD>1.234e-03</TD><TD>-6.70</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>3882</TD><TD>20</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,RBM11,SATB2,EPHA3,GPC5,PCDH17,BMPR1B,GRIA2,ZFHX4,MEIS2,PAX9,CPEB2,PCDH11X,CRB1,PAPPA,IL7,GALNT13,KYNU,CDKN2A,PEX5L</TD></TR>
<TR><TD>1.243e-03</TD><TD>-6.69</TD><TD>PRC2_EED_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>PRC2_EED_UP.V1_UP</TD><TD>177</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,GPC5,PLAG1,MTSS1</TD></TR>
<TR><TD>1.269e-03</TD><TD>-6.67</TD><TD>GSE3982_DC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_DC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>178</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ALX1,AZGP1,EDA2R</TD></TR>
<TR><TD>1.276e-03</TD><TD>-6.66</TD><TD>cartilage condensation</TD><TD>biological process</TD><TD>GO:0001502</TD><TD>20</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,ALX1</TD></TR>
<TR><TD>1.278e-03</TD><TD>-6.66</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>MSigDB lists</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>20</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,CDKN2A</TD></TR>
<TR><TD>1.278e-03</TD><TD>-6.66</TD><TD>GO_CELL_AGGREGATION</TD><TD>MSigDB lists</TD><TD>GO_CELL_AGGREGATION</TD><TD>20</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,BMPR1B</TD></TR>
<TR><TD>1.278e-03</TD><TD>-6.66</TD><TD>GO_AMINE_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AMINE_CATABOLIC_PROCESS</TD><TD>20</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.311e-03</TD><TD>-6.64</TD><TD>cation binding</TD><TD>molecular function</TD><TD>GO:0043169</TD><TD>4228</TD><TD>20</TD><TD>17306</TD><TD>43</TD>
<TD>PCDH20,BMPR1B,PLEKHM3,ZFHX4,PCDH17,PCDH11X,ENPP5,PLAG1,PAPPA,EYA4,ZIC1,ZIC4,NPTX2,IDO2,CRB1,RNF128,GALNT13,STAC,ARHGAP45,PLCH1</TD></TR>
<TR><TD>1.349e-03</TD><TD>-6.61</TD><TD>GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_1H_DN</TD><TD>MSigDB lists</TD><TD>GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_1H_DN</TD><TD>181</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,SCGB3A2,STAC,PLCH1</TD></TR>
<TR><TD>1.377e-03</TD><TD>-6.59</TD><TD>P53_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>P53_DN.V1_UP</TD><TD>182</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,AZGP1,CDKN2A,MEIS2</TD></TR>
<TR><TD>1.391e-03</TD><TD>-6.58</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATORY_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATORY_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>312</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,ZIC1,PAX9,MEIS2,PLAG1</TD></TR>
<TR><TD>1.405e-03</TD><TD>-6.57</TD><TD>GSE7460_TREG_VS_TCONV_ACT_WITH_TGFB_UP</TD><TD>MSigDB lists</TD><TD>GSE7460_TREG_VS_TCONV_ACT_WITH_TGFB_UP</TD><TD>183</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,MEIS2,IL7,PCDH11X</TD></TR>
<TR><TD>1.407e-03</TD><TD>-6.57</TD><TD>cell aggregation</TD><TD>biological process</TD><TD>GO:0098743</TD><TD>21</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,BMPR1B</TD></TR>
<TR><TD>1.407e-03</TD><TD>-6.57</TD><TD>cellular biogenic amine catabolic process</TD><TD>biological process</TD><TD>GO:0042402</TD><TD>21</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.407e-03</TD><TD>-6.57</TD><TD>amine catabolic process</TD><TD>biological process</TD><TD>GO:0009310</TD><TD>21</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.492e-03</TD><TD>-6.51</TD><TD>FOXD3_01</TD><TD>MSigDB lists</TD><TD>FOXD3_01</TD><TD>186</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PCDH17,RNF128,FST</TD></TR>
<TR><TD>1.521e-03</TD><TD>-6.49</TD><TD>GSE36392_TYPE_2_MYELOID_VS_MAC_IL25_TREATED_LUNG_UP</TD><TD>MSigDB lists</TD><TD>GSE36392_TYPE_2_MYELOID_VS_MAC_IL25_TREATED_LUNG_UP</TD><TD>187</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,FST,PCDH11X,PCDH20</TD></TR>
<TR><TD>1.549e-03</TD><TD>-6.47</TD><TD>GO_BENZENE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_BENZENE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>22</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.549e-03</TD><TD>-6.47</TD><TD>NEWMAN_ERCC6_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NEWMAN_ERCC6_TARGETS_UP</TD><TD>22</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,ALX1</TD></TR>
<TR><TD>1.551e-03</TD><TD>-6.47</TD><TD>GSE19825_NAIVE_VS_IL2RALOW_DAY3_EFF_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE19825_NAIVE_VS_IL2RALOW_DAY3_EFF_CD8_TCELL_UP</TD><TD>188</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GPC5,PLAG1,AZGP1,CRB1</TD></TR>
<TR><TD>1.565e-03</TD><TD>-6.46</TD><TD>sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0043565</TD><TD>1130</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>SATB2,ZFHX4,ALX1,PLAG1,MEIS2,PAX9,ZIC1,HEY1,ZIC4</TD></TR>
<TR><TD>1.578e-03</TD><TD>-6.45</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>2787</TD><TD>16</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,GALNT13,STAC,PEX5L,PCDH11X,CRB1,PLAG1,PAPPA,PLCH1,ZFHX4,MEIS2,PAX9,PCDH20,GPC5,EPHA3,PCDH17</TD></TR>
<TR><TD>1.578e-03</TD><TD>-6.45</TD><TD>lung-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-squamous_cell_carcinoma</TD><TD>15000</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>AZGP1,MTSS1,CPEB2,EDA2R,PAPPA,PLAG1,ENPP5,STAC,CXCL14,KYNU,FST,IL7,SLC6A15,PLEKHM3,PEX5L,DCDC2,BMPR1B,GPC5,EPHA3,NPTX2,GRIA2,PLCH1,SAA2,PAX9,MEIS2,RNF128,ZIC1,IDO2,SCGB3A2,CRB1,PCDH11X,CLDN1,SPAG6,ALX1,GABRB2,CDKN2A,GALNT13,LSR,SATB2,RBM11,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20</TD></TR>
<TR><TD>1.584e-03</TD><TD>-6.45</TD><TD>SIX2 (SIX homeobox 2)</TD><TD>protein interactions</TD><TD>10736</TD><TD>22</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A,EYA4</TD></TR>
<TR><TD>1.602e-03</TD><TD>-6.44</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>MSigDB lists</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>87</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,PAPPA,IL7</TD></TR>
<TR><TD>1.613e-03</TD><TD>-6.43</TD><TD>GSE17721_POLYIC_VS_CPG_0.5H_BMDC_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_CPG_0.5H_BMDC_DN</TD><TD>190</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,MTSS1,ZFHX4,RNF128</TD></TR>
<TR><TD>1.676e-03</TD><TD>-6.39</TD><TD>GSE339_CD4POS_VS_CD4CD8DN_DC_IN_CULTURE_DN</TD><TD>MSigDB lists</TD><TD>GSE339_CD4POS_VS_CD4CD8DN_DC_IN_CULTURE_DN</TD><TD>192</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,MEIS2,GABRB2,ZIC4</TD></TR>
<TR><TD>1.676e-03</TD><TD>-6.39</TD><TD>GO_CELL_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>192</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,PCDH20,PCDH11X,CLDN1</TD></TR>
<TR><TD>1.680e-03</TD><TD>-6.39</TD><TD>GO_SENSORY_ORGAN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_SENSORY_ORGAN_DEVELOPMENT</TD><TD>483</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,BMPR1B,GABRB2,MEIS2,CXCL14,CRB1</TD></TR>
<TR><TD>1.687e-03</TD><TD>-6.38</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K27ME3</TD><TD>326</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,GALNT13,CXCL14,ALX1,LSR</TD></TR>
<TR><TD>1.694e-03</TD><TD>-6.38</TD><TD>LI_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>LI_CISPLATIN_RESISTANCE_UP</TD><TD>23</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,KYNU</TD></TR>
<TR><TD>1.710e-03</TD><TD>-6.37</TD><TD>BONCI_TARGETS_OF_MIR15A_AND_MIR16_1</TD><TD>MSigDB lists</TD><TD>BONCI_TARGETS_OF_MIR15A_AND_MIR16_1</TD><TD>89</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,PLAG1,PAPPA</TD></TR>
<TR><TD>1.732e-03</TD><TD>-6.36</TD><TD>ALOXE3 (arachidonate lipoxygenase 3)</TD><TD>protein interactions</TD><TD>59344</TD><TD>23</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>ZFHX4,ZIC1</TD></TR>
<TR><TD>1.807e-03</TD><TD>-6.32</TD><TD>ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN</TD><TD>MSigDB lists</TD><TD>ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN</TD><TD>196</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,ZFHX4,PCDH11X,SATB2</TD></TR>
<TR><TD>1.822e-03</TD><TD>-6.31</TD><TD>CAATGCA_MIR33</TD><TD>MSigDB lists</TD><TD>CAATGCA_MIR33</TD><TD>91</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,MEIS2,SATB2</TD></TR>
<TR><TD>1.834e-03</TD><TD>-6.30</TD><TD>human chr2q22.2</TD><TD>chromosome location</TD><TD>human chr2q22.2</TD><TD>1</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.834e-03</TD><TD>-6.30</TD><TD>human chr3p22.3-p22.2</TD><TD>chromosome location</TD><TD>human chr3p22.3-p22.2</TD><TD>1</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>STAC</TD></TR>
<TR><TD>1.834e-03</TD><TD>-6.30</TD><TD>human chr2q23.3-q24.1</TD><TD>chromosome location</TD><TD>human chr2q23.3-q24.1</TD><TD>1</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>GALNT13</TD></TR>
<TR><TD>1.840e-03</TD><TD>-6.30</TD><TD>indole-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0042430</TD><TD>24</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.841e-03</TD><TD>-6.30</TD><TD>TTTGCAG_MIR518A2</TD><TD>MSigDB lists</TD><TD>TTTGCAG_MIR518A2</TD><TD>197</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,CPEB2,ZIC1,SATB2</TD></TR>
<TR><TD>1.929e-03</TD><TD>-6.25</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>676</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,DCDC2,KYNU,CPEB2,BMPR1B,PLCH1,MTSS1</TD></TR>
<TR><TD>1.951e-03</TD><TD>-6.24</TD><TD>AAAYRNCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AAAYRNCTG_UNKNOWN</TD><TD>337</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,BMPR1B,ZIC4,PCDH17,FST</TD></TR>
<TR><TD>1.981e-03</TD><TD>-6.22</TD><TD>ATGCTGC_MIR103_MIR107</TD><TD>MSigDB lists</TD><TD>ATGCTGC_MIR103_MIR107</TD><TD>201</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ZIC1,MTSS1,PLAG1</TD></TR>
<TR><TD>1.997e-03</TD><TD>-6.22</TD><TD>benzene-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0042537</TD><TD>25</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>2.001e-03</TD><TD>-6.21</TD><TD>GO_INDOLE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_INDOLE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>25</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.046e-03</TD><TD>-6.19</TD><TD>FCGR1A (Fc fragment of IgG receptor Ia)</TD><TD>protein interactions</TD><TD>2209</TD><TD>25</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20,PCDH17</TD></TR>
<TR><TD>2.091e-03</TD><TD>-6.17</TD><TD>CART1_01</TD><TD>MSigDB lists</TD><TD>CART1_01</TD><TD>204</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,KYNU,MEIS2,PAPPA</TD></TR>
<TR><TD>2.104e-03</TD><TD>-6.16</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>MSigDB lists</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>505</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,EPHA3,ENPP5,PAPPA,RNF128,GABRB2</TD></TR>
<TR><TD>2.165e-03</TD><TD>-6.14</TD><TD>DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY</TD><TD>MSigDB lists</TD><TD>DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY</TD><TD>26</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>2.213e-03</TD><TD>-6.11</TD><TD>AZGP1 (alpha-2-glycoprotein 1, zinc-binding)</TD><TD>protein interactions</TD><TD>563</TD><TD>26</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1,AZGP1</TD></TR>
<TR><TD>2.251e-03</TD><TD>-6.10</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>2067</TD><TD>13</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,CRB1,EPHA3,GPC5,SPAG6,PAPPA,PLCH1,GRIA2,GALNT13,KYNU,CDKN2A,STAC,PCDH20</TD></TR>
<TR><TD>2.254e-03</TD><TD>-6.10</TD><TD>system development</TD><TD>biological process</TD><TD>GO:0048731</TD><TD>4365</TD><TD>21</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1,LSR,ZIC1,PAX9,IL7,ZIC4,GABRB2,PCDH17,EPHA3,BMPR1B,CRB1,FST,CXCL14,MEIS2,PLAG1,CLDN1,DCDC2,MTSS1,NPTX2,SATB2,ALX1</TD></TR>
<TR><TD>2.266e-03</TD><TD>-6.09</TD><TD>nervous system development</TD><TD>biological process</TD><TD>GO:0007399</TD><TD>2329</TD><TD>14</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,ALX1,PCDH17,EPHA3,NPTX2,SATB2,ZIC4,GABRB2,CLDN1,DCDC2,ZIC1,HEY1,PLAG1,CRB1</TD></TR>
<TR><TD>2.282e-03</TD><TD>-6.08</TD><TD>CTTTGT_LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGT_LEF1_Q2</TD><TD>1817</TD><TD>12</TD><TD>17275</TD><TD>46</TD>
<TD>FST,HEY1,BMPR1B,PCDH17,GABRB2,PCDH11X,EYA4,LSR,SCGB3A2,ZIC4,ZIC1,MEIS2</TD></TR>
<TR><TD>2.334e-03</TD><TD>-6.06</TD><TD>chr8q12</TD><TD>MSigDB lists</TD><TD>chr8q12</TD><TD>27</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,IL7</TD></TR>
<TR><TD>2.334e-03</TD><TD>-6.06</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G2</TD><TD>MSigDB lists</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G2</TD><TD>27</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,MEIS2</TD></TR>
<TR><TD>2.334e-03</TD><TD>-6.06</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_METABOLIC_PROCESS</TD><TD>27</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.339e-03</TD><TD>-6.06</TD><TD>dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>dedifferentiated</TD><TD>27</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>2.385e-03</TD><TD>-6.04</TD><TD>GSE37605_C57BL6_VS_NOD_FOXP3_FUSION_GFP_TREG_UP</TD><TD>MSigDB lists</TD><TD>GSE37605_C57BL6_VS_NOD_FOXP3_FUSION_GFP_TREG_UP</TD><TD>100</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,CDKN2A,EYA4</TD></TR>
<TR><TD>2.387e-03</TD><TD>-6.04</TD><TD>YATTNATC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YATTNATC_UNKNOWN</TD><TD>353</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,SPAG6,ZIC1,SCGB3A2,NPTX2</TD></TR>
<TR><TD>2.404e-03</TD><TD>-6.03</TD><TD>NKX3A_01</TD><TD>MSigDB lists</TD><TD>NKX3A_01</TD><TD>212</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,PAX9,RNF128</TD></TR>
<TR><TD>2.413e-03</TD><TD>-6.03</TD><TD>mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>mantle_cell_lymphoma</TD><TD>2900</TD><TD>16</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH20,PAX9,MEIS2,ZFHX4,PLCH1,PCDH17,GPC5,EPHA3,PEX5L,STAC,GALNT13,CDKN2A,PAPPA,PLAG1,CRB1,PCDH11X</TD></TR>
<TR><TD>2.444e-03</TD><TD>-6.01</TD><TD>liver-carcinoma-hepatocellular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>liver-carcinoma-hepatocellular_carcinoma</TD><TD>15143</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,GPC5,EPHA3,BMPR1B,GRIA2,PLCH1,NPTX2,ZIC1,IDO2,PAX9,SAA2,MEIS2,RNF128,CPEB2,EDA2R,AZGP1,MTSS1,ENPP5,PAPPA,PLAG1,IL7,FST,CXCL14,STAC,KYNU,PEX5L,PLEKHM3,SLC6A15,ZIC4,SATB2,RBM11,PCDH17,HEY1,EYA4,ZFHX4,PCDH20,PCDH11X,SCGB3A2,CRB1,CLDN1,SPAG6,LSR,ALX1,GALNT13,GABRB2,CDKN2A</TD></TR>
<TR><TD>2.444e-03</TD><TD>-6.01</TD><TD>hepatocellular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>hepatocellular_carcinoma</TD><TD>15143</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>GALNT13,CDKN2A,GABRB2,ALX1,LSR,CLDN1,CRB1,SCGB3A2,PCDH11X,SPAG6,ZFHX4,EYA4,PCDH20,RBM11,SATB2,ZIC4,HEY1,PCDH17,KYNU,CXCL14,STAC,FST,IL7,SLC6A15,PLEKHM3,PEX5L,MTSS1,AZGP1,EDA2R,CPEB2,PLAG1,PAPPA,ENPP5,NPTX2,GRIA2,PLCH1,MEIS2,RNF128,SAA2,PAX9,IDO2,ZIC1,DCDC2,BMPR1B,GPC5,EPHA3</TD></TR>
<TR><TD>2.459e-03</TD><TD>-6.01</TD><TD>YCATTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YCATTAA_UNKNOWN</TD><TD>521</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,SATB2,ZIC4,PAX9,CXCL14,PLAG1</TD></TR>
<TR><TD>2.485e-03</TD><TD>-6.00</TD><TD>3-hydroxykynureninase activity</TD><TD>molecular function</TD><TD>GO:0061981</TD><TD>1</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.485e-03</TD><TD>-6.00</TD><TD>kynureninase activity</TD><TD>molecular function</TD><TD>GO:0030429</TD><TD>1</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.485e-03</TD><TD>-6.00</TD><TD>calcium-dependent phospholipase C activity</TD><TD>molecular function</TD><TD>GO:0050429</TD><TD>1</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>PLCH1</TD></TR>
<TR><TD>2.497e-03</TD><TD>-5.99</TD><TD>central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour</TD><TD>214</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>PLEKHM3,PCDH17,CDKN2A,GABRB2</TD></TR>
<TR><TD>2.497e-03</TD><TD>-5.99</TD><TD>atypical_teratoid-rhabdoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>atypical_teratoid-rhabdoid_tumour</TD><TD>214</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH17,PLEKHM3,GABRB2,CDKN2A</TD></TR>
<TR><TD>2.504e-03</TD><TD>-5.99</TD><TD>NAD biosynthetic process</TD><TD>biological process</TD><TD>GO:0009435</TD><TD>28</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.504e-03</TD><TD>-5.99</TD><TD>aromatic amino acid family catabolic process</TD><TD>biological process</TD><TD>GO:0009074</TD><TD>28</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.509e-03</TD><TD>-5.99</TD><TD>STAEGE_EWING_FAMILY_TUMOR</TD><TD>MSigDB lists</TD><TD>STAEGE_EWING_FAMILY_TUMOR</TD><TD>28</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH11X,PAPPA</TD></TR>
<TR><TD>2.509e-03</TD><TD>-5.99</TD><TD>GO_PROTEOGLYCAN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_PROTEOGLYCAN_BINDING</TD><TD>28</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GPC5,FST</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>CXCL14</TD><TD>interpro domains</TD><TD>IPR039088</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>CXCL14</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>PLC-eta1</TD><TD>interpro domains</TD><TD>IPR028392</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>ALX1</TD><TD>interpro domains</TD><TD>IPR033209</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>ALX1</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>RBM11_RRM</TD><TD>interpro domains</TD><TD>IPR034501</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>RBM11</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>PAX9</TD><TD>interpro domains</TD><TD>IPR033204</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>PAPPA</TD><TD>interpro domains</TD><TD>IPR030433</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>IL-7</TD><TD>interpro domains</TD><TD>IPR001181</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>IL7</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>STAC1</TD><TD>interpro domains</TD><TD>IPR035508</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>STAC</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>IL7_sf</TD><TD>interpro domains</TD><TD>IPR038325</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>IL7</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>Claudin1</TD><TD>interpro domains</TD><TD>IPR003548</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>DCDC2</TD><TD>interpro domains</TD><TD>IPR033036</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>Protocadherin-17</TD><TD>interpro domains</TD><TD>IPR030709</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PCDH17</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>Tumor_suppres_ARF</TD><TD>interpro domains</TD><TD>IPR010868</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>PEX5-rel</TD><TD>interpro domains</TD><TD>IPR024112</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PEX5L</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>PLEKHM3_PH_1</TD><TD>interpro domains</TD><TD>IPR037812</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>Glypican-5</TD><TD>interpro domains</TD><TD>IPR031188</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GPC5</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>TNFRSF27_N</TD><TD>interpro domains</TD><TD>IPR034060</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>EphA3_rcpt_lig-bd</TD><TD>interpro domains</TD><TD>IPR034266</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>MTSS1</TD><TD>interpro domains</TD><TD>IPR027682</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>Kynureninase</TD><TD>interpro domains</TD><TD>IPR010111</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>TNFR_27</TD><TD>interpro domains</TD><TD>IPR022319</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.578e-03</TD><TD>-5.96</TD><TD>EYA4</TD><TD>interpro domains</TD><TD>IPR028478</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EYA4</TD></TR>
<TR><TD>2.646e-03</TD><TD>-5.93</TD><TD>P19Arf_N</TD><TD>pfam domains</TD><TD>PF07392</TD><TD>1</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.656e-03</TD><TD>-5.93</TD><TD>cell adhesion</TD><TD>biological process</TD><TD>GO:0007155</TD><TD>917</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1,PCDH11X,PCDH20,CRB1,PCDH17,EPHA3,MTSS1,AZGP1</TD></TR>
<TR><TD>2.659e-03</TD><TD>-5.93</TD><TD>presynaptic active zone assembly</TD><TD>biological process</TD><TD>GO:1904071</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH17</TD></TR>
<TR><TD>2.659e-03</TD><TD>-5.93</TD><TD>response to vitamin B6</TD><TD>biological process</TD><TD>GO:0034516</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.659e-03</TD><TD>-5.93</TD><TD>cellular response to butyrate</TD><TD>biological process</TD><TD>GO:1903545</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.659e-03</TD><TD>-5.93</TD><TD>response to butyrate</TD><TD>biological process</TD><TD>GO:1903544</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.659e-03</TD><TD>-5.93</TD><TD>tricellular tight junction assembly</TD><TD>biological process</TD><TD>GO:1904274</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>2.659e-03</TD><TD>-5.93</TD><TD>xenobiotic transport across blood-nerve barrier</TD><TD>biological process</TD><TD>GO:0061772</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.690e-03</TD><TD>-5.92</TD><TD>MODULE_497</TD><TD>MSigDB lists</TD><TD>MODULE_497</TD><TD>29</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ALX1</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>PIGL (phosphatidylinositol glycan anchor biosynthesis class L)</TD><TD>protein interactions</TD><TD>9487</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Srgap1 (SLIT-ROBO Rho GTPase activating protein 1)</TD><TD>protein interactions</TD><TD>117600</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Nptxr (neuronal pentraxin receptor)</TD><TD>protein interactions</TD><TD>81005</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Arhgdib (Rho, GDP dissociation inhibitor (GDI) beta)</TD><TD>protein interactions</TD><TD>11857</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>RNF128</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Lztr1 (leucine-zipper-like transcriptional regulator, 1)</TD><TD>protein interactions</TD><TD>66863</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>1700006A11Rik (RIKEN cDNA 1700006A11 gene)</TD><TD>protein interactions</TD><TD>71824</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Dcaf7 (DDB1 and CUL4 associated factor 7)</TD><TD>protein interactions</TD><TD>71833</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>CCDC78 (coiled-coil domain containing 78)</TD><TD>protein interactions</TD><TD>124093</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Nptx1 (neuronal pentraxin 1)</TD><TD>protein interactions</TD><TD>266777</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Eda2r (ectodysplasin A2 receptor)</TD><TD>protein interactions</TD><TD>245527</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Bcl6 (B cell leukemia/lymphoma 6)</TD><TD>protein interactions</TD><TD>12053</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.692e-03</TD><TD>-5.92</TD><TD>Arhgdia (Rho GDP dissociation inhibitor (GDI) alpha)</TD><TD>protein interactions</TD><TD>192662</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>RNF128</TD></TR>
<TR><TD>2.703e-03</TD><TD>-5.91</TD><TD>NKX61_01</TD><TD>MSigDB lists</TD><TD>NKX61_01</TD><TD>219</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,ZIC4,SATB2,SLC6A15</TD></TR>
<TR><TD>2.748e-03</TD><TD>-5.90</TD><TD>EVI1_04</TD><TD>MSigDB lists</TD><TD>EVI1_04</TD><TD>220</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,MEIS2,PLAG1</TD></TR>
<TR><TD>2.748e-03</TD><TD>-5.90</TD><TD>CCTGCTG_MIR214</TD><TD>MSigDB lists</TD><TD>CCTGCTG_MIR214</TD><TD>220</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH20,PAPPA,ZIC1,PCDH17</TD></TR>
<TR><TD>2.779e-03</TD><TD>-5.89</TD><TD>anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0009653</TD><TD>2114</TD><TD>13</TD><TD>18054</TD><TD>48</TD>
<TD>MTSS1,SATB2,IL7,BMPR1B,ALX1,EPHA3,CRB1,EYA4,DCDC2,ZIC1,PAX9,HEY1,PLAG1</TD></TR>
<TR><TD>2.784e-03</TD><TD>-5.88</TD><TD>biological adhesion</TD><TD>biological process</TD><TD>GO:0022610</TD><TD>924</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>AZGP1,MTSS1,PCDH17,EPHA3,PCDH20,CRB1,PCDH11X,CLDN1</TD></TR>
<TR><TD>2.789e-03</TD><TD>-5.88</TD><TD>Cadherin_CS</TD><TD>interpro domains</TD><TD>IPR020894</TD><TD>109</TD><TD>3</TD><TD>18616</TD><TD>48</TD>
<TD>PCDH17,PCDH20,PCDH11X</TD></TR>
<TR><TD>2.816e-03</TD><TD>-5.87</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.20.1250.50</TD><TD>1</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>IL7</TD></TR>
<TR><TD>2.884e-03</TD><TD>-5.85</TD><TD>bone-pelvis-chondrosarcoma-central</TD><TD>COSMIC cancer mutations</TD><TD>bone-pelvis-chondrosarcoma-central</TD><TD>30</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>2.889e-03</TD><TD>-5.85</TD><TD>sensory organ development</TD><TD>biological process</TD><TD>GO:0007423</TD><TD>538</TD><TD>6</TD><TD>18054</TD><TD>48</TD>
<TD>CRB1,CXCL14,GABRB2,BMPR1B,ZIC1,MEIS2</TD></TR>
<TR><TD>2.925e-03</TD><TD>-5.83</TD><TD>ODONNELL_TFRC_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ODONNELL_TFRC_TARGETS_UP</TD><TD>370</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>GALNT13,PAPPA,CLDN1,IL7,PCDH11X</TD></TR>
<TR><TD>2.958e-03</TD><TD>-5.82</TD><TD>intrinsic component of plasma membrane</TD><TD>cellular component</TD><TD>GO:0031226</TD><TD>1704</TD><TD>11</TD><TD>18985</TD><TD>48</TD>
<TD>GRIA2,PCDH17,CLDN1,EDA2R,EPHA3,GABRB2,GPC5,BMPR1B,PCDH11X,PCDH20,SLC6A15</TD></TR>
<TR><TD>2.967e-03</TD><TD>-5.82</TD><TD>COMP1_01</TD><TD>MSigDB lists</TD><TD>COMP1_01</TD><TD>108</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ZIC4,ZIC1</TD></TR>
<TR><TD>2.977e-03</TD><TD>-5.82</TD><TD>Homeobox_dom</TD><TD>interpro domains</TD><TD>IPR001356</TD><TD>232</TD><TD>4</TD><TD>18616</TD><TD>48</TD>
<TD>ZFHX4,SATB2,MEIS2,ALX1</TD></TR>
<TR><TD>3.064e-03</TD><TD>-5.79</TD><TD>nicotinamide nucleotide biosynthetic process</TD><TD>biological process</TD><TD>GO:0019359</TD><TD>31</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.064e-03</TD><TD>-5.79</TD><TD>pyridine nucleotide biosynthetic process</TD><TD>biological process</TD><TD>GO:0019363</TD><TD>31</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.065e-03</TD><TD>-5.79</TD><TD>cell development</TD><TD>biological process</TD><TD>GO:0048468</TD><TD>1628</TD><TD>11</TD><TD>18054</TD><TD>48</TD>
<TD>CRB1,DCDC2,LSR,SPAG6,CLDN1,GABRB2,SATB2,NPTX2,EPHA3,ALX1,BMPR1B</TD></TR>
<TR><TD>3.071e-03</TD><TD>-5.79</TD><TD>FRIDMAN_IMMORTALIZATION_DN</TD><TD>MSigDB lists</TD><TD>FRIDMAN_IMMORTALIZATION_DN</TD><TD>31</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,CXCL14</TD></TR>
<TR><TD>3.075e-03</TD><TD>-5.78</TD><TD>FOXO1_01</TD><TD>MSigDB lists</TD><TD>FOXO1_01</TD><TD>227</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,FST,PAPPA,PLAG1</TD></TR>
<TR><TD>3.078e-03</TD><TD>-5.78</TD><TD>bone-pelvis-chondrosarcoma-peripheral</TD><TD>COSMIC cancer mutations</TD><TD>bone-pelvis-chondrosarcoma-peripheral</TD><TD>31</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,ZFHX4</TD></TR>
<TR><TD>3.122e-03</TD><TD>-5.77</TD><TD>receptor complex</TD><TD>cellular component</TD><TD>GO:0043235</TD><TD>395</TD><TD>5</TD><TD>18985</TD><TD>48</TD>
<TD>EPHA3,PEX5L,BMPR1B,GABRB2,GRIA2</TD></TR>
<TR><TD>3.166e-03</TD><TD>-5.76</TD><TD>Cadherin-like_dom</TD><TD>interpro domains</TD><TD>IPR002126</TD><TD>114</TD><TD>3</TD><TD>18616</TD><TD>48</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>3.174e-03</TD><TD>-5.75</TD><TD>E47_02</TD><TD>MSigDB lists</TD><TD>E47_02</TD><TD>229</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,PCDH17,NPTX2,LSR</TD></TR>
<TR><TD>3.174e-03</TD><TD>-5.75</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>229</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,ZIC1,MEIS2,ZFHX4</TD></TR>
<TR><TD>3.184e-03</TD><TD>-5.75</TD><TD>multicellular organismal process</TD><TD>biological process</TD><TD>GO:0032501</TD><TD>6841</TD><TD>28</TD><TD>18054</TD><TD>48</TD>
<TD>FST,CRB1,CXCL14,EYA4,CLDN1,DCDC2,MEIS2,PLAG1,EDA2R,MTSS1,SATB2,NPTX2,AZGP1,RBM11,STAC,ALX1,LSR,SPAG6,ZIC1,PAX9,PAPPA,HEY1,IL7,ZIC4,GABRB2,BMPR1B,PCDH17,EPHA3</TD></TR>
<TR><TD>3.224e-03</TD><TD>-5.74</TD><TD>GATA1_04</TD><TD>MSigDB lists</TD><TD>GATA1_04</TD><TD>230</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PAPPA,ZIC1,EYA4</TD></TR>
<TR><TD>3.263e-03</TD><TD>-5.73</TD><TD>nicotinamide nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0046496</TD><TD>32</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.263e-03</TD><TD>-5.73</TD><TD>pyridine nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0019362</TD><TD>32</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.303e-03</TD><TD>-5.71</TD><TD>TAATTA_CHX10_01</TD><TD>MSigDB lists</TD><TD>TAATTA_CHX10_01</TD><TD>744</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>FST,STAC,BMPR1B,ZIC1,ZIC4,MTSS1,ZFHX4</TD></TR>
<TR><TD>3.312e-03</TD><TD>-5.71</TD><TD>Cadherin</TD><TD>pfam domains</TD><TD>PF00028</TD><TD>113</TD><TD>3</TD><TD>17385</TD><TD>46</TD>
<TD>PCDH20,PCDH17,PCDH11X</TD></TR>
<TR><TD>3.325e-03</TD><TD>-5.71</TD><TD>Cadherin-like_sf</TD><TD>interpro domains</TD><TD>IPR015919</TD><TD>116</TD><TD>3</TD><TD>18616</TD><TD>48</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>3.335e-03</TD><TD>-5.70</TD><TD>TTGTTT_FOXO4_01</TD><TD>MSigDB lists</TD><TD>TTGTTT_FOXO4_01</TD><TD>1901</TD><TD>12</TD><TD>17275</TD><TD>46</TD>
<TD>FST,PEX5L,NPTX2,HEY1,PLAG1,PCDH17,SATB2,SCGB3A2,PAPPA,ZIC1,ZIC4,MEIS2</TD></TR>
<TR><TD>3.377e-03</TD><TD>-5.69</TD><TD>S8_01</TD><TD>MSigDB lists</TD><TD>S8_01</TD><TD>233</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,FST,CXCL14,ZFHX4</TD></TR>
<TR><TD>3.377e-03</TD><TD>-5.69</TD><TD>CDX2_Q5</TD><TD>MSigDB lists</TD><TD>CDX2_Q5</TD><TD>233</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,PLAG1,ZIC4,MEIS2</TD></TR>
<TR><TD>3.473e-03</TD><TD>-5.66</TD><TD>face</TD><TD>COSMIC cancer mutations</TD><TD>face</TD><TD>2170</TD><TD>13</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,GRIA2,STAC,KYNU,CDKN2A,GALNT13,PCDH20,DCDC2,CRB1,SPAG6,GPC5,EPHA3,PAPPA</TD></TR>
<TR><TD>3.535e-03</TD><TD>-5.65</TD><TD>HSIAO_LIVER_SPECIFIC_GENES</TD><TD>MSigDB lists</TD><TD>HSIAO_LIVER_SPECIFIC_GENES</TD><TD>236</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,FST,KYNU,LSR</TD></TR>
<TR><TD>3.588e-03</TD><TD>-5.63</TD><TD>PBX1_01</TD><TD>MSigDB lists</TD><TD>PBX1_01</TD><TD>237</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,BMPR1B,PAPPA</TD></TR>
<TR><TD>3.643e-03</TD><TD>-5.62</TD><TD>FOXO4_02</TD><TD>MSigDB lists</TD><TD>FOXO4_02</TD><TD>238</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,MEIS2,PLAG1,PAPPA</TD></TR>
<TR><TD>3.657e-03</TD><TD>-5.61</TD><TD>TNFACTORR27</TD><TD>prints domains</TD><TD>PR01973</TD><TD>1</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>EDA2R</TD></TR>
<TR><TD>3.657e-03</TD><TD>-5.61</TD><TD>INTERLEUKIN7</TD><TD>prints domains</TD><TD>PR00435</TD><TD>1</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>IL7</TD></TR>
<TR><TD>3.657e-03</TD><TD>-5.61</TD><TD>CLAUDIN1</TD><TD>prints domains</TD><TD>PR01377</TD><TD>1</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.686e-03</TD><TD>-5.60</TD><TD>CERVERA_SDHB_TARGETS_1_DN</TD><TD>MSigDB lists</TD><TD>CERVERA_SDHB_TARGETS_1_DN</TD><TD>34</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,NPTX2</TD></TR>
<TR><TD>3.694e-03</TD><TD>-5.60</TD><TD>IL7</TD><TD>smart domains</TD><TD>SM00127</TD><TD>1</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>IL7</TD></TR>
<TR><TD>3.718e-03</TD><TD>-5.59</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>117</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,SATB2,MTSS1</TD></TR>
<TR><TD>3.744e-03</TD><TD>-5.59</TD><TD>AATGTGA_MIR23A_MIR23B</TD><TD>MSigDB lists</TD><TD>AATGTGA_MIR23A_MIR23B</TD><TD>392</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ZIC1,CPEB2,MTSS1,MEIS2</TD></TR>
<TR><TD>3.753e-03</TD><TD>-5.59</TD><TD>TEF_Q6</TD><TD>MSigDB lists</TD><TD>TEF_Q6</TD><TD>240</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH11X,HEY1,CRB1,NPTX2</TD></TR>
<TR><TD>3.870e-03</TD><TD>-5.55</TD><TD>pharynx</TD><TD>COSMIC cancer mutations</TD><TD>pharynx</TD><TD>2748</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>EYA4,PLCH1,ALX1,ZFHX4,CDKN2A,ZIC1,PEX5L,PCDH20,PLEKHM3,PAX9,CRB1,MTSS1,PCDH17,GPC5,EPHA3</TD></TR>
<TR><TD>3.894e-03</TD><TD>-5.55</TD><TD>pyridine-containing compound biosynthetic process</TD><TD>biological process</TD><TD>GO:0072525</TD><TD>35</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.899e-03</TD><TD>-5.55</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>119</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,HEY1,IL7</TD></TR>
<TR><TD>3.899e-03</TD><TD>-5.55</TD><TD>EVI1_02</TD><TD>MSigDB lists</TD><TD>EVI1_02</TD><TD>119</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,KYNU,IL7</TD></TR>
<TR><TD>3.923e-03</TD><TD>-5.54</TD><TD>NKX25_02</TD><TD>MSigDB lists</TD><TD>NKX25_02</TD><TD>243</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,MEIS2,PLAG1,CXCL14</TD></TR>
<TR><TD>3.940e-03</TD><TD>-5.54</TD><TD>lipoprotein particle</TD><TD>cellular component</TD><TD>GO:1990777</TD><TD>37</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>SAA2,LSR</TD></TR>
<TR><TD>3.940e-03</TD><TD>-5.54</TD><TD>plasma lipoprotein particle</TD><TD>cellular component</TD><TD>GO:0034358</TD><TD>37</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>LSR,SAA2</TD></TR>
<TR><TD>3.980e-03</TD><TD>-5.53</TD><TD>Cytokine-cytokine receptor interaction</TD><TD>KEGG pathways</TD><TD>hsa04060</TD><TD>270</TD><TD>4</TD><TD>7161</TD><TD>18</TD>
<TD>CXCL14,BMPR1B,IL7,EDA2R</TD></TR>
<TR><TD>3.980e-03</TD><TD>-5.53</TD><TD>Cytokine-cytokine receptor interaction</TD><TD>KEGG pathways</TD><TD>ko04060</TD><TD>270</TD><TD>4</TD><TD>7161</TD><TD>18</TD>
<TD>CXCL14,EDA2R,IL7,BMPR1B</TD></TR>
<TR><TD>3.980e-03</TD><TD>-5.53</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN</TD><TD>MSigDB lists</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN</TD><TD>244</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,PAX9,ZIC1,PAPPA</TD></TR>
<TR><TD>4.022e-03</TD><TD>-5.52</TD><TD>GO_BIOLOGICAL_ADHESION</TD><TD>MSigDB lists</TD><TD>GO_BIOLOGICAL_ADHESION</TD><TD>982</TD><TD>8</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,PCDH20,EPHA3,AZGP1,CLDN1,MTSS1,IL7,PCDH11X</TD></TR>
<TR><TD>4.036e-03</TD><TD>-5.51</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>399</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,NPTX2,EPHA3,GRIA2,PCDH17</TD></TR>
<TR><TD>4.097e-03</TD><TD>-5.50</TD><TD>OSF2_Q6</TD><TD>MSigDB lists</TD><TD>OSF2_Q6</TD><TD>246</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,FST,ZIC4,ZIC1</TD></TR>
<TR><TD>4.116e-03</TD><TD>-5.49</TD><TD>negative regulation of extrinsic apoptotic signaling pathway in absence of ligand</TD><TD>biological process</TD><TD>GO:2001240</TD><TD>36</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>4.116e-03</TD><TD>-5.49</TD><TD>negative regulation of signal transduction in absence of ligand</TD><TD>biological process</TD><TD>GO:1901099</TD><TD>36</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>4.199e-03</TD><TD>-5.47</TD><TD>GO_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>989</TD><TD>8</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,ALX1,PLAG1,PAX9,ZFHX4,SATB2,ZIC1,MEIS2</TD></TR>
<TR><TD>4.273e-03</TD><TD>-5.46</TD><TD>Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-6788656</TD><TD>44</TD><TD>2</TD><TD>10287</TD><TD>23</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.277e-03</TD><TD>-5.45</TD><TD>POU3F2_02</TD><TD>MSigDB lists</TD><TD>POU3F2_02</TD><TD>249</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,NPTX2,PLAG1,ZIC4</TD></TR>
<TR><TD>4.277e-03</TD><TD>-5.45</TD><TD>AREB6_01</TD><TD>MSigDB lists</TD><TD>AREB6_01</TD><TD>249</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,ZIC1,ZIC4,PLAG1</TD></TR>
<TR><TD>4.344e-03</TD><TD>-5.44</TD><TD>tight junction assembly</TD><TD>biological process</TD><TD>GO:0120192</TD><TD>37</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>4.354e-03</TD><TD>-5.44</TD><TD>CTCTATG_MIR368</TD><TD>MSigDB lists</TD><TD>CTCTATG_MIR368</TD><TD>37</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,EYA4</TD></TR>
<TR><TD>4.370e-03</TD><TD>-5.43</TD><TD>protein-lipid complex</TD><TD>cellular component</TD><TD>GO:0032994</TD><TD>39</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>LSR,SAA2</TD></TR>
<TR><TD>4.399e-03</TD><TD>-5.43</TD><TD>Nicotine addiction</TD><TD>KEGG pathways</TD><TD>hsa05033</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>4.399e-03</TD><TD>-5.43</TD><TD>Tryptophan metabolism</TD><TD>KEGG pathways</TD><TD>ko00380</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.399e-03</TD><TD>-5.43</TD><TD>Tryptophan metabolism</TD><TD>KEGG pathways</TD><TD>hsa00380</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.399e-03</TD><TD>-5.43</TD><TD>Nicotine addiction</TD><TD>KEGG pathways</TD><TD>ko05033</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>4.446e-03</TD><TD>-5.42</TD><TD>endometrium-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-serous_carcinoma</TD><TD>1461</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC1,ZFHX4,CDKN2A,PLCH1,PAPPA,PLAG1,PCDH17,GPC5,EPHA3,CRB1</TD></TR>
<TR><TD>4.450e-03</TD><TD>-5.41</TD><TD>EPHA3 (EPH receptor A3)</TD><TD>protein interactions</TD><TD>2042</TD><TD>37</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>4.481e-03</TD><TD>-5.41</TD><TD>mast_cell_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>mast_cell_neoplasm</TD><TD>252</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,CRB1,ZFHX4,GALNT13</TD></TR>
<TR><TD>4.481e-03</TD><TD>-5.41</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm</TD><TD>252</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,CRB1,ZFHX4,GALNT13</TD></TR>
<TR><TD>4.576e-03</TD><TD>-5.39</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>126</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,PCDH17,HEY1</TD></TR>
<TR><TD>4.590e-03</TD><TD>-5.38</TD><TD>bone-humerus-chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-chondrosarcoma</TD><TD>126</TD><TD>3</TD><TD>17255</TD><TD>46</TD>
<TD>EYA4,CDKN2A,ZFHX4</TD></TR>
<TR><TD>4.653e-03</TD><TD>-5.37</TD><TD>ATTCTTT_MIR186</TD><TD>MSigDB lists</TD><TD>ATTCTTT_MIR186</TD><TD>255</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,CPEB2,ZFHX4,PAPPA</TD></TR>
<TR><TD>4.653e-03</TD><TD>-5.37</TD><TD>KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION</TD><TD>MSigDB lists</TD><TD>KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION</TD><TD>255</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>EDA2R,IL7,BMPR1B,CXCL14</TD></TR>
<TR><TD>4.682e-03</TD><TD>-5.36</TD><TD>skin-neck-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma</TD><TD>1233</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,CRB1,GPC5,EPHA3,PAPPA,PLCH1,KYNU,CDKN2A,SLC6A15</TD></TR>
<TR><TD>4.690e-03</TD><TD>-5.36</TD><TD>TMEM231 (transmembrane protein 231)</TD><TD>protein interactions</TD><TD>79583</TD><TD>38</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>LSR,EPHA3</TD></TR>
<TR><TD>4.718e-03</TD><TD>-5.36</TD><TD>IK1_01</TD><TD>MSigDB lists</TD><TD>IK1_01</TD><TD>256</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,PCDH17,ZIC4,RNF128</TD></TR>
<TR><TD>4.718e-03</TD><TD>-5.36</TD><TD>AP1_Q4</TD><TD>MSigDB lists</TD><TD>AP1_Q4</TD><TD>256</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,ZIC1,ZIC4,PAPPA</TD></TR>
<TR><TD>4.817e-03</TD><TD>-5.34</TD><TD>tight junction organization</TD><TD>biological process</TD><TD>GO:0120193</TD><TD>39</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>4.817e-03</TD><TD>-5.34</TD><TD>aromatic amino acid family metabolic process</TD><TD>biological process</TD><TD>GO:0009072</TD><TD>39</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.828e-03</TD><TD>-5.33</TD><TD>MUELLER_METHYLATED_IN_GLIOBLASTOMA</TD><TD>MSigDB lists</TD><TD>MUELLER_METHYLATED_IN_GLIOBLASTOMA</TD><TD>39</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,NPTX2</TD></TR>
<TR><TD>4.828e-03</TD><TD>-5.33</TD><TD>KEGG_TRYPTOPHAN_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_TRYPTOPHAN_METABOLISM</TD><TD>39</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.885e-03</TD><TD>-5.32</TD><TD>neck</TD><TD>COSMIC cancer mutations</TD><TD>neck</TD><TD>1241</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,CRB1,GPC5,EPHA3,PAPPA,PLCH1,CDKN2A,KYNU,SLC6A15</TD></TR>
<TR><TD>4.963e-03</TD><TD>-5.31</TD><TD>activin receptor antagonist activity</TD><TD>molecular function</TD><TD>GO:0038102</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>FST</TD></TR>
<TR><TD>4.963e-03</TD><TD>-5.31</TD><TD>peroxisome matrix targeting signal-1 binding</TD><TD>molecular function</TD><TD>GO:0005052</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>PEX5L</TD></TR>
<TR><TD>4.963e-03</TD><TD>-5.31</TD><TD>indoleamine 2,3-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0033754</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>IDO2</TD></TR>
<TR><TD>4.963e-03</TD><TD>-5.31</TD><TD>proline:sodium symporter activity</TD><TD>molecular function</TD><TD>GO:0005298</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.963e-03</TD><TD>-5.31</TD><TD>interleukin-7 receptor binding</TD><TD>molecular function</TD><TD>GO:0005139</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>IL7</TD></TR>
<TR><TD>4.983e-03</TD><TD>-5.30</TD><TD>MORF_MDM2</TD><TD>MSigDB lists</TD><TD>MORF_MDM2</TD><TD>260</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,PAX9,GABRB2</TD></TR>
<TR><TD>5.062e-03</TD><TD>-5.29</TD><TD>pyridine-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0072524</TD><TD>40</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>5.085e-03</TD><TD>-5.28</TD><TD>lower_back</TD><TD>COSMIC cancer mutations</TD><TD>lower_back</TD><TD>40</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>5.119e-03</TD><TD>-5.27</TD><TD>STK33_UP</TD><TD>MSigDB lists</TD><TD>STK33_UP</TD><TD>262</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,CLDN1,CPEB2,MTSS1</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>SATB1/SATB2</TD><TD>interpro domains</TD><TD>IPR039673</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>PTS1R_family</TD><TD>interpro domains</TD><TD>IPR024111</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PEX5L</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>Peptidase_M43</TD><TD>interpro domains</TD><TD>IPR008754</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>ULD</TD><TD>interpro domains</TD><TD>IPR032392</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>Indolamine_dOase</TD><TD>interpro domains</TD><TD>IPR000898</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>IDO2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>Secretoglobin_3A</TD><TD>interpro domains</TD><TD>IPR040301</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>SATB_ULD_sf</TD><TD>interpro domains</TD><TD>IPR038224</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>CUTL</TD><TD>interpro domains</TD><TD>IPR032355</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>MTSS1/MTSS2</TD><TD>interpro domains</TD><TD>IPR030127</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>IL-7/IL-9_CS</TD><TD>interpro domains</TD><TD>IPR018049</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>IL7</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>SATB_CUTL_sf</TD><TD>interpro domains</TD><TD>IPR038216</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.150e-03</TD><TD>-5.27</TD><TD>TMEM255</TD><TD>interpro domains</TD><TD>IPR028014</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>TMEM255A</TD></TR>
<TR><TD>5.159e-03</TD><TD>-5.27</TD><TD>CADHERIN_1</TD><TD>prosite domains</TD><TD>PS00232</TD><TD>109</TD><TD>3</TD><TD>12079</TD><TD>39</TD>
<TD>PCDH11X,PCDH17,PCDH20</TD></TR>
<TR><TD>5.188e-03</TD><TD>-5.26</TD><TD>lymph_node</TD><TD>COSMIC cancer mutations</TD><TD>lymph_node</TD><TD>1744</TD><TD>11</TD><TD>17255</TD><TD>46</TD>
<TD>MEIS2,GRIA2,CDKN2A,ZFHX4,EPHA3,GPC5,SPAG6,PLAG1,ZIC4,SATB2,PCDH11X</TD></TR>
<TR><TD>5.246e-03</TD><TD>-5.25</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>608</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,NPTX2,CLDN1,CDKN2A,PLCH1,ZIC1</TD></TR>
<TR><TD>5.258e-03</TD><TD>-5.25</TD><TD>GATA1_05</TD><TD>MSigDB lists</TD><TD>GATA1_05</TD><TD>264</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,ZIC1,IL7,HEY1</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>Peptidase_M43</TD><TD>pfam domains</TD><TD>PF05572</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PAPPA</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>IDO</TD><TD>pfam domains</TD><TD>PF01231</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>IDO2</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>CUTL</TD><TD>pfam domains</TD><TD>PF16557</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>FAM70</TD><TD>pfam domains</TD><TD>PF14967</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>TMEM255A</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>ULD</TD><TD>pfam domains</TD><TD>PF16534</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.310e-03</TD><TD>-5.24</TD><TD>fasciculation of motor neuron axon</TD><TD>biological process</TD><TD>GO:0097156</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>5.310e-03</TD><TD>-5.24</TD><TD>umbilical cord development</TD><TD>biological process</TD><TD>GO:0061027</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>5.310e-03</TD><TD>-5.24</TD><TD>tryptophan catabolic process to acetyl-CoA</TD><TD>biological process</TD><TD>GO:0019442</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>5.310e-03</TD><TD>-5.24</TD><TD>negative regulation of cytoplasmic translational elongation</TD><TD>biological process</TD><TD>GO:1900248</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>5.310e-03</TD><TD>-5.24</TD><TD>nephron tubule epithelial cell differentiation</TD><TD>biological process</TD><TD>GO:0072160</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>5.310e-03</TD><TD>-5.24</TD><TD>umbilical cord morphogenesis</TD><TD>biological process</TD><TD>GO:0036304</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>5.324e-03</TD><TD>-5.24</TD><TD>PID_BMP_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_BMP_PATHWAY</TD><TD>41</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,FST</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Klhl1 (kelch-like 1)</TD><TD>protein interactions</TD><TD>93688</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Bmpr2 (bone morphogenetic protein receptor, type II (serine/threonine kinase))</TD><TD>protein interactions</TD><TD>12168</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Grip1 (glutamate receptor interacting protein 1)</TD><TD>protein interactions</TD><TD>84016</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GRIA2</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Fkbp1b (FK506 binding protein 1b)</TD><TD>protein interactions</TD><TD>14226</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Mknk2 (MAP kinase-interacting serine/threonine kinase 2)</TD><TD>protein interactions</TD><TD>17347</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Sh3kbp1 (SH3-domain kinase binding protein 1)</TD><TD>protein interactions</TD><TD>58194</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Fbxo34 (F-box protein 34)</TD><TD>protein interactions</TD><TD>78938</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Bcr (breakpoint cluster region)</TD><TD>protein interactions</TD><TD>110279</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform)</TD><TD>protein interactions</TD><TD>19057</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Atg16l1 (autophagy related 16-like 1 (S. cerevisiae))</TD><TD>protein interactions</TD><TD>77040</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Fkbp1a (FK506 binding protein 1a)</TD><TD>protein interactions</TD><TD>14225</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>Irf7 (interferon regulatory factor 7)</TD><TD>protein interactions</TD><TD>54123</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.378e-03</TD><TD>-5.23</TD><TD>MGC34796 (sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) pseudogene)</TD><TD>protein interactions</TD><TD>414927</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>5.402e-03</TD><TD>-5.22</TD><TD>animal organ development</TD><TD>biological process</TD><TD>GO:0048513</TD><TD>3131</TD><TD>16</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,SATB2,MTSS1,PLAG1,MEIS2,CLDN1,CXCL14,FST,CRB1,BMPR1B,GABRB2,IL7,HEY1,ZIC1,PAX9,LSR</TD></TR>
<TR><TD>5.414e-03</TD><TD>-5.22</TD><TD>GO_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>612</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,ALX1,PLAG1,ZIC1,PAX9,MEIS2</TD></TR>
<TR><TD>5.420e-03</TD><TD>-5.22</TD><TD>pattern specification process</TD><TD>biological process</TD><TD>GO:0007389</TD><TD>428</TD><TD>5</TD><TD>18054</TD><TD>48</TD>
<TD>ZIC1,BMPR1B,HEY1,ALX1,SATB2</TD></TR>
<TR><TD>5.519e-03</TD><TD>-5.20</TD><TD>HOMEOBOX_2</TD><TD>prosite domains</TD><TD>PS50071</TD><TD>222</TD><TD>4</TD><TD>12079</TD><TD>39</TD>
<TD>MEIS2,ZFHX4,SATB2,ALX1</TD></TR>
<TR><TD>5.543e-03</TD><TD>-5.20</TD><TD>MORF_CAMK4</TD><TD>MSigDB lists</TD><TD>MORF_CAMK4</TD><TD>268</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,PAX9,GABRB2</TD></TR>
<TR><TD>5.544e-03</TD><TD>-5.20</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>135</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,SLC6A15,GRIA2</TD></TR>
<TR><TD>5.544e-03</TD><TD>-5.20</TD><TD>RORA2_01</TD><TD>MSigDB lists</TD><TD>RORA2_01</TD><TD>135</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,MEIS2,GABRB2</TD></TR>
<TR><TD>5.616e-03</TD><TD>-5.18</TD><TD>MORF_NOS2A</TD><TD>MSigDB lists</TD><TD>MORF_NOS2A</TD><TD>269</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,PAX9,GABRB2,STAC</TD></TR>
<TR><TD>5.625e-03</TD><TD>-5.18</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.260.70</TD><TD>2</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.625e-03</TD><TD>-5.18</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.10.20.710</TD><TD>2</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.662e-03</TD><TD>-5.17</TD><TD>lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>lymphoid_neoplasm</TD><TD>12511</TD><TD>41</TD><TD>17255</TD><TD>46</TD>
<TD>GRIA2,PLCH1,NPTX2,ZIC1,IDO2,PAX9,MEIS2,RNF128,DCDC2,GPC5,EPHA3,BMPR1B,IL7,FST,STAC,KYNU,PEX5L,PLEKHM3,SLC6A15,CPEB2,AZGP1,MTSS1,PAPPA,PLAG1,EYA4,ZFHX4,PCDH20,ZIC4,SATB2,RBM11,PCDH17,LSR,ALX1,GALNT13,GABRB2,CDKN2A,SCGB3A2,CRB1,PCDH11X,CLDN1,SPAG6</TD></TR>
<TR><TD>5.690e-03</TD><TD>-5.17</TD><TD>ACTTTAT_MIR1425P</TD><TD>MSigDB lists</TD><TD>ACTTTAT_MIR1425P</TD><TD>270</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,PAPPA,CPEB2,RNF128</TD></TR>
<TR><TD>5.690e-03</TD><TD>-5.17</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>2575</TD><TD>14</TD><TD>17255</TD><TD>46</TD>
<TD>GABRB2,CDKN2A,GALNT13,ZFHX4,PEX5L,RNF128,MEIS2,SLC6A15,PLEKHM3,DCDC2,PCDH11X,EPHA3,GPC5,PAPPA</TD></TR>
<TR><TD>5.775e-03</TD><TD>-5.15</TD><TD>MEL18_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>MEL18_DN.V1_DN</TD><TD>137</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,EPHA3,EYA4</TD></TR>
<TR><TD>5.803e-03</TD><TD>-5.15</TD><TD>DELYS_THYROID_CANCER_UP</TD><TD>MSigDB lists</TD><TD>DELYS_THYROID_CANCER_UP</TD><TD>435</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,PLAG1,CLDN1,NPTX2,LSR</TD></TR>
<TR><TD>5.844e-03</TD><TD>-5.14</TD><TD>CADHERIN_2</TD><TD>prosite domains</TD><TD>PS50268</TD><TD>114</TD><TD>3</TD><TD>12079</TD><TD>39</TD>
<TD>PCDH11X,PCDH17,PCDH20</TD></TR>
<TR><TD>5.854e-03</TD><TD>-5.14</TD><TD>brainstem</TD><TD>COSMIC cancer mutations</TD><TD>brainstem</TD><TD>3161</TD><TD>16</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH11X,PAPPA,ALX1,GABRB2,CDKN2A,GALNT13,PEX5L,SLC6A15,PLEKHM3,DCDC2,SATB2,GPC5,EPHA3,ZFHX4,RNF128,MEIS2</TD></TR>
<TR><TD>6.112e-03</TD><TD>-5.10</TD><TD>ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>MSigDB lists</TD><TD>ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>44</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,IL7</TD></TR>
<TR><TD>6.157e-03</TD><TD>-5.09</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>1286</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>IDO2,PCDH20,LSR,GRIA2,ALX1,CDKN2A,PCDH17,EPHA3,SCGB3A2</TD></TR>
<TR><TD>6.157e-03</TD><TD>-5.09</TD><TD>plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>plasma_cell_myeloma</TD><TD>1286</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,ALX1,GRIA2,LSR,PCDH20,IDO2,SCGB3A2,EPHA3,PCDH17</TD></TR>
<TR><TD>6.253e-03</TD><TD>-5.07</TD><TD>GSE1112_OT1_CD8AB_VS_HY_CD8AA_THYMOCYTE_RTOC_CULTURE_UP</TD><TD>MSigDB lists</TD><TD>GSE1112_OT1_CD8AB_VS_HY_CD8AA_THYMOCYTE_RTOC_CULTURE_UP</TD><TD>141</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,PLEKHM3,RBM11</TD></TR>
<TR><TD>6.376e-03</TD><TD>-5.06</TD><TD>GO_CARTILAGE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CARTILAGE_DEVELOPMENT</TD><TD>142</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,SATB2,ALX1</TD></TR>
<TR><TD>6.385e-03</TD><TD>-5.05</TD><TD>TCTAGAG_MIR517</TD><TD>MSigDB lists</TD><TD>TCTAGAG_MIR517</TD><TD>45</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>FST,PAPPA</TD></TR>
<TR><TD>6.385e-03</TD><TD>-5.05</TD><TD>OSADA_ASCL1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>OSADA_ASCL1_TARGETS_UP</TD><TD>45</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,MTSS1</TD></TR>
<TR><TD>6.385e-03</TD><TD>-5.05</TD><TD>SILIGAN_BOUND_BY_EWS_FLT1_FUSION</TD><TD>MSigDB lists</TD><TD>SILIGAN_BOUND_BY_EWS_FLT1_FUSION</TD><TD>45</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,PAPPA</TD></TR>
<TR><TD>6.447e-03</TD><TD>-5.04</TD><TD>INTERLEUKIN_7_9</TD><TD>prosite domains</TD><TD>PS00255</TD><TD>2</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>IL7</TD></TR>
<TR><TD>6.460e-03</TD><TD>-5.04</TD><TD>MORF_MLLT10</TD><TD>MSigDB lists</TD><TD>MORF_MLLT10</TD><TD>280</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,GABRB2,PAX9,IL7</TD></TR>
<TR><TD>6.558e-03</TD><TD>-5.03</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>448</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,CXCL14,MTSS1,FST,NPTX2</TD></TR>
<TR><TD>6.599e-03</TD><TD>-5.02</TD><TD>integral component of plasma membrane</TD><TD>cellular component</TD><TD>GO:0005887</TD><TD>1625</TD><TD>10</TD><TD>18985</TD><TD>48</TD>
<TD>GRIA2,CLDN1,PCDH17,EDA2R,EPHA3,BMPR1B,GABRB2,PCDH20,PCDH11X,SLC6A15</TD></TR>
<TR><TD>6.627e-03</TD><TD>-5.02</TD><TD>GO_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS</TD><TD>MSigDB lists</TD><TD>GO_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS</TD><TD>144</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,DCDC2,GABRB2</TD></TR>
<TR><TD>6.679e-03</TD><TD>-5.01</TD><TD>vulva</TD><TD>COSMIC cancer mutations</TD><TD>vulva</TD><TD>46</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,PLCH1</TD></TR>
<TR><TD>6.740e-03</TD><TD>-5.00</TD><TD>sensory perception of sound</TD><TD>biological process</TD><TD>GO:0007605</TD><TD>145</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>GABRB2,EYA4,DCDC2</TD></TR>
<TR><TD>6.796e-03</TD><TD>-4.99</TD><TD>lung-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-adenocarcinoma</TD><TD>15483</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>CLDN1,PCDH11X,CRB1,SCGB3A2,SPAG6,GABRB2,GALNT13,CDKN2A,ALX1,LSR,RBM11,SATB2,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20,MTSS1,AZGP1,EDA2R,CPEB2,PLAG1,PAPPA,ENPP5,KYNU,STAC,CXCL14,FST,IL7,SLC6A15,PLEKHM3,PEX5L,DCDC2,BMPR1B,GPC5,EPHA3,NPTX2,GRIA2,PLCH1,MEIS2,RNF128,SAA2,PAX9,IDO2,ZIC1</TD></TR>
<TR><TD>6.811e-03</TD><TD>-4.99</TD><TD>CEACAM21 (carcinoembryonic antigen related cell adhesion molecule 21)</TD><TD>protein interactions</TD><TD>90273</TD><TD>46</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20,EPHA3</TD></TR>
<TR><TD>6.883e-03</TD><TD>-4.98</TD><TD>GO_HOMOPHILIC_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>MSigDB lists</TD><TD>GO_HOMOPHILIC_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>146</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>6.933e-03</TD><TD>-4.97</TD><TD>regulation of extrinsic apoptotic signaling pathway in absence of ligand</TD><TD>biological process</TD><TD>GO:2001239</TD><TD>47</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>6.943e-03</TD><TD>-4.97</TD><TD>RTAAACA_FREAC2_01</TD><TD>MSigDB lists</TD><TD>RTAAACA_FREAC2_01</TD><TD>853</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PAPPA,ZFHX4,RNF128,FST,SATB2,CRB1</TD></TR>
<TR><TD>6.949e-03</TD><TD>-4.97</TD><TD>YAMASHITA_LIVER_CANCER_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>YAMASHITA_LIVER_CANCER_STEM_CELL_UP</TD><TD>47</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,CLDN1</TD></TR>
<TR><TD>7.002e-03</TD><TD>-4.96</TD><TD>superpathway of tryptophan utilization</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-401</TD><TD>32</TD><TD>2</TD><TD>902</TD><TD>4</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>7.104e-03</TD><TD>-4.95</TD><TD>negative regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010558</TD><TD>1562</TD><TD>10</TD><TD>18054</TD><TD>48</TD>
<TD>FST,ZFHX4,PAX9,MEIS2,HEY1,SATB2,RNF128,CPEB2,ALX1,CDKN2A</TD></TR>
<TR><TD>7.198e-03</TD><TD>-4.93</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>6151</TD><TD>25</TD><TD>17255</TD><TD>46</TD>
<TD>CLDN1,MTSS1,PCDH11X,ENPP5,SPAG6,PAPPA,GABRB2,GALNT13,CDKN2A,KYNU,PEX5L,PLEKHM3,ZIC4,DCDC2,SATB2,GPC5,EPHA3,PCDH17,PLCH1,GRIA2,EYA4,NPTX2,ZIC1,RNF128,PAX9</TD></TR>
<TR><TD>7.206e-03</TD><TD>-4.93</TD><TD>skin-upper_leg-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-malignant_melanoma</TD><TD>858</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,STAC,CDKN2A,GABRB2,PEX5L,EPHA3,PCDH20</TD></TR>
<TR><TD>7.213e-03</TD><TD>-4.93</TD><TD>stomach-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-adenocarcinoma</TD><TD>15503</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>RNF128,MEIS2,PAX9,SAA2,IDO2,ZIC1,NPTX2,GRIA2,PLCH1,BMPR1B,EPHA3,GPC5,DCDC2,SLC6A15,PLEKHM3,PEX5L,KYNU,CXCL14,STAC,FST,IL7,PLAG1,PAPPA,ENPP5,MTSS1,AZGP1,EDA2R,CPEB2,PCDH20,ZFHX4,EYA4,HEY1,PCDH17,RBM11,SATB2,ZIC4,GALNT13,CDKN2A,GABRB2,ALX1,LSR,SPAG6,CLDN1,CRB1,SCGB3A2,PCDH11X</TD></TR>
<TR><TD>7.232e-03</TD><TD>-4.93</TD><TD>transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>transitional_cell_carcinoma</TD><TD>6153</TD><TD>25</TD><TD>17255</TD><TD>46</TD>
<TD>CLDN1,MTSS1,PCDH11X,PAPPA,ENPP5,SPAG6,GALNT13,GABRB2,CDKN2A,KYNU,PLEKHM3,PEX5L,SATB2,ZIC4,DCDC2,EPHA3,GPC5,PCDH17,NPTX2,PLCH1,GRIA2,EYA4,RNF128,PAX9,ZIC1</TD></TR>
<TR><TD>7.238e-03</TD><TD>-4.93</TD><TD>MCDOWELL_ACUTE_LUNG_INJURY_DN</TD><TD>MSigDB lists</TD><TD>MCDOWELL_ACUTE_LUNG_INJURY_DN</TD><TD>48</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SCGB3A2,HEY1</TD></TR>
<TR><TD>7.279e-03</TD><TD>-4.92</TD><TD>GSE9988_LPS_VS_LOW_LPS_MONOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE9988_LPS_VS_LOW_LPS_MONOCYTE_DN</TD><TD>149</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,CRB1,EPHA3</TD></TR>
<TR><TD>7.317e-03</TD><TD>-4.92</TD><TD>human chr3p11.1</TD><TD>chromosome location</TD><TD>human chr3p11.1</TD><TD>4</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>7.414e-03</TD><TD>-4.90</TD><TD>GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN</TD><TD>MSigDB lists</TD><TD>GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN</TD><TD>150</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,RBM11,MEIS2</TD></TR>
<TR><TD>7.420e-03</TD><TD>-4.90</TD><TD>CADHERIN</TD><TD>prints domains</TD><TD>PR00205</TD><TD>113</TD><TD>3</TD><TD>4648</TD><TD>17</TD>
<TD>PCDH20,PCDH17,PCDH11X</TD></TR>
<TR><TD>7.436e-03</TD><TD>-4.90</TD><TD>hydrolase activity, acting on acid carbon-carbon bonds</TD><TD>molecular function</TD><TD>GO:0016822</TD><TD>3</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.436e-03</TD><TD>-4.90</TD><TD>hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances</TD><TD>molecular function</TD><TD>GO:0016823</TD><TD>3</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.436e-03</TD><TD>-4.90</TD><TD>tryptophan 2,3-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0004833</TD><TD>3</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>IDO2</TD></TR>
<TR><TD>7.469e-03</TD><TD>-4.90</TD><TD>pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pulmonary_blastoma</TD><TD>654</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH20,SLC6A15,BMPR1B,SATB2,ZFHX4,STAC</TD></TR>
<TR><TD>7.469e-03</TD><TD>-4.90</TD><TD>pleura-pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pleura-pulmonary_blastoma</TD><TD>654</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>STAC,SATB2,ZFHX4,SLC6A15,PCDH20,BMPR1B</TD></TR>
<TR><TD>7.517e-03</TD><TD>-4.89</TD><TD>oxidoreduction coenzyme metabolic process</TD><TD>biological process</TD><TD>GO:0006733</TD><TD>49</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>7.534e-03</TD><TD>-4.89</TD><TD>GO_PROTEIN_TRANSMEMBRANE_TRANSPORT</TD><TD>MSigDB lists</TD><TD>GO_PROTEIN_TRANSMEMBRANE_TRANSPORT</TD><TD>49</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,PEX5L</TD></TR>
<TR><TD>7.550e-03</TD><TD>-4.89</TD><TD>SNF5_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>SNF5_DN.V1_DN</TD><TD>151</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,CDKN2A,RNF128</TD></TR>
<TR><TD>7.566e-03</TD><TD>-4.88</TD><TD>senescence-associated heterochromatin focus</TD><TD>cellular component</TD><TD>GO:0035985</TD><TD>3</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.715e-03</TD><TD>-4.86</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>MSigDB lists</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>466</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,EDA2R,SLC6A15,PAPPA,GALNT13</TD></TR>
<TR><TD>7.716e-03</TD><TD>-4.86</TD><TD>GABAAb_rcpt</TD><TD>interpro domains</TD><TD>IPR002289</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>7.716e-03</TD><TD>-4.86</TD><TD>STAC1/2/3</TD><TD>interpro domains</TD><TD>IPR039688</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>STAC</TD></TR>
<TR><TD>7.716e-03</TD><TD>-4.86</TD><TD>LISCH7</TD><TD>interpro domains</TD><TD>IPR008664</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>7.716e-03</TD><TD>-4.86</TD><TD>Trp/Indoleamine_2_3_dOase-like</TD><TD>interpro domains</TD><TD>IPR037217</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>IDO2</TD></TR>
<TR><TD>7.716e-03</TD><TD>-4.86</TD><TD>Myxo_disulph_rpt</TD><TD>interpro domains</TD><TD>IPR011936</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>7.834e-03</TD><TD>-4.85</TD><TD>chr8q21</TD><TD>MSigDB lists</TD><TD>chr8q21</TD><TD>50</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,ZFHX4</TD></TR>
<TR><TD>7.852e-03</TD><TD>-4.85</TD><TD>upper_aerodigestive_tract-tonsil-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-tonsil-carcinoma-squamous_cell_carcinoma</TD><TD>50</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,KYNU</TD></TR>
<TR><TD>7.917e-03</TD><TD>-4.84</TD><TD>LSR</TD><TD>pfam domains</TD><TD>PF05624</TD><TD>3</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>LSR</TD></TR>
<TR><TD>7.931e-03</TD><TD>-4.84</TD><TD>negative regulation of cellular process</TD><TD>biological process</TD><TD>GO:0048523</TD><TD>4821</TD><TD>21</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1,ZFHX4,PAX9,PCDH11X,CDKN2A,PCDH17,EPHA3,BMPR1B,CPEB2,IL7,GABRB2,RNF128,MEIS2,EYA4,FST,PLCH1,CXCL14,ALX1,AZGP1,MTSS1,SATB2</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>positive regulation of macrophage apoptotic process</TD><TD>biological process</TD><TD>GO:2000111</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>establishment of blood-nerve barrier</TD><TD>biological process</TD><TD>GO:0008065</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>leucine transport</TD><TD>biological process</TD><TD>GO:0015820</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>fasciculation of sensory neuron axon</TD><TD>biological process</TD><TD>GO:0097155</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>ovarian cumulus expansion</TD><TD>biological process</TD><TD>GO:0001550</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>anthranilate metabolic process</TD><TD>biological process</TD><TD>GO:0043420</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>quinolinate biosynthetic process</TD><TD>biological process</TD><TD>GO:0019805</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>negative regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation</TD><TD>biological process</TD><TD>GO:2000820</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>L-kynurenine catabolic process</TD><TD>biological process</TD><TD>GO:0097053</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>fused antrum stage</TD><TD>biological process</TD><TD>GO:0048165</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>7.955e-03</TD><TD>-4.83</TD><TD>senescence-associated heterochromatin focus assembly</TD><TD>biological process</TD><TD>GO:0035986</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.966e-03</TD><TD>-4.83</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>663</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>EYA4,STAC,PCDH11X,EPHA3,SPAG6,MEIS2</TD></TR>
<TR><TD>7.968e-03</TD><TD>-4.83</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_UP</TD><TD>154</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,ZFHX4,PAPPA</TD></TR>
<TR><TD>7.968e-03</TD><TD>-4.83</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_4H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_4H_ACT_CD4_TCELL_DN</TD><TD>154</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,GRIA2,GPC5</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>telangiectatic</TD><TD>COSMIC cancer mutations</TD><TD>telangiectatic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>central_nervous_system-tectum-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-tectum-glioma-astrocytoma_Grade_I</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>liver-other-normal</TD><TD>COSMIC cancer mutations</TD><TD>liver-other-normal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-back-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-dysplastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-upper_leg-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-benign_melanocytic_nevus-dysplastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-buttock-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-buttock-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-breast-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-breast-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-clavicle-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-clavicle-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-abdomen-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-abdomen-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-back-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>central_nervous_system-frontotemporal-glioma-gliosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-glioma-gliosarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>vulva-in_situ_neoplasm-vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>vulva-in_situ_neoplasm-vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-breast-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-breast-benign_melanocytic_nevus-intradermal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-buttock-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-buttock-benign_melanocytic_nevus-dysplastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>central_nervous_system-frontotemporal-glioma-oligodendroglioma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-glioma-oligodendroglioma_Grade_III</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-lower_extremity-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_extremity-malignant_melanoma-superficial_spreading</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-tibia-osteosarcoma-fibroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma-fibroblastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>upper_aerodigestive_tract-larynx-other-papilloma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-other-papilloma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-upper_leg-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-forearm-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-forearm-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-ischium-osteosarcoma-chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-ischium-osteosarcoma-chondroblastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-back-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-elbow-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-elbow-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>thymus-thymoma-epithelial_predominant</TD><TD>COSMIC cancer mutations</TD><TD>thymus-thymoma-epithelial_predominant</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-osteosarcoma-mixed</TD><TD>COSMIC cancer mutations</TD><TD>bone-osteosarcoma-mixed</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>soft_tissue-nerve_sheath-malignant_peripheral_nerve_sheath_tumour-with_rhabdomyosarcomatous_differentiation</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-nerve_sheath-malignant_peripheral_nerve_sheath_tumour-with_rhabdomyosarcomatous_differentiation</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-buttock-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-buttock-benign_melanocytic_nevus-intradermal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-leg-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>genital_tract-extragonadal-germ_cell_tumour-choriocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>genital_tract-extragonadal-germ_cell_tumour-choriocarcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>salivary_gland-mandible-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-mandible-carcinoma-mucoepidermoid_carcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-flank-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-flank-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-pelvis-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-pelvis-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-genital-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-genital-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-acral-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-acral-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>central_nervous_system-supratentorial-glioma-ependymoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-supratentorial-glioma-ependymoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>salivary_gland-parotid-carcinoma-salivary_duct_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-carcinoma-salivary_duct_carcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_I</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>with_rhabdomyosarcomatous_differentiation</TD><TD>COSMIC cancer mutations</TD><TD>with_rhabdomyosarcomatous_differentiation</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>epithelial_predominant</TD><TD>COSMIC cancer mutations</TD><TD>epithelial_predominant</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-shoulder-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-shoulder-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-humerus-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-femur-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>bone-tibia-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-sun_exposed_site-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-sun_exposed_site-carcinoma-squamous_cell_carcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-upper_extremity-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_extremity-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>skin-sun_exposed_site-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>skin-sun_exposed_site-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>7.977e-03</TD><TD>-4.83</TD><TD>parosteal</TD><TD>COSMIC cancer mutations</TD><TD>parosteal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.006e-03</TD><TD>-4.83</TD><TD>CEBPE (CCAAT enhancer binding protein epsilon)</TD><TD>protein interactions</TD><TD>1053</TD><TD>50</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>IL7,EDA2R</TD></TR>
<TR><TD>8.023e-03</TD><TD>-4.83</TD><TD>SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>SHH_subtype</TD><TD>664</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>EYA4,STAC,PCDH11X,SPAG6,EPHA3,MEIS2</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Fbxw5 (F-box and WD-40 domain protein 5)</TD><TD>protein interactions</TD><TD>30839</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>PLA2G4E (phospholipase A2 group IVE)</TD><TD>protein interactions</TD><TD>123745</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Chn1 (chimerin 1)</TD><TD>protein interactions</TD><TD>108699</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1)</TD><TD>protein interactions</TD><TD>27276</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>MEIS3 (Meis homeobox 3)</TD><TD>protein interactions</TD><TD>56917</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Rap2a (RAS related protein 2a)</TD><TD>protein interactions</TD><TD>76108</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Smad6 (SMAD family member 6)</TD><TD>protein interactions</TD><TD>17130</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Usp45 (ubiquitin specific petidase 45)</TD><TD>protein interactions</TD><TD>77593</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>MARCO (macrophage receptor with collagenous structure)</TD><TD>protein interactions</TD><TD>8685</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>8.056e-03</TD><TD>-4.82</TD><TD>Stk35 (serine/threonine kinase 35)</TD><TD>protein interactions</TD><TD>67333</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.093e-03</TD><TD>-4.82</TD><TD>regulation of extrinsic apoptotic signaling pathway</TD><TD>biological process</TD><TD>GO:2001236</TD><TD>155</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>IL7,BMPR1B,EYA4</TD></TR>
<TR><TD>8.107e-03</TD><TD>-4.82</TD><TD>GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT</TD><TD>1594</TD><TD>10</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,ALX1,HEY1,FST,BMPR1B,PAX9,CDKN2A,PLAG1,IL7,MEIS2</TD></TR>
<TR><TD>8.140e-03</TD><TD>-4.81</TD><TD>ROVERSI_GLIOMA_COPY_NUMBER_DN</TD><TD>MSigDB lists</TD><TD>ROVERSI_GLIOMA_COPY_NUMBER_DN</TD><TD>51</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,CDKN2A</TD></TR>
<TR><TD>8.140e-03</TD><TD>-4.81</TD><TD>MORF_ITGA2</TD><TD>MSigDB lists</TD><TD>MORF_ITGA2</TD><TD>51</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC</TD></TR>
<TR><TD>8.188e-03</TD><TD>-4.81</TD><TD>CA</TD><TD>smart domains</TD><TD>SM00112</TD><TD>113</TD><TD>3</TD><TD>9476</TD><TD>35</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>8.207e-03</TD><TD>-4.80</TD><TD>skin-trunk-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-malignant_melanoma</TD><TD>2683</TD><TD>14</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,CPEB2,MTSS1,CRB1,SPAG6,PAPPA,PLCH1,GRIA2,EYA4,CDKN2A,CXCL14,ZFHX4,MEIS2,SLC6A15</TD></TR>
<TR><TD>8.256e-03</TD><TD>-4.80</TD><TD>GGGAGGRR_MAZ_Q6</TD><TD>MSigDB lists</TD><TD>GGGAGGRR_MAZ_Q6</TD><TD>2127</TD><TD>12</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ZIC4,PAPPA,CXCL14,LSR,PCDH11X,PCDH17,PLAG1,AZGP1,PEX5L,PCDH20,DCDC2</TD></TR>
<TR><TD>8.452e-03</TD><TD>-4.77</TD><TD>CDPCR3_01</TD><TD>MSigDB lists</TD><TD>CDPCR3_01</TD><TD>52</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1</TD></TR>
<TR><TD>8.500e-03</TD><TD>-4.77</TD><TD>cell migration</TD><TD>biological process</TD><TD>GO:0016477</TD><TD>886</TD><TD>7</TD><TD>18054</TD><TD>48</TD>
<TD>SAA2,DCDC2,ALX1,EPHA3,SATB2,CXCL14,GPC5</TD></TR>
<TR><TD>8.586e-03</TD><TD>-4.76</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>304</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,CLDN1,AZGP1,PLCH1</TD></TR>
<TR><TD>8.639e-03</TD><TD>-4.75</TD><TD>upper_leg</TD><TD>COSMIC cancer mutations</TD><TD>upper_leg</TD><TD>888</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,GABRB2,STAC,PLCH1,PCDH20,EPHA3,PEX5L</TD></TR>
<TR><TD>8.708e-03</TD><TD>-4.74</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>480</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,MTSS1,FST,PCDH20,HEY1</TD></TR>
<TR><TD>8.775e-03</TD><TD>-4.74</TD><TD>GO_CELL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CELL_DEVELOPMENT</TD><TD>1361</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,SPAG6,GABRB2,CRB1,ALX1,HEY1,EPHA3,SATB2,LSR</TD></TR>
<TR><TD>8.824e-03</TD><TD>-4.73</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>481</TD><TD>5</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,EPHA3,MEIS2,CDKN2A,PCDH11X</TD></TR>
<TR><TD>8.860e-03</TD><TD>-4.73</TD><TD>TGTTTGY_HNF3_Q6</TD><TD>MSigDB lists</TD><TD>TGTTTGY_HNF3_Q6</TD><TD>679</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,PCDH11X,RBM11,MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>8.915e-03</TD><TD>-4.72</TD><TD>Antagonism of Activin by Follistatin</TD><TD>REACTOME pathways</TD><TD>R-HSA-2473224</TD><TD>4</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>FST</TD></TR>
<TR><TD>8.915e-03</TD><TD>-4.72</TD><TD>Activation of AMPA receptors</TD><TD>REACTOME pathways</TD><TD>R-HSA-399710</TD><TD>4</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GRIA2</TD></TR>
<TR><TD>8.961e-03</TD><TD>-4.71</TD><TD>HOX</TD><TD>smart domains</TD><TD>SM00389</TD><TD>224</TD><TD>4</TD><TD>9476</TD><TD>35</TD>
<TD>MEIS2,ZFHX4,SATB2,ALX1</TD></TR>
<TR><TD>8.995e-03</TD><TD>-4.71</TD><TD>GSE21063_WT_VS_NFATC1_KO_16H_ANTI_IGM_STIM_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE21063_WT_VS_NFATC1_KO_16H_ANTI_IGM_STIM_BCELL_DN</TD><TD>161</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,MTSS1,SATB2</TD></TR>
<TR><TD>9.015e-03</TD><TD>-4.71</TD><TD>bone-humerus-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-other-chondroblastoma</TD><TD>308</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,PCDH11X,KYNU,MTSS1</TD></TR>
<TR><TD>9.090e-03</TD><TD>-4.70</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>MSigDB lists</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>54</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,FST</TD></TR>
<TR><TD>9.153e-03</TD><TD>-4.69</TD><TD>negative regulation of cellular biosynthetic process</TD><TD>biological process</TD><TD>GO:0031327</TD><TD>1621</TD><TD>10</TD><TD>18054</TD><TD>48</TD>
<TD>ZFHX4,PAX9,HEY1,MEIS2,FST,ALX1,CDKN2A,RNF128,SATB2,CPEB2</TD></TR>
<TR><TD>9.418e-03</TD><TD>-4.67</TD><TD>EVI1_03</TD><TD>MSigDB lists</TD><TD>EVI1_03</TD><TD>55</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,IL7</TD></TR>
<TR><TD>9.418e-03</TD><TD>-4.67</TD><TD>WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2</TD><TD>MSigDB lists</TD><TD>WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2</TD><TD>55</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,CLDN1</TD></TR>
<TR><TD>9.418e-03</TD><TD>-4.67</TD><TD>GO_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>55</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,IL7</TD></TR>
<TR><TD>9.459e-03</TD><TD>-4.66</TD><TD>GSE22601_DOUBLE_NEGATIVE_VS_DOUBLE_POSITIVE_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE22601_DOUBLE_NEGATIVE_VS_DOUBLE_POSITIVE_THYMOCYTE_UP</TD><TD>164</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ENPP5,GRIA2,GALNT13</TD></TR>
<TR><TD>9.459e-03</TD><TD>-4.66</TD><TD>GSE45365_HEALTHY_VS_MCMV_INFECTION_CD11B_DC_IFNAR_KO_DN</TD><TD>MSigDB lists</TD><TD>GSE45365_HEALTHY_VS_MCMV_INFECTION_CD11B_DC_IFNAR_KO_DN</TD><TD>164</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,MEIS2,RBM11</TD></TR>
<TR><TD>9.459e-03</TD><TD>-4.66</TD><TD>MORF_PRKCA</TD><TD>MSigDB lists</TD><TD>MORF_PRKCA</TD><TD>164</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,GABRB2,STAC</TD></TR>
<TR><TD>9.595e-03</TD><TD>-4.65</TD><TD>sensory perception of mechanical stimulus</TD><TD>biological process</TD><TD>GO:0050954</TD><TD>165</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>GABRB2,DCDC2,EYA4</TD></TR>
<TR><TD>9.729e-03</TD><TD>-4.63</TD><TD>cellular biogenic amine metabolic process</TD><TD>biological process</TD><TD>GO:0006576</TD><TD>56</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>9.729e-03</TD><TD>-4.63</TD><TD>positive regulation of protein localization to plasma membrane</TD><TD>biological process</TD><TD>GO:1903078</TD><TD>56</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>STAC,EPHA3</TD></TR>
<TR><TD>9.750e-03</TD><TD>-4.63</TD><TD>HUTTMANN_B_CLL_POOR_SURVIVAL_DN</TD><TD>MSigDB lists</TD><TD>HUTTMANN_B_CLL_POOR_SURVIVAL_DN</TD><TD>56</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,MTSS1</TD></TR>
<TR><TD>9.750e-03</TD><TD>-4.63</TD><TD>TATCTGG_MIR488</TD><TD>MSigDB lists</TD><TD>TATCTGG_MIR488</TD><TD>56</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,SATB2</TD></TR>
<TR><TD>9.771e-03</TD><TD>-4.63</TD><TD>peripheral</TD><TD>COSMIC cancer mutations</TD><TD>peripheral</TD><TD>56</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,CDKN2A</TD></TR>
<TR><TD>9.775e-03</TD><TD>-4.63</TD><TD>MORF_BCL2L11</TD><TD>MSigDB lists</TD><TD>MORF_BCL2L11</TD><TD>166</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,PAX9,STAC</TD></TR>
<TR><TD>9.775e-03</TD><TD>-4.63</TD><TD>GSE2706_R848_VS_LPS_8H_STIM_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE2706_R848_VS_LPS_8H_STIM_DC_DN</TD><TD>166</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,IDO2,NPTX2</TD></TR>
<TR><TD>9.775e-03</TD><TD>-4.63</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>1383</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,EYA4,PEX5L,ZIC1,CRB1,PCDH11X,ZIC4,PAPPA,PCDH17</TD></TR>
<TR><TD>9.903e-03</TD><TD>-4.61</TD><TD>AMPA glutamate receptor activity</TD><TD>molecular function</TD><TD>GO:0004971</TD><TD>4</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GRIA2</TD></TR>
<TR><TD>9.914e-03</TD><TD>-4.61</TD><TD>homophilic cell adhesion via plasma membrane adhesion molecules</TD><TD>biological process</TD><TD>GO:0007156</TD><TD>167</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH20,PCDH11X,PCDH17</TD></TR>
<TR><TD>9.940e-03</TD><TD>-4.61</TD><TD>cell-cell adhesion</TD><TD>biological process</TD><TD>GO:0098609</TD><TD>496</TD><TD>5</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH11X,PCDH20,CRB1,CLDN1,PCDH17</TD></TR>
<TR><TD>9.996e-03</TD><TD>-4.61</TD><TD>breast-carcinoma-ductolobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-ductolobular_carcinoma</TD><TD>1642</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>PEX5L,PCDH20,EYA4,CDKN2A,ZFHX4,EPHA3,SPAG6,CRB1,PCDH11X,SCGB3A2</TD></TR>
<TR><TD>9.996e-03</TD><TD>-4.61</TD><TD>ductolobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ductolobular_carcinoma</TD><TD>1642</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH11X,SCGB3A2,CRB1,EPHA3,SPAG6,CDKN2A,ZFHX4,EYA4,PCDH20,PEX5L</TD></TR>
<TR><TD>1.006e-02</TD><TD>-4.60</TD><TD>transmitter-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0022824</TD><TD>61</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.006e-02</TD><TD>-4.60</TD><TD>transmitter-gated channel activity</TD><TD>molecular function</TD><TD>GO:0022835</TD><TD>61</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.007e-02</TD><TD>-4.60</TD><TD>cellular amine metabolic process</TD><TD>biological process</TD><TD>GO:0044106</TD><TD>57</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.008e-02</TD><TD>-4.60</TD><TD>tricellular tight junction</TD><TD>cellular component</TD><TD>GO:0061689</TD><TD>4</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>1.010e-02</TD><TD>-4.60</TD><TD>MORF_MAP2K7</TD><TD>MSigDB lists</TD><TD>MORF_MAP2K7</TD><TD>168</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,GABRB2,IL7</TD></TR>
<TR><TD>1.011e-02</TD><TD>-4.59</TD><TD>negative regulation of biosynthetic process</TD><TD>biological process</TD><TD>GO:0009890</TD><TD>1645</TD><TD>10</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1,MEIS2,ZFHX4,PAX9,FST,ALX1,CDKN2A,CPEB2,RNF128,SATB2</TD></TR>
<TR><TD>1.023e-02</TD><TD>-4.58</TD><TD>Endoderm Differentiation</TD><TD>WikiPathways</TD><TD>WP2853</TD><TD>145</TD><TD>3</TD><TD>5311</TD><TD>17</TD>
<TD>PAX9,PLCH1,ZFHX4</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>EYA_dom_metazoan</TD><TD>interpro domains</TD><TD>IPR042577</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>LamG-like</TD><TD>interpro domains</TD><TD>IPR006558</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>EYA_fam</TD><TD>interpro domains</TD><TD>IPR028472</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>Serum_amyloid_A</TD><TD>interpro domains</TD><TD>IPR000096</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SAA2</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>CEBP_ZZ</TD><TD>interpro domains</TD><TD>IPR032296</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>EYA_dom_sf</TD><TD>interpro domains</TD><TD>IPR038102</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>CEBP_ZZ_sf</TD><TD>interpro domains</TD><TD>IPR038446</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.027e-02</TD><TD>-4.58</TD><TD>EYA_dom</TD><TD>interpro domains</TD><TD>IPR006545</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.034e-02</TD><TD>-4.57</TD><TD>GO_RECEPTOR_COMPLEX</TD><TD>MSigDB lists</TD><TD>GO_RECEPTOR_COMPLEX</TD><TD>321</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,BMPR1B,GRIA2,GABRB2</TD></TR>
<TR><TD>1.040e-02</TD><TD>-4.57</TD><TD>cartilage development</TD><TD>biological process</TD><TD>GO:0051216</TD><TD>170</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,ALX1,BMPR1B</TD></TR>
<TR><TD>1.041e-02</TD><TD>-4.57</TD><TD>middle_lobe</TD><TD>COSMIC cancer mutations</TD><TD>middle_lobe</TD><TD>1397</TD><TD>9</TD><TD>17255</TD><TD>46</TD>
<TD>PEX5L,ZIC1,EYA4,ZFHX4,PCDH17,PAPPA,ZIC4,CRB1,PCDH11X</TD></TR>
<TR><TD>1.043e-02</TD><TD>-4.56</TD><TD>GSE36476_YOUNG_VS_OLD_DONOR_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE36476_YOUNG_VS_OLD_DONOR_MEMORY_CD4_TCELL_DN</TD><TD>170</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,FST,SPAG6</TD></TR>
<TR><TD>1.043e-02</TD><TD>-4.56</TD><TD>GSE37416_CTRL_VS_48H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>MSigDB lists</TD><TD>GSE37416_CTRL_VS_48H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>170</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,PAPPA,SATB2</TD></TR>
<TR><TD>1.045e-02</TD><TD>-4.56</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>322</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,HEY1,MEIS2,ZFHX4</TD></TR>
<TR><TD>1.052e-02</TD><TD>-4.55</TD><TD>RNA polymerase II proximal promoter sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000978</TD><TD>540</TD><TD>5</TD><TD>17306</TD><TD>43</TD>
<TD>ZFHX4,MEIS2,PLAG1,SATB2,ZIC1</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>CEBP_ZZ</TD><TD>pfam domains</TD><TD>PF16366</TD><TD>4</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>RRM_7</TD><TD>pfam domains</TD><TD>PF16367</TD><TD>4</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>SAA</TD><TD>pfam domains</TD><TD>PF00277</TD><TD>4</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>SAA2</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>GSE30971_CTRL_VS_LPS_STIM_MACROPHAGE_WBP7_KO_2H_UP</TD><TD>MSigDB lists</TD><TD>GSE30971_CTRL_VS_LPS_STIM_MACROPHAGE_WBP7_KO_2H_UP</TD><TD>171</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,EYA4,HEY1</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>microspike assembly</TD><TD>biological process</TD><TD>GO:0030035</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>positive regulation of cardiac muscle myoblast proliferation</TD><TD>biological process</TD><TD>GO:0110024</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>negative regulation of chondrocyte proliferation</TD><TD>biological process</TD><TD>GO:1902731</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>negative regulation of translational elongation</TD><TD>biological process</TD><TD>GO:0045900</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>positive regulation of bicellular tight junction assembly</TD><TD>biological process</TD><TD>GO:1903348</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>epithelial cell proliferation involved in renal tubule morphogenesis</TD><TD>biological process</TD><TD>GO:2001013</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>protein import into peroxisome matrix, docking</TD><TD>biological process</TD><TD>GO:0016560</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PEX5L</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>quinolinate metabolic process</TD><TD>biological process</TD><TD>GO:0046874</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.061e-02</TD><TD>-4.55</TD><TD>MODULE_95</TD><TD>MSigDB lists</TD><TD>MODULE_95</TD><TD>504</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,GPC5,SCGB3A2,GALNT13,CRB1</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>metacarpus</TD><TD>COSMIC cancer mutations</TD><TD>metacarpus</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-ear-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-shoulder-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-shoulder-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>central_nervous_system-other-neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-other-neoplasm</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>small_cell_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_cell_adenocarcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-ankle-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-ankle-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-neck-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-benign_melanocytic_nevus-compound</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>pituitary-adenoma-FSH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-FSH</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>FSH</TD><TD>COSMIC cancer mutations</TD><TD>FSH</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>stomach-carcinoma-small_cell_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-small_cell_adenocarcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>pancreas-carcinoma-large_cell_neuroendocrine_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-large_cell_neuroendocrine_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>amelanotic</TD><TD>COSMIC cancer mutations</TD><TD>amelanotic</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_leukaemia_not_otherwise_specified</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_leukaemia_not_otherwise_specified</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-leg-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-benign_melanocytic_nevus-compound</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-knee-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-knee-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-face-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-benign_melanocytic_nevus-dysplastic</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>bone-humerus-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-osteosarcoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>upper_aerodigestive_tract-head_neck-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-head_neck-other-dysplasia</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>vertical_growth_phase</TD><TD>COSMIC cancer mutations</TD><TD>vertical_growth_phase</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-lower_extremity-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_extremity-malignant_melanoma-nodular</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>vocal_cord</TD><TD>COSMIC cancer mutations</TD><TD>vocal_cord</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>bone-humerus-chondrosarcoma-dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-chondrosarcoma-dedifferentiated</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-back-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-flank-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-flank-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>upper_aerodigestive_tract-vocal_cord-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-vocal_cord-carcinoma-squamous_cell_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-arm-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-benign_melanocytic_nevus-compound</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-malignant_melanoma-amelanotic</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-amelanotic</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>central_nervous_system-frontotemporal-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-glioma-astrocytoma_Grade_IV</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-face-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-malignant_melanoma-superficial_spreading</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>oesophagus-other-intraepithelial_neoplasia</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-other-intraepithelial_neoplasia</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>pancreas-carcinoma-small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-small_cell_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>salivary_gland-tongue-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-tongue-carcinoma-mucoepidermoid_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>T_cell_leukaemia_not_otherwise_specified</TD><TD>COSMIC cancer mutations</TD><TD>T_cell_leukaemia_not_otherwise_specified</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-forearm-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-forearm-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>oesophagus-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-other-dysplasia</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-upper_arm-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_arm-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.54</TD><TD>skin-malignant_melanoma-vertical_growth_phase</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-vertical_growth_phase</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Rhebl1 (Ras homolog enriched in brain like 1)</TD><TD>protein interactions</TD><TD>69159</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>HLA-DOB (major histocompatibility complex, class II, DO beta)</TD><TD>protein interactions</TD><TD>3112</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit)</TD><TD>protein interactions</TD><TD>67877</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>ATP6 (ATP synthase F0 subunit 6)</TD><TD>protein interactions</TD><TD>4508</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Pick1 (protein interacting with PRKCA 1)</TD><TD>protein interactions</TD><TD>84591</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GRIA2</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6)</TD><TD>protein interactions</TD><TD>73341</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Cdk14 (cyclin-dependent kinase 14)</TD><TD>protein interactions</TD><TD>18647</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Nkiras1 (NFKB inhibitor interacting Ras-like protein 1)</TD><TD>protein interactions</TD><TD>69721</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>ZGRF1 (zinc finger GRF-type containing 1)</TD><TD>protein interactions</TD><TD>55345</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>SSX4 (SSX family member 4)</TD><TD>protein interactions</TD><TD>6759</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PAX9</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Cdk4 (cyclin-dependent kinase 4)</TD><TD>protein interactions</TD><TD>12567</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>CCDC196 (coiled-coil domain containing 196)</TD><TD>protein interactions</TD><TD>440184</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C)</TD><TD>protein interactions</TD><TD>67444</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>VEPH1 (ventricular zone expressed PH domain containing 1)</TD><TD>protein interactions</TD><TD>79674</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.073e-02</TD><TD>-4.53</TD><TD>CARF (calcium responsive transcription factor)</TD><TD>protein interactions</TD><TD>79800</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.075e-02</TD><TD>-4.53</TD><TD>protein transmembrane transport</TD><TD>biological process</TD><TD>GO:0071806</TD><TD>59</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>PEX5L,AZGP1</TD></TR>
<TR><TD>1.076e-02</TD><TD>-4.53</TD><TD>MORF_CTSB</TD><TD>MSigDB lists</TD><TD>MORF_CTSB</TD><TD>172</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,GABRB2,STAC</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>GABAARBETA</TD><TD>prints domains</TD><TD>PR01160</TD><TD>3</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>GABRB2</TD></TR>
<TR><TD>1.096e-02</TD><TD>-4.51</TD><TD>MODULE_163</TD><TD>MSigDB lists</TD><TD>MODULE_163</TD><TD>508</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,GPC5,SCGB3A2,GALNT13,BMPR1B</TD></TR>
<TR><TD>1.096e-02</TD><TD>-4.51</TD><TD>human chrXq21.31</TD><TD>chromosome location</TD><TD>human chrXq21.31</TD><TD>6</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PCDH11X</TD></TR>
<TR><TD>1.102e-02</TD><TD>-4.51</TD><TD>GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>1668</TD><TD>10</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,MEIS2,EDA2R,SATB2,BMPR1B,PAX9,CDKN2A,PLAG1,HEY1,ALX1</TD></TR>
<TR><TD>1.113e-02</TD><TD>-4.50</TD><TD>YRCCAKNNGNCGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YRCCAKNNGNCGC_UNKNOWN</TD><TD>60</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,PEX5L</TD></TR>
<TR><TD>1.114e-02</TD><TD>-4.50</TD><TD>GO_REGULATION_OF_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CELL_DIFFERENTIATION</TD><TD>1414</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,HEY1,EPHA3,CDKN2A,PLAG1,BMPR1B,IL7,CXCL14,MEIS2</TD></TR>
<TR><TD>1.122e-02</TD><TD>-4.49</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.30.40.130</TD><TD>4</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.122e-02</TD><TD>-4.49</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.40.50.12350</TD><TD>4</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.127e-02</TD><TD>-4.49</TD><TD>FREAC7_01</TD><TD>MSigDB lists</TD><TD>FREAC7_01</TD><TD>175</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,PCDH11X,PLAG1</TD></TR>
<TR><TD>1.127e-02</TD><TD>-4.49</TD><TD>GSE2585_AIRE_KO_VS_WT_CD80_LOW_MTEC_UP</TD><TD>MSigDB lists</TD><TD>GSE2585_AIRE_KO_VS_WT_CD80_LOW_MTEC_UP</TD><TD>175</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,EDA2R,SLC6A15</TD></TR>
<TR><TD>1.151e-02</TD><TD>-4.46</TD><TD>temporoparietal</TD><TD>COSMIC cancer mutations</TD><TD>temporoparietal</TD><TD>61</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>AZGP1,CDKN2A</TD></TR>
<TR><TD>1.163e-02</TD><TD>-4.45</TD><TD>GSE3982_MAST_CELL_VS_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_DC_UP</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,GABRB2,HEY1</TD></TR>
<TR><TD>1.163e-02</TD><TD>-4.45</TD><TD>MORF_IL4</TD><TD>MSigDB lists</TD><TD>MORF_IL4</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,GABRB2</TD></TR>
<TR><TD>1.163e-02</TD><TD>-4.45</TD><TD>GSE2585_CTEC_VS_THYMIC_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE2585_CTEC_VS_THYMIC_DC_UP</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,IDO2,PAX9</TD></TR>
<TR><TD>1.174e-02</TD><TD>-4.44</TD><TD>proximal promoter sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000987</TD><TD>555</TD><TD>5</TD><TD>17306</TD><TD>43</TD>
<TD>SATB2,ZIC1,PLAG1,MEIS2,ZFHX4</TD></TR>
<TR><TD>1.180e-02</TD><TD>-4.44</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_TAK1_KO_BCELL_3H_DN</TD><TD>MSigDB lists</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_TAK1_KO_BCELL_3H_DN</TD><TD>178</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SPAG6,ZIC1,LSR</TD></TR>
<TR><TD>1.180e-02</TD><TD>-4.44</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY5_POST_POLARIZATION_DN</TD><TD>MSigDB lists</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY5_POST_POLARIZATION_DN</TD><TD>178</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,CLDN1,RBM11</TD></TR>
<TR><TD>1.180e-02</TD><TD>-4.44</TD><TD>GSE29618_PRE_VS_DAY7_POST_TIV_FLU_VACCINE_MONOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE29618_PRE_VS_DAY7_POST_TIV_FLU_VACCINE_MONOCYTE_UP</TD><TD>178</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,ZIC1,RNF128</TD></TR>
<TR><TD>1.185e-02</TD><TD>-4.44</TD><TD>GO_REGULATION_OF_SMOOTHENED_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_SMOOTHENED_SIGNALING_PATHWAY</TD><TD>62</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,DCDC2</TD></TR>
<TR><TD>1.186e-02</TD><TD>-4.43</TD><TD>PE/DAG-bd</TD><TD>interpro domains</TD><TD>IPR002219</TD><TD>64</TD><TD>2</TD><TD>18616</TD><TD>48</TD>
<TD>STAC,ARHGAP45</TD></TR>
<TR><TD>1.186e-02</TD><TD>-4.43</TD><TD>Cadherin_N</TD><TD>interpro domains</TD><TD>IPR013164</TD><TD>64</TD><TD>2</TD><TD>18616</TD><TD>48</TD>
<TD>PCDH17,PCDH11X</TD></TR>
<TR><TD>1.189e-02</TD><TD>-4.43</TD><TD>GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>1429</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,MEIS2,HEY1,ALX1,FST,CPEB2,PAX9,CDKN2A,PLAG1</TD></TR>
<TR><TD>1.198e-02</TD><TD>-4.42</TD><TD>ESC_J1_UP_LATE.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_J1_UP_LATE.V1_UP</TD><TD>179</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,ENPP5,RNF128</TD></TR>
<TR><TD>1.198e-02</TD><TD>-4.42</TD><TD>GSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN</TD><TD>MSigDB lists</TD><TD>GSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN</TD><TD>179</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,AZGP1,SLC6A15</TD></TR>
<TR><TD>1.216e-02</TD><TD>-4.41</TD><TD>AAAGACA_MIR511</TD><TD>MSigDB lists</TD><TD>AAAGACA_MIR511</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,SATB2,EYA4</TD></TR>
<TR><TD>1.216e-02</TD><TD>-4.41</TD><TD>GSE32986_GMCSF_AND_CURDLAN_LOWDOSE_VS_GMCSF_AND_CURDLAN_HIGHDOSE_STIM_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE32986_GMCSF_AND_CURDLAN_LOWDOSE_VS_GMCSF_AND_CURDLAN_HIGHDOSE_STIM_DC_UP</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,PLEKHM3,EYA4</TD></TR>
<TR><TD>1.216e-02</TD><TD>-4.41</TD><TD>GSE9960_HEALTHY_VS_GRAM_NEG_SEPSIS_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE9960_HEALTHY_VS_GRAM_NEG_SEPSIS_PBMC_DN</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLEKHM3,GABRB2,IL7</TD></TR>
<TR><TD>1.219e-02</TD><TD>-4.41</TD><TD>positive regulation of protein localization to cell periphery</TD><TD>biological process</TD><TD>GO:1904377</TD><TD>63</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>STAC,EPHA3</TD></TR>
<TR><TD>1.220e-02</TD><TD>-4.41</TD><TD>ion binding</TD><TD>molecular function</TD><TD>GO:0043167</TD><TD>6160</TD><TD>23</TD><TD>17306</TD><TD>43</TD>
<TD>NPTX2,ZIC4,ZIC1,PAPPA,EYA4,PCDH11X,PLAG1,ENPP5,ZFHX4,PCDH17,PLEKHM3,BMPR1B,PCDH20,PLCH1,EPHA3,STAC,ARHGAP45,KYNU,GALNT13,FST,RNF128,CRB1,IDO2</TD></TR>
<TR><TD>1.232e-02</TD><TD>-4.40</TD><TD>CTAWWWATA_RSRFC4_Q2</TD><TD>MSigDB lists</TD><TD>CTAWWWATA_RSRFC4_Q2</TD><TD>338</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,ZIC4,STAC,PCDH11X</TD></TR>
<TR><TD>1.234e-02</TD><TD>-4.39</TD><TD>GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY7_DN</TD><TD>MSigDB lists</TD><TD>GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY7_DN</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,KYNU,FST</TD></TR>
<TR><TD>1.234e-02</TD><TD>-4.39</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_UP</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,GABRB2,HEY1</TD></TR>
<TR><TD>1.234e-02</TD><TD>-4.39</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,PEX5L,ZIC1</TD></TR>
<TR><TD>1.236e-02</TD><TD>-4.39</TD><TD>peroxisome targeting sequence binding</TD><TD>molecular function</TD><TD>GO:0000268</TD><TD>5</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>PEX5L</TD></TR>
<TR><TD>1.238e-02</TD><TD>-4.39</TD><TD>GO_DOUBLE_STRANDED_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_DOUBLE_STRANDED_DNA_BINDING</TD><TD>730</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,PAX9,MEIS2,PLAG1,ALX1,HEY1</TD></TR>
<TR><TD>1.244e-02</TD><TD>-4.39</TD><TD>Cadherin_2</TD><TD>pfam domains</TD><TD>PF08266</TD><TD>64</TD><TD>2</TD><TD>17385</TD><TD>46</TD>
<TD>PCDH17,PCDH11X</TD></TR>
<TR><TD>1.253e-02</TD><TD>-4.38</TD><TD>KONDO_PROSTATE_CANCER_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>KONDO_PROSTATE_CANCER_WITH_H3K27ME3</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,ENPP5</TD></TR>
<TR><TD>1.253e-02</TD><TD>-4.38</TD><TD>GSE3982_DC_VS_NEUTROPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_DC_VS_NEUTROPHIL_DN</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,HEY1,AZGP1</TD></TR>
<TR><TD>1.253e-02</TD><TD>-4.38</TD><TD>GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_PDC_UP</TD><TD>MSigDB lists</TD><TD>GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_PDC_UP</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EDA2R,CXCL14,ZIC4</TD></TR>
<TR><TD>1.259e-02</TD><TD>-4.37</TD><TD>GO_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION</TD><TD>64</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,EPHA3</TD></TR>
<TR><TD>1.259e-02</TD><TD>-4.37</TD><TD>GENTILE_UV_LOW_DOSE_DN</TD><TD>MSigDB lists</TD><TD>GENTILE_UV_LOW_DOSE_DN</TD><TD>64</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,SATB2</TD></TR>
<TR><TD>1.259e-02</TD><TD>-4.37</TD><TD>GO_CELLULAR_KETONE_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_KETONE_METABOLIC_PROCESS</TD><TD>64</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.271e-02</TD><TD>-4.37</TD><TD>GSE3982_NEUTROPHIL_VS_CENT_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_NEUTROPHIL_VS_CENT_MEMORY_CD4_TCELL_DN</TD><TD>183</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,MTSS1,CLDN1</TD></TR>
<TR><TD>1.275e-02</TD><TD>-4.36</TD><TD>primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>15696</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,BMPR1B,EPHA3,GPC5,NPTX2,PLCH1,GRIA2,MEIS2,RNF128,PAX9,SAA2,IDO2,ZIC1,MTSS1,AZGP1,EDA2R,CPEB2,PLAG1,PAPPA,ENPP5,KYNU,STAC,CXCL14,IL7,FST,PLEKHM3,SLC6A15,PEX5L,RBM11,SATB2,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20,CLDN1,SCGB3A2,CRB1,PCDH11X,SPAG6,GABRB2,GALNT13,CDKN2A,ALX1,LSR</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>I-BAR_dom</TD><TD>interpro domains</TD><TD>IPR013606</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>Protocadherin</TD><TD>interpro domains</TD><TD>IPR013585</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PCDH11X</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>Follistatin/Osteonectin_EGF</TD><TD>interpro domains</TD><TD>IPR015369</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>Zf-RING_9</TD><TD>interpro domains</TD><TD>IPR025258</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>Pentaxin_CS</TD><TD>interpro domains</TD><TD>IPR030476</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>NPTX2</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>Neutral_aa_SLC6</TD><TD>interpro domains</TD><TD>IPR002438</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>PKNOX/Meis_N</TD><TD>interpro domains</TD><TD>IPR032453</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>CPEB</TD><TD>interpro domains</TD><TD>IPR034819</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.285e-02</TD><TD>-4.35</TD><TD>SAA</TD><TD>prosite domains</TD><TD>PS00992</TD><TD>4</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>SAA2</TD></TR>
<TR><TD>1.290e-02</TD><TD>-4.35</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MARGINAL_ZONE_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MARGINAL_ZONE_BCELL_UP</TD><TD>184</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,RNF128,CXCL14</TD></TR>
<TR><TD>1.293e-02</TD><TD>-4.35</TD><TD>GO_CELL_CELL_SIGNALING</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_SIGNALING</TD><TD>737</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,NPTX2,CRB1,CXCL14,GABRB2,GRIA2</TD></TR>
<TR><TD>1.296e-02</TD><TD>-4.35</TD><TD>positive regulation of transcription by RNA polymerase II</TD><TD>biological process</TD><TD>GO:0045944</TD><TD>1199</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1,MEIS2,PLAG1,ZIC1,PAX9,SATB2,ALX1,BMPR1B</TD></TR>
<TR><TD>1.299e-02</TD><TD>-4.34</TD><TD>TATAAA_TATA_01</TD><TD>MSigDB lists</TD><TD>TATAAA_TATA_01</TD><TD>1200</TD><TD>8</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,BMPR1B,PLAG1,FST,MEIS2,PAPPA,STAC,SATB2</TD></TR>
<TR><TD>1.300e-02</TD><TD>-4.34</TD><TD>skin-foot-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-malignant_melanoma-acral_lentiginous</TD><TD>65</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>1.302e-02</TD><TD>-4.34</TD><TD>negative regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045892</TD><TD>1200</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,CDKN2A,SATB2,HEY1,MEIS2,ZFHX4,PAX9,FST</TD></TR>
<TR><TD>1.306e-02</TD><TD>-4.34</TD><TD>GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>1711</TD><TD>10</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,PLAG1,BMPR1B,PAX9,FST,HEY1,ALX1,ZIC1,MEIS2,SATB2</TD></TR>
<TR><TD>1.309e-02</TD><TD>-4.34</TD><TD>GSE7568_CTRL_VS_24H_TGFB_TREATED_MACROPHAGES_WITH_IL4_AND_DEXAMETHASONE_DN</TD><TD>MSigDB lists</TD><TD>GSE7568_CTRL_VS_24H_TGFB_TREATED_MACROPHAGES_WITH_IL4_AND_DEXAMETHASONE_DN</TD><TD>185</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,CLDN1,ALX1</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>zf-RING_9</TD><TD>pfam domains</TD><TD>PF13901</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>IMD</TD><TD>pfam domains</TD><TD>PF08397</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Protocadherin</TD><TD>pfam domains</TD><TD>PF08374</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PCDH11X</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Meis_PKNOX_N</TD><TD>pfam domains</TD><TD>PF16493</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>FOLN</TD><TD>pfam domains</TD><TD>PF09289</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>1.322e-02</TD><TD>-4.33</TD><TD>cellular response to lead ion</TD><TD>biological process</TD><TD>GO:0071284</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>1.322e-02</TD><TD>-4.33</TD><TD>positive regulation of protein catabolic process in the vacuole</TD><TD>biological process</TD><TD>GO:1904352</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>RNF128</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>ALONSO_METASTASIS_EMT_DN</TD><TD>MSigDB lists</TD><TD>ALONSO_METASTASIS_EMT_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>RAFFEL_VEGFA_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RAFFEL_VEGFA_TARGETS_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_DN</TD><TD>MSigDB lists</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>chr3p11</TD><TD>MSigDB lists</TD><TD>chr3p11</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_UP</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>TCGATGG_MIR213</TD><TD>MSigDB lists</TD><TD>TCGATGG_MIR213</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>JU_AGING_TERC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>JU_AGING_TERC_TARGETS_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>IL7</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-back-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-other-atypical_Spitzoid_tumour</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-foot-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-other-atypical_Spitzoid_tumour</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_II</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>complex-atypical</TD><TD>COSMIC cancer mutations</TD><TD>complex-atypical</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>bone-chondrosarcoma-peripheral</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-peripheral</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>thyroid-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thyroid-carcinoma-mucoepidermoid_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>intraepithelial_neoplasia</TD><TD>COSMIC cancer mutations</TD><TD>intraepithelial_neoplasia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>astroblastoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>astroblastoma_Grade_III</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>acetabulum</TD><TD>COSMIC cancer mutations</TD><TD>acetabulum</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>bone-humerus-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-osteosarcoma-osteoblastic</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>upper_aerodigestive_tract-mouth-other-leukoplakia-hyperplakia-erythroplakia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-other-leukoplakia-hyperplakia-erythroplakia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>large_intestine-colon-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-colon-other-dysplasia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>urinary_tract-renal_pelvis-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-renal_pelvis-carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>pineoblastoma</TD><TD>COSMIC cancer mutations</TD><TD>pineoblastoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>bone-osteosarcoma-chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-osteosarcoma-chondroblastic</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>lung-right-other-papilloma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right-other-papilloma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-frontotemporal-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-head_neck-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-other-keratoacanthoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>ependymoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>ependymoma_Grade_I</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>autonomic_ganglia-abdomen-paraganglioma-malignant</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-abdomen-paraganglioma-malignant</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>haematopoietic_and_lymphoid_tissue-mouth-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-mouth-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-trunk-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-other-keratoacanthoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_III</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>large_cell_neuroendocrine_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_cell_neuroendocrine_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>endometrium-hyperplasia-complex-atypical</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-hyperplasia-complex-atypical</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>haematopoietic_and_lymphoid_tissue-extranodal-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-extranodal-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>large_intestine-anus-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-anus-carcinoma-adenocarcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-frontoparietal-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontoparietal-glioma-astrocytoma_Grade_IV</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>cervical_intraepithelial_neoplasia_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>cervical_intraepithelial_neoplasia_Grade_II</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-trunk-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-carcinoma-squamous_cell_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-primary_effusion_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-primary_effusion_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>tectum</TD><TD>COSMIC cancer mutations</TD><TD>tectum</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>endometrium-carcinoma-mixed_serous_and_clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mixed_serous_and_clear_cell_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>cerebral_hemisphere</TD><TD>COSMIC cancer mutations</TD><TD>cerebral_hemisphere</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-ear-malignant_melanoma-spitzoid</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-malignant_melanoma-spitzoid</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>primary_effusion_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>primary_effusion_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_IV</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>mixed_serous_and_clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>mixed_serous_and_clear_cell_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-pineal_gland-primitive_neuroectodermal_tumour-medulloblastoma-pineoblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-pineal_gland-primitive_neuroectodermal_tumour-medulloblastoma-pineoblastoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>bone-extraskeletal-chondrosarcoma-mesenchymal</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-chondrosarcoma-mesenchymal</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>leukoplakia-hyperplakia-erythroplakia</TD><TD>COSMIC cancer mutations</TD><TD>leukoplakia-hyperplakia-erythroplakia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>bone-tibia-osteosarcoma-chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma-chondroblastic</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>upper_aerodigestive_tract-trachea-other-papilloma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-trachea-other-papilloma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_III</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>skin-leg-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-other-keratoacanthoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_IV</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.328e-02</TD><TD>-4.32</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MEMORY_BCELL_DAY40_DN</TD><TD>MSigDB lists</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MEMORY_BCELL_DAY40_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,ZFHX4,RBM11</TD></TR>
<TR><TD>1.328e-02</TD><TD>-4.32</TD><TD>GSE43863_DAY6_EFF_VS_DAY150_MEM_TFH_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE43863_DAY6_EFF_VS_DAY150_MEM_TFH_CD4_TCELL_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,ZIC4,GABRB2</TD></TR>
<TR><TD>1.328e-02</TD><TD>-4.32</TD><TD>GSE22611_MUTANT_NOD2_TRANSDUCED_VS_CTRL_HEK293T_STIMULATED_WITH_MDP_6H_DN</TD><TD>MSigDB lists</TD><TD>GSE22611_MUTANT_NOD2_TRANSDUCED_VS_CTRL_HEK293T_STIMULATED_WITH_MDP_6H_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,CXCL14,SATB2</TD></TR>
<TR><TD>1.328e-02</TD><TD>-4.32</TD><TD>GSE3982_MAST_CELL_VS_NEUTROPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_NEUTROPHIL_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,GRIA2,CXCL14</TD></TR>
<TR><TD>1.332e-02</TD><TD>-4.32</TD><TD>amine metabolic process</TD><TD>biological process</TD><TD>GO:0009308</TD><TD>66</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.335e-02</TD><TD>-4.32</TD><TD>LINDSTEDT_DENDRITIC_CELL_MATURATION_A</TD><TD>MSigDB lists</TD><TD>LINDSTEDT_DENDRITIC_CELL_MATURATION_A</TD><TD>66</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,KYNU</TD></TR>
<TR><TD>1.335e-02</TD><TD>-4.32</TD><TD>NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON</TD><TD>66</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,AZGP1</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>Rab38 (RAB38, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>72433</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>SASH3 (SAM and SH3 domain containing 3)</TD><TD>protein interactions</TD><TD>54440</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>GDF6 (growth differentiation factor 6)</TD><TD>protein interactions</TD><TD>392255</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>KLHL1 (kelch like family member 1)</TD><TD>protein interactions</TD><TD>57626</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>Rhobtb1 (Rho-related BTB domain containing 1)</TD><TD>protein interactions</TD><TD>69288</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>Rhoj (ras homolog family member J)</TD><TD>protein interactions</TD><TD>80837</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>Rras2 (related RAS viral (r-ras) oncogene 2)</TD><TD>protein interactions</TD><TD>66922</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>TLCD1 (TLC domain containing 1)</TD><TD>protein interactions</TD><TD>116238</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>Rab6b (RAB6B, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>270192</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>NPTXR (neuronal pentraxin receptor)</TD><TD>protein interactions</TD><TD>23467</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>NPTX2</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>ZNF774 (zinc finger protein 774)</TD><TD>protein interactions</TD><TD>342132</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>RBM11</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>Vhl (von Hippel-Lindau tumor suppressor)</TD><TD>protein interactions</TD><TD>24874</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>PBX4 (PBX homeobox 4)</TD><TD>protein interactions</TD><TD>80714</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.344e-02</TD><TD>-4.31</TD><TD>regulation of protein localization to membrane</TD><TD>biological process</TD><TD>GO:1905475</TD><TD>187</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>GPC5,EPHA3,STAC</TD></TR>
<TR><TD>1.347e-02</TD><TD>-4.31</TD><TD>CTTGTAT_MIR381</TD><TD>MSigDB lists</TD><TD>CTTGTAT_MIR381</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,MEIS2,MTSS1</TD></TR>
<TR><TD>1.347e-02</TD><TD>-4.31</TD><TD>HEN1_02</TD><TD>MSigDB lists</TD><TD>HEN1_02</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,CRB1,SPAG6</TD></TR>
<TR><TD>1.347e-02</TD><TD>-4.31</TD><TD>GO_CONNECTIVE_TISSUE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CONNECTIVE_TISSUE_DEVELOPMENT</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ALX1,BMPR1B</TD></TR>
<TR><TD>1.350e-02</TD><TD>-4.30</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>347</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>SATB2,PCDH11X,CDKN2A,GPC5</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>Tryptophan Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP0000063</TD><TD>19</TD><TD>1</TD><TD>1394</TD><TD>1</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.366e-02</TD><TD>-4.29</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_24H_BMDC_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_24H_BMDC_UP</TD><TD>188</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,SATB2,CDKN2A</TD></TR>
<TR><TD>1.377e-02</TD><TD>-4.29</TD><TD>vertebrae</TD><TD>COSMIC cancer mutations</TD><TD>vertebrae</TD><TD>67</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>1.386e-02</TD><TD>-4.28</TD><TD>GSE17721_0.5H_VS_4H_POLYIC_BMDC_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_0.5H_VS_4H_POLYIC_BMDC_UP</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,CDKN2A,ENPP5</TD></TR>
<TR><TD>1.386e-02</TD><TD>-4.28</TD><TD>MORF_IFNA1</TD><TD>MSigDB lists</TD><TD>MORF_IFNA1</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,GABRB2</TD></TR>
<TR><TD>1.386e-02</TD><TD>-4.28</TD><TD>GSE39556_UNTREATED_VS_3H_POLYIC_INJ_MOUSE_CD8A_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE39556_UNTREATED_VS_3H_POLYIC_INJ_MOUSE_CD8A_DC_UP</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,AZGP1,FST</TD></TR>
<TR><TD>1.386e-02</TD><TD>-4.28</TD><TD>GSE16385_ROSIGLITAZONE_IFNG_TNF_VS_IL4_STIM_MACROPHAGE_UP</TD><TD>MSigDB lists</TD><TD>GSE16385_ROSIGLITAZONE_IFNG_TNF_VS_IL4_STIM_MACROPHAGE_UP</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,SCGB3A2,GALNT13</TD></TR>
<TR><TD>1.392e-02</TD><TD>-4.27</TD><TD>GABA-ergic synapse</TD><TD>cellular component</TD><TD>GO:0098982</TD><TD>71</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>PCDH17,GABRB2</TD></TR>
<TR><TD>1.392e-02</TD><TD>-4.27</TD><TD>plasma membrane bounded cell projection</TD><TD>cellular component</TD><TD>GO:0120025</TD><TD>2099</TD><TD>11</TD><TD>18985</TD><TD>48</TD>
<TD>GRIA2,SPAG6,CRB1,EPHA3,MTSS1,GABRB2,CPEB2,BMPR1B,ARHGAP45,DCDC2,NPTX2</TD></TR>
<TR><TD>1.402e-02</TD><TD>-4.27</TD><TD>ZF_DAG_PE_1</TD><TD>prosite domains</TD><TD>PS00479</TD><TD>56</TD><TD>2</TD><TD>12079</TD><TD>39</TD>
<TD>STAC,ARHGAP45</TD></TR>
<TR><TD>1.402e-02</TD><TD>-4.27</TD><TD>inner ear development</TD><TD>biological process</TD><TD>GO:0048839</TD><TD>190</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>ZIC1,CXCL14,GABRB2</TD></TR>
<TR><TD>1.406e-02</TD><TD>-4.26</TD><TD>GSE27670_CTRL_VS_LMP1_TRANSDUCED_GC_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE27670_CTRL_VS_LMP1_TRANSDUCED_GC_BCELL_UP</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,LSR,CLDN1</TD></TR>
<TR><TD>1.406e-02</TD><TD>-4.26</TD><TD>GSE46606_DAY1_VS_DAY3_CD40L_IL2_IL5_STIMULATED_IRF4HIGH_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE46606_DAY1_VS_DAY3_CD40L_IL2_IL5_STIMULATED_IRF4HIGH_BCELL_UP</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EDA2R,GABRB2,MTSS1</TD></TR>
<TR><TD>1.406e-02</TD><TD>-4.26</TD><TD>GSE29164_DAY3_VS_DAY7_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DN</TD><TD>MSigDB lists</TD><TD>GSE29164_DAY3_VS_DAY7_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DN</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SPAG6,DCDC2,CRB1</TD></TR>
<TR><TD>1.406e-02</TD><TD>-4.26</TD><TD>GSE7764_IL15_TREATED_VS_CTRL_NK_CELL_24H_DN</TD><TD>MSigDB lists</TD><TD>GSE7764_IL15_TREATED_VS_CTRL_NK_CELL_24H_DN</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,CPEB2,RBM11</TD></TR>
<TR><TD>1.420e-02</TD><TD>-4.25</TD><TD>GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS</TD><TD>1733</TD><TD>10</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,EDA2R,ZIC1,MEIS2,HEY1,ALX1,CDKN2A,PLAG1,BMPR1B,PAX9</TD></TR>
<TR><TD>1.425e-02</TD><TD>-4.25</TD><TD>CEBP_C</TD><TD>MSigDB lists</TD><TD>CEBP_C</TD><TD>191</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,PLAG1</TD></TR>
<TR><TD>1.425e-02</TD><TD>-4.25</TD><TD>GSE43955_1H_VS_10H_ACT_CD4_TCELL_WITH_TGFB_IL6_DN</TD><TD>MSigDB lists</TD><TD>GSE43955_1H_VS_10H_ACT_CD4_TCELL_WITH_TGFB_IL6_DN</TD><TD>191</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,BMPR1B,CXCL14</TD></TR>
<TR><TD>1.425e-02</TD><TD>-4.25</TD><TD>GSE43955_TH0_VS_TGFB_IL6_TH17_ACT_CD4_TCELL_60H_DN</TD><TD>MSigDB lists</TD><TD>GSE43955_TH0_VS_TGFB_IL6_TH17_ACT_CD4_TCELL_60H_DN</TD><TD>191</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,ZIC4,BMPR1B</TD></TR>
<TR><TD>1.425e-02</TD><TD>-4.25</TD><TD>GSE41978_ID2_KO_VS_ID2_KO_AND_BIM_KO_KLRG1_LOW_EFFECTOR_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE41978_ID2_KO_VS_ID2_KO_AND_BIM_KO_KLRG1_LOW_EFFECTOR_CD8_TCELL_UP</TD><TD>191</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,SPAG6,PCDH20</TD></TR>
<TR><TD>1.443e-02</TD><TD>-4.24</TD><TD>negative regulation of cellular macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:2000113</TD><TD>1474</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,CDKN2A,CPEB2,SATB2,HEY1,MEIS2,ZFHX4,PAX9,FST</TD></TR>
<TR><TD>1.445e-02</TD><TD>-4.24</TD><TD>GSE17721_POLYIC_VS_CPG_1H_BMDC_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_CPG_1H_BMDC_DN</TD><TD>192</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2,CPEB2</TD></TR>
<TR><TD>1.445e-02</TD><TD>-4.24</TD><TD>GO_EAR_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_EAR_DEVELOPMENT</TD><TD>192</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,GABRB2,ZIC1</TD></TR>
<TR><TD>1.455e-02</TD><TD>-4.23</TD><TD>SERUMAMYLOID</TD><TD>prints domains</TD><TD>PR00306</TD><TD>4</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>SAA2</TD></TR>
<TR><TD>1.457e-02</TD><TD>-4.23</TD><TD>GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN</TD><TD>MSigDB lists</TD><TD>GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN</TD><TD>984</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>PLEKHM3,RNF128,PCDH17,GRIA2,CPEB2,ENPP5,HEY1</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>TGGAAA_NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>TGGAAA_NFAT_Q4_01</TD><TD>1740</TD><TD>10</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,PCDH20,FST,RNF128,SPAG6,PLAG1,SATB2,MTSS1,ZIC1,ZIC4</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>human chr13q21.1</TD><TD>chromosome location</TD><TD>human chr13q21.1</TD><TD>8</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PCDH17</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>human chr13q21.2</TD><TD>chromosome location</TD><TD>human chr13q21.2</TD><TD>8</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PCDH20</TD></TR>
<TR><TD>1.461e-02</TD><TD>-4.23</TD><TD>DODD_NASOPHARYNGEAL_CARCINOMA_UP</TD><TD>MSigDB lists</TD><TD>DODD_NASOPHARYNGEAL_CARCINOMA_UP</TD><TD>1478</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,MEIS2,EYA4,ENPP5,SPAG6,BMPR1B,PCDH20,DCDC2,HEY1</TD></TR>
<TR><TD>1.461e-02</TD><TD>-4.23</TD><TD>locomotion</TD><TD>biological process</TD><TD>GO:0040011</TD><TD>1225</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>CXCL14,DCDC2,GPC5,SATB2,EPHA3,ALX1,BMPR1B,SAA2</TD></TR>
<TR><TD>1.466e-02</TD><TD>-4.22</TD><TD>neuron differentiation</TD><TD>biological process</TD><TD>GO:0030182</TD><TD>985</TD><TD>7</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3,DCDC2,BMPR1B,CRB1,GABRB2,SATB2,NPTX2</TD></TR>
<TR><TD>1.469e-02</TD><TD>-4.22</TD><TD>DNA-binding transcription factor activity, RNA polymerase II-specific</TD><TD>molecular function</TD><TD>GO:0000981</TD><TD>1591</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>PLAG1,MEIS2,ALX1,ZFHX4,SATB2,ZIC4,ZIC1,HEY1,PAX9</TD></TR>
<TR><TD>1.469e-02</TD><TD>-4.22</TD><TD>SAA</TD><TD>smart domains</TD><TD>SM00197</TD><TD>4</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>SAA2</TD></TR>
<TR><TD>1.469e-02</TD><TD>-4.22</TD><TD>LamGL</TD><TD>smart domains</TD><TD>SM00560</TD><TD>4</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.486e-02</TD><TD>-4.21</TD><TD>MODULE_67</TD><TD>MSigDB lists</TD><TD>MODULE_67</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,EYA4,STAC</TD></TR>
<TR><TD>1.486e-02</TD><TD>-4.21</TD><TD>GSE17721_PAM3CSK4_VS_GADIQUIMOD_12H_BMDC_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_PAM3CSK4_VS_GADIQUIMOD_12H_BMDC_DN</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH20,EPHA3,GABRB2</TD></TR>
<TR><TD>1.486e-02</TD><TD>-4.21</TD><TD>GO_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,ALX1,SATB2</TD></TR>
<TR><TD>1.492e-02</TD><TD>-4.21</TD><TD>extracellular ligand-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0005230</TD><TD>75</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.510e-02</TD><TD>-4.19</TD><TD>chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastoma</TD><TD>550</TD><TD>5</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,GALNT13,KYNU,PCDH11X,GPC5</TD></TR>
<TR><TD>1.521e-02</TD><TD>-4.19</TD><TD>MORF_RAD51L3</TD><TD>MSigDB lists</TD><TD>MORF_RAD51L3</TD><TD>360</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,GABRB2,PAX9,STAC</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>196</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,FST,MEIS2</TD></TR>
<TR><TD>1.531e-02</TD><TD>-4.18</TD><TD>cellular ketone metabolic process</TD><TD>biological process</TD><TD>GO:0042180</TD><TD>71</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.534e-02</TD><TD>-4.18</TD><TD>GCAAGGA_MIR502</TD><TD>MSigDB lists</TD><TD>GCAAGGA_MIR502</TD><TD>71</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,GABRB2</TD></TR>
<TR><TD>1.534e-02</TD><TD>-4.18</TD><TD>GO_ASSOCIATIVE_LEARNING</TD><TD>MSigDB lists</TD><TD>GO_ASSOCIATIVE_LEARNING</TD><TD>71</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,MEIS2</TD></TR>
<TR><TD>1.537e-02</TD><TD>-4.18</TD><TD>Aminotrans_V_dom</TD><TD>interpro domains</TD><TD>IPR000192</TD><TD>6</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.537e-02</TD><TD>-4.18</TD><TD>Glypican_CS</TD><TD>interpro domains</TD><TD>IPR019803</TD><TD>6</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.537e-02</TD><TD>-4.18</TD><TD>Glypican</TD><TD>interpro domains</TD><TD>IPR001863</TD><TD>6</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.537e-02</TD><TD>-4.18</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-squamous_cell_carcinoma</TD><TD>71</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,PCDH17</TD></TR>
<TR><TD>1.548e-02</TD><TD>-4.17</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>197</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>DCDC2,CLDN1,CXCL14</TD></TR>
<TR><TD>1.550e-02</TD><TD>-4.17</TD><TD>localization of cell</TD><TD>biological process</TD><TD>GO:0051674</TD><TD>996</TD><TD>7</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,CXCL14,GPC5,DCDC2,SAA2,ALX1,EPHA3</TD></TR>
<TR><TD>1.550e-02</TD><TD>-4.17</TD><TD>cell motility</TD><TD>biological process</TD><TD>GO:0048870</TD><TD>996</TD><TD>7</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,CXCL14,GPC5,SAA2,DCDC2,EPHA3,ALX1</TD></TR>
<TR><TD>1.567e-02</TD><TD>-4.16</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>14500</TD><TD>44</TD><TD>17255</TD><TD>46</TD>
<TD>RBM11,SATB2,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20,SCGB3A2,CRB1,PCDH11X,SPAG6,GALNT13,GABRB2,CDKN2A,ALX1,LSR,DCDC2,BMPR1B,GPC5,EPHA3,NPTX2,PLCH1,GRIA2,MEIS2,SAA2,PAX9,IDO2,ZIC1,MTSS1,AZGP1,EDA2R,CPEB2,PLAG1,PAPPA,ENPP5,KYNU,STAC,CXCL14,IL7,FST,SLC6A15,PLEKHM3,PEX5L</TD></TR>
<TR><TD>1.575e-02</TD><TD>-4.15</TD><TD>GO_CILIARY_PLASM</TD><TD>MSigDB lists</TD><TD>GO_CILIARY_PLASM</TD><TD>72</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SPAG6,DCDC2</TD></TR>
<TR><TD>1.575e-02</TD><TD>-4.15</TD><TD>GO_CELL_CELL_JUNCTION_ASSEMBLY</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_JUNCTION_ASSEMBLY</TD><TD>72</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>1.577e-02</TD><TD>-4.15</TD><TD>Glypican</TD><TD>pfam domains</TD><TD>PF01153</TD><TD>6</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.577e-02</TD><TD>-4.15</TD><TD>Aminotran_5</TD><TD>pfam domains</TD><TD>PF00266</TD><TD>6</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.579e-02</TD><TD>-4.15</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-cortisol_producing</TD><TD>COSMIC cancer mutations</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-cortisol_producing</TD><TD>72</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>GRIA2,PCDH17</TD></TR>
<TR><TD>1.579e-02</TD><TD>-4.15</TD><TD>cortisol_producing</TD><TD>COSMIC cancer mutations</TD><TD>cortisol_producing</TD><TD>72</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>GRIA2,PCDH17</TD></TR>
<TR><TD>1.585e-02</TD><TD>-4.14</TD><TD>positive regulation of natural killer cell chemotaxis</TD><TD>biological process</TD><TD>GO:2000503</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CXCL14</TD></TR>
<TR><TD>1.585e-02</TD><TD>-4.14</TD><TD>arterial endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0060842</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.585e-02</TD><TD>-4.14</TD><TD>histone dephosphorylation</TD><TD>biological process</TD><TD>GO:0016576</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.585e-02</TD><TD>-4.14</TD><TD>branched-chain amino acid transport</TD><TD>biological process</TD><TD>GO:0015803</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.586e-02</TD><TD>-4.14</TD><TD>TGACAGNY_MEIS1_01</TD><TD>MSigDB lists</TD><TD>TGACAGNY_MEIS1_01</TD><TD>771</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,EYA4,PCDH17,MTSS1,ZFHX4,MEIS2</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>chr6p11</TD><TD>MSigDB lists</TD><TD>chr6p11</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ENPP5</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>GGCGGCA_MIR371</TD><TD>MSigDB lists</TD><TD>GGCGGCA_MIR371</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>PLASARI_TGFB1_TARGETS_1HR_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_1HR_DN</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>SEF1_C</TD><TD>MSigDB lists</TD><TD>SEF1_C</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>WEBER_METHYLATED_HCP_IN_FIBROBLAST_UP</TD><TD>MSigDB lists</TD><TD>WEBER_METHYLATED_HCP_IN_FIBROBLAST_UP</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SPAG6</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-adenoid_cystic_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastic</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-benign_melanocytic_nevus-dysplastic</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>central_nervous_system-parietal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-parietal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>pituitary-adenoma-TSH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-TSH</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>bone-chondrosarcoma-clear_cell</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-clear_cell</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>ganglioneuroma</TD><TD>COSMIC cancer mutations</TD><TD>ganglioneuroma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-trunk-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>plexiform</TD><TD>COSMIC cancer mutations</TD><TD>plexiform</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>epithelial_hyperplasia</TD><TD>COSMIC cancer mutations</TD><TD>epithelial_hyperplasia</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>skin-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>autonomic_ganglia-ganglioneuroma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-ganglioneuroma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>clavicle</TD><TD>COSMIC cancer mutations</TD><TD>clavicle</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>salivary_gland-head_neck-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-head_neck-carcinoma-adenoid_cystic_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-leg-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-other-atypical_Spitzoid_tumour</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-upper_arm-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_arm-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>psammomatous</TD><TD>COSMIC cancer mutations</TD><TD>psammomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_II</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-hand-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-hand-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>bone-fibula-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-fibula-osteosarcoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>bone-cranium-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-cranium-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_III</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>TSH</TD><TD>COSMIC cancer mutations</TD><TD>TSH</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_II</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>upper_aerodigestive_tract-mouth-other-epithelial_hyperplasia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-other-epithelial_hyperplasia</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>bone-extraskeletal-chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-chondrosarcoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>meninges-meningioma-angiomatous</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-angiomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-arm-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>spitzoid</TD><TD>COSMIC cancer mutations</TD><TD>spitzoid</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-malignant_melanoma-in_situ_melanotic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-in_situ_melanotic_neoplasm</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>angiomatous</TD><TD>COSMIC cancer mutations</TD><TD>angiomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>ischium</TD><TD>COSMIC cancer mutations</TD><TD>ischium</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>central_nervous_system-temporal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>lung-left_lower_lobe-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-left_lower_lobe-carcinoma-squamous_cell_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>central_nervous_system-frontal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-head_neck-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-malignant_melanoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>urinary_tract-ureter-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-ureter-carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-penis-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-penis-carcinoma-squamous_cell_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>meninges-meningioma-psammomatous</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-psammomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>bone-femur-chondrosarcoma-dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-chondrosarcoma-dedifferentiated</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>pituitary-adenoma-ACTH_non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-ACTH_non_functioning</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>in_situ_melanotic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>in_situ_melanotic_neoplasm</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>soft_tissue-nerve_sheath-neurofibroma-plexiform</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-nerve_sheath-neurofibroma-plexiform</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>skin-foot-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.590e-02</TD><TD>-4.14</TD><TD>MODULE_342</TD><TD>MSigDB lists</TD><TD>MODULE_342</TD><TD>199</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,CXCL14,CDKN2A</TD></TR>
<TR><TD>1.604e-02</TD><TD>-4.13</TD><TD>IMD</TD><TD>prosite domains</TD><TD>PS51338</TD><TD>5</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.604e-02</TD><TD>-4.13</TD><TD>PTX_1</TD><TD>prosite domains</TD><TD>PS00289</TD><TD>5</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>NPTX2</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>Map2k3 (mitogen-activated protein kinase kinase 3)</TD><TD>protein interactions</TD><TD>26397</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>TRMO (tRNA methyltransferase O)</TD><TD>protein interactions</TD><TD>51531</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>STAC</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>GDPD3 (glycerophosphodiester phosphodiesterase domain containing 3)</TD><TD>protein interactions</TD><TD>79153</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>Rps27a (ribosomal protein S27A)</TD><TD>protein interactions</TD><TD>78294</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>SEMA4B (semaphorin 4B)</TD><TD>protein interactions</TD><TD>10509</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>Fancl (Fanconi anemia, complementation group L)</TD><TD>protein interactions</TD><TD>67030</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>SPAG16 (sperm associated antigen 16)</TD><TD>protein interactions</TD><TD>79582</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SPAG6</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>Rhod (ras homolog family member D)</TD><TD>protein interactions</TD><TD>11854</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.605e-02</TD><TD>-4.13</TD><TD>TMA7 (translation machinery associated 7 homolog)</TD><TD>protein interactions</TD><TD>51372</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.609e-02</TD><TD>-4.13</TD><TD>PTPRD (protein tyrosine phosphatase receptor type D)</TD><TD>protein interactions</TD><TD>5789</TD><TD>72</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>MTSS1,PCDH20</TD></TR>
<TR><TD>1.611e-02</TD><TD>-4.13</TD><TD>ATATGCA_MIR448</TD><TD>MSigDB lists</TD><TD>ATATGCA_MIR448</TD><TD>200</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,CPEB2,PAPPA</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>773</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>GALNT13,ZFHX4,CRB1,PEX5L,EPHA3,GPC5</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>regulation of neurotransmitter receptor activity</TD><TD>biological process</TD><TD>GO:0099601</TD><TD>73</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>NPTX2,GRIA2</TD></TR>
<TR><TD>1.617e-02</TD><TD>-4.12</TD><TD>GO_EXTRACELLULAR_LIGAND_GATED_ION_CHANNEL_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_EXTRACELLULAR_LIGAND_GATED_ION_CHANNEL_ACTIVITY</TD><TD>73</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.639e-02</TD><TD>-4.11</TD><TD>human chr4q22.3</TD><TD>chromosome location</TD><TD>human chr4q22.3</TD><TD>9</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.639e-02</TD><TD>-4.11</TD><TD>human chrXq12</TD><TD>chromosome location</TD><TD>human chrXq12</TD><TD>9</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>EDA2R</TD></TR>
<TR><TD>1.644e-02</TD><TD>-4.11</TD><TD>AH/BAR_dom_sf</TD><TD>interpro domains</TD><TD>IPR027267</TD><TD>76</TD><TD>2</TD><TD>18616</TD><TD>48</TD>
<TD>ARHGAP45,MTSS1</TD></TR>
<TR><TD>1.648e-02</TD><TD>-4.11</TD><TD>Homeodomain</TD><TD>pfam domains</TD><TD>PF00046</TD><TD>203</TD><TD>3</TD><TD>17385</TD><TD>46</TD>
<TD>SATB2,ALX1,ZFHX4</TD></TR>
<TR><TD>1.649e-02</TD><TD>-4.11</TD><TD>ZF_DAG_PE_2</TD><TD>prosite domains</TD><TD>PS50081</TD><TD>61</TD><TD>2</TD><TD>12079</TD><TD>39</TD>
<TD>ARHGAP45,STAC</TD></TR>
<TR><TD>1.652e-02</TD><TD>-4.10</TD><TD>BMPR2 (bone morphogenetic protein receptor type 2)</TD><TD>protein interactions</TD><TD>659</TD><TD>73</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B,FST</TD></TR>
<TR><TD>1.654e-02</TD><TD>-4.10</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>202</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,GPC5,PLAG1</TD></TR>
<TR><TD>1.656e-02</TD><TD>-4.10</TD><TD>negative regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903507</TD><TD>1253</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>MEIS2,HEY1,PAX9,ZFHX4,FST,CDKN2A,ALX1,SATB2</TD></TR>
<TR><TD>1.670e-02</TD><TD>-4.09</TD><TD>negative regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902679</TD><TD>1255</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>FST,PAX9,ZFHX4,HEY1,MEIS2,SATB2,CDKN2A,ALX1</TD></TR>
<TR><TD>1.673e-02</TD><TD>-4.09</TD><TD>pancreas-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma</TD><TD>15111</TD><TD>45</TD><TD>17255</TD><TD>46</TD>
<TD>RNF128,MEIS2,PAX9,IDO2,ZIC1,NPTX2,PLCH1,GRIA2,BMPR1B,EPHA3,GPC5,DCDC2,SLC6A15,PLEKHM3,PEX5L,KYNU,STAC,CXCL14,FST,IL7,PLAG1,PAPPA,ENPP5,MTSS1,AZGP1,EDA2R,CPEB2,PCDH20,ZFHX4,EYA4,HEY1,PCDH17,RBM11,SATB2,ZIC4,GALNT13,GABRB2,CDKN2A,ALX1,LSR,SPAG6,CLDN1,PCDH11X,CRB1,SCGB3A2</TD></TR>
<TR><TD>1.681e-02</TD><TD>-4.09</TD><TD>SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP</TD><TD>MSigDB lists</TD><TD>SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP</TD><TD>371</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,PLAG1,FST,KYNU</TD></TR>
<TR><TD>1.695e-02</TD><TD>-4.08</TD><TD>C6orf141 (chromosome 6 open reading frame 141)</TD><TD>protein interactions</TD><TD>135398</TD><TD>74</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>SATB2,PLCH1</TD></TR>
<TR><TD>1.702e-02</TD><TD>-4.07</TD><TD>CTCCAAG_MIR432</TD><TD>MSigDB lists</TD><TD>CTCCAAG_MIR432</TD><TD>75</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,CPEB2</TD></TR>
<TR><TD>1.702e-02</TD><TD>-4.07</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>MSigDB lists</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>75</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,CDKN2A</TD></TR>
<TR><TD>1.708e-02</TD><TD>-4.07</TD><TD>prostate-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma</TD><TD>9161</TD><TD>32</TD><TD>17255</TD><TD>46</TD>
<TD>BMPR1B,GPC5,EPHA3,DCDC2,SAA2,MEIS2,ZIC1,NPTX2,GRIA2,PLCH1,PAPPA,PLAG1,AZGP1,MTSS1,CPEB2,SLC6A15,PLEKHM3,PEX5L,STAC,CXCL14,KYNU,HEY1,PCDH17,SATB2,ZIC4,ZFHX4,SPAG6,CRB1,PCDH11X,GABRB2,CDKN2A,GALNT13</TD></TR>
<TR><TD>1.715e-02</TD><TD>-4.07</TD><TD>NRAS (NRAS proto-oncogene, GTPase)</TD><TD>protein interactions</TD><TD>4893</TD><TD>369</TD><TD>4</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15,PCDH11X,LSR,EPHA3</TD></TR>
<TR><TD>1.717e-02</TD><TD>-4.06</TD><TD>stomach-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-adenocarcinoma</TD><TD>4170</TD><TD>18</TD><TD>17255</TD><TD>46</TD>
<TD>EPHA3,GPC5,HEY1,GRIA2,PLCH1,EYA4,ZIC1,MEIS2,PCDH20,SAA2,MTSS1,PCDH11X,SPAG6,PAPPA,LSR,GALNT13,ALX1,PLEKHM3</TD></TR>
<TR><TD>1.718e-02</TD><TD>-4.06</TD><TD>lung-carcinoma-bronchioloalveolar_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-bronchioloalveolar_adenocarcinoma</TD><TD>784</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>BMPR1B,EPHA3,SATB2,PCDH11X,CDKN2A,GALNT13</TD></TR>
<TR><TD>1.718e-02</TD><TD>-4.06</TD><TD>bronchioloalveolar_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>bronchioloalveolar_adenocarcinoma</TD><TD>784</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>GALNT13,CDKN2A,PCDH11X,SATB2,EPHA3,BMPR1B</TD></TR>
<TR><TD>1.723e-02</TD><TD>-4.06</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.20.1270.60</TD><TD>72</TD><TD>2</TD><TD>8522</TD><TD>24</TD>
<TD>ARHGAP45,MTSS1</TD></TR>
<TR><TD>1.726e-02</TD><TD>-4.06</TD><TD>transmembrane receptor protein kinase activity</TD><TD>molecular function</TD><TD>GO:0019199</TD><TD>81</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>BMPR1B,EPHA3</TD></TR>
<TR><TD>1.727e-02</TD><TD>-4.06</TD><TD>GPI-linked ephrin receptor activity</TD><TD>molecular function</TD><TD>GO:0005004</TD><TD>7</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>EPHA3</TD></TR>
<TR><TD>1.727e-02</TD><TD>-4.06</TD><TD>transforming growth factor beta receptor activity, type I</TD><TD>molecular function</TD><TD>GO:0005025</TD><TD>7</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.735e-02</TD><TD>-4.05</TD><TD>cell periphery</TD><TD>cellular component</TD><TD>GO:0071944</TD><TD>5419</TD><TD>21</TD><TD>18985</TD><TD>48</TD>
<TD>LSR,CLDN1,ENPP5,SLC6A15,PLCH1,DCDC2,ARHGAP45,GPC5,BMPR1B,EPHA3,EDA2R,CRB1,PCDH17,GRIA2,NPTX2,AZGP1,PCDH20,PCDH11X,PLEKHM3,STAC,GABRB2</TD></TR>
<TR><TD>1.741e-02</TD><TD>-4.05</TD><TD>GO_SINGLE_ORGANISM_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_SINGLE_ORGANISM_BEHAVIOR</TD><TD>375</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,PCDH17,MEIS2,NPTX2</TD></TR>
<TR><TD>1.742e-02</TD><TD>-4.05</TD><TD>AAGCAAT_MIR137</TD><TD>MSigDB lists</TD><TD>AAGCAAT_MIR137</TD><TD>206</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>DCDC2,MEIS2,RNF128</TD></TR>
<TR><TD>1.745e-02</TD><TD>-4.05</TD><TD>STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP</TD><TD>MSigDB lists</TD><TD>STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP</TD><TD>76</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,BMPR1B</TD></TR>
<TR><TD>1.757e-02</TD><TD>-4.04</TD><TD>AAGCACA_MIR218</TD><TD>MSigDB lists</TD><TD>AAGCACA_MIR218</TD><TD>376</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,SATB2,GRIA2,GALNT13</TD></TR>
<TR><TD>1.763e-02</TD><TD>-4.04</TD><TD>generation of neurons</TD><TD>biological process</TD><TD>GO:0048699</TD><TD>1524</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,EPHA3,SATB2,NPTX2,GABRB2,DCDC2,HEY1,PLAG1,CRB1</TD></TR>
<TR><TD>1.775e-02</TD><TD>-4.03</TD><TD>Release of Hh-Np from the secreting cell</TD><TD>REACTOME pathways</TD><TD>R-HSA-5362798</TD><TD>8</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.777e-02</TD><TD>-4.03</TD><TD>cell projection</TD><TD>cellular component</TD><TD>GO:0042995</TD><TD>2174</TD><TD>11</TD><TD>18985</TD><TD>48</TD>
<TD>BMPR1B,GABRB2,CPEB2,ARHGAP45,DCDC2,NPTX2,GRIA2,SPAG6,CRB1,EPHA3,MTSS1</TD></TR>
<TR><TD>1.784e-02</TD><TD>-4.03</TD><TD>regulation of smoothened signaling pathway</TD><TD>biological process</TD><TD>GO:0008589</TD><TD>77</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>DCDC2,ZIC1</TD></TR>
<TR><TD>1.791e-02</TD><TD>-4.02</TD><TD>GS_dom</TD><TD>interpro domains</TD><TD>IPR003605</TD><TD>7</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.791e-02</TD><TD>-4.02</TD><TD>CUT_dom</TD><TD>interpro domains</TD><TD>IPR003350</TD><TD>7</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.791e-02</TD><TD>-4.02</TD><TD>Notch_dom</TD><TD>interpro domains</TD><TD>IPR000800</TD><TD>7</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.797e-02</TD><TD>-4.02</TD><TD>positive regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045893</TD><TD>1529</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>ZIC1,PAX9,ZFHX4,HEY1,PLAG1,MEIS2,BMPR1B,ALX1,SATB2</TD></TR>
<TR><TD>1.816e-02</TD><TD>-4.01</TD><TD>ORPHTRNSPORT</TD><TD>prints domains</TD><TD>PR01206</TD><TD>5</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.819e-02</TD><TD>-4.01</TD><TD>human chr14q13.3</TD><TD>chromosome location</TD><TD>human chr14q13.3</TD><TD>10</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PAX9</TD></TR>
<TR><TD>1.826e-02</TD><TD>-4.00</TD><TD>Nedd4 (neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase)</TD><TD>protein interactions</TD><TD>25489</TD><TD>77</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B,STAC</TD></TR>
<TR><TD>1.828e-02</TD><TD>-4.00</TD><TD>associative learning</TD><TD>biological process</TD><TD>GO:0008306</TD><TD>78</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>MEIS2,NPTX2</TD></TR>
<TR><TD>1.832e-02</TD><TD>-4.00</TD><TD>MCAATNNNNNGCG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>MCAATNNNNNGCG_UNKNOWN</TD><TD>78</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,ZIC1</TD></TR>
<TR><TD>1.832e-02</TD><TD>-4.00</TD><TD>LEIN_MIDBRAIN_MARKERS</TD><TD>MSigDB lists</TD><TD>LEIN_MIDBRAIN_MARKERS</TD><TD>78</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GPC5,ZFHX4</TD></TR>
<TR><TD>1.834e-02</TD><TD>-4.00</TD><TD>DUF4206</TD><TD>smart domains</TD><TD>SM01175</TD><TD>5</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>DCX</TD><TD>pfam domains</TD><TD>PF03607</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>DCDC2</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>TGF_beta_GS</TD><TD>pfam domains</TD><TD>PF08515</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>CUT</TD><TD>pfam domains</TD><TD>PF02376</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.842e-02</TD><TD>-3.99</TD><TD>TGF-beta signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04350</TD><TD>84</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>BMPR1B,FST</TD></TR>
<TR><TD>1.842e-02</TD><TD>-3.99</TD><TD>TGF-beta signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04350</TD><TD>84</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>FST,BMPR1B</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>ectodermal cell differentiation</TD><TD>biological process</TD><TD>GO:0010668</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>EDA2R</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>mammalian oogenesis stage</TD><TD>biological process</TD><TD>GO:0022605</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>L-kynurenine metabolic process</TD><TD>biological process</TD><TD>GO:0097052</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>establishment of blood-brain barrier</TD><TD>biological process</TD><TD>GO:0060856</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>presynaptic active zone organization</TD><TD>biological process</TD><TD>GO:1990709</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH17</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>antral ovarian follicle growth</TD><TD>biological process</TD><TD>GO:0001547</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>regulation of cardiac muscle myoblast proliferation</TD><TD>biological process</TD><TD>GO:0110022</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>commitment of neuronal cell to specific neuron type in forebrain</TD><TD>biological process</TD><TD>GO:0021902</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>IKEDA_MIR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>IKEDA_MIR1_TARGETS_DN</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>chrxq11</TD><TD>MSigDB lists</TD><TD>chrxq11</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>EDA2R</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_9</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_9</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1</TD></TR>
<TR><TD>1.849e-02</TD><TD>-3.99</TD><TD>LUCAS_HNF4A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>LUCAS_HNF4A_TARGETS_DN</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-femur-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-osteosarcoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>stomach-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-extraskeletal-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-chordoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>mixed_serous_and_endometrioid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>mixed_serous_and_endometrioid_carcinoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>Barrett_oesophagus</TD><TD>COSMIC cancer mutations</TD><TD>Barrett_oesophagus</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>skin-face-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-malignant_melanoma-nodular</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>skin-upper_extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_extremity-malignant_melanoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>skin-lower_back-benign_melanocytic_nevus-congenital</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_back-benign_melanocytic_nevus-congenital</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-osteosarcoma-osteoblastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>endometrium-carcinoma-mixed_serous_and_endometrioid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mixed_serous_and_endometrioid_carcinoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_III</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>central_nervous_system-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-femur-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-osteosarcoma-osteoblastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>Askins_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Askins_tumour</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-scapula-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-scapula-chordoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_II</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>skin-face-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-malignant_melanoma-acral_lentiginous</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>dysplastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>pituitary-adenoma-multihormonal</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-multihormonal</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>central_nervous_system-occipital_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-occipital_lobe-glioma-astrocytoma_Grade_II</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-extraskeletal-Askins_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-Askins_tumour</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>oesophagus-other-Barrett_oesophagus</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-other-Barrett_oesophagus</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>soft_tissue-blood_vessel-haemangioblastoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-blood_vessel-haemangioblastoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>haemangioblastoma</TD><TD>COSMIC cancer mutations</TD><TD>haemangioblastoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>skin-lower_extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_extremity-malignant_melanoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>skin-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-benign_melanocytic_nevus-intradermal</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>bone-tibia-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma-osteoblastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.853e-02</TD><TD>-3.99</TD><TD>thyroid-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thyroid-carcinoma</TD><TD>4202</TD><TD>18</TD><TD>17255</TD><TD>46</TD>
<TD>LSR,KYNU,CDKN2A,SPAG6,PLAG1,AZGP1,PCDH11X,CRB1,ZIC1,RNF128,EYA4,PLCH1,GRIA2,ZFHX4,NPTX2,GPC5,DCDC2,RBM11</TD></TR>
<TR><TD>1.859e-02</TD><TD>-3.99</TD><TD>neuron development</TD><TD>biological process</TD><TD>GO:0048666</TD><TD>799</TD><TD>6</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3,DCDC2,BMPR1B,GABRB2,CRB1,NPTX2</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>TBRG1 (transforming growth factor beta regulator 1)</TD><TD>protein interactions</TD><TD>84897</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>HOXA13 (homeobox A13)</TD><TD>protein interactions</TD><TD>3209</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>TEX2 (testis expressed 2)</TD><TD>protein interactions</TD><TD>55852</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>EFNA2 (ephrin A2)</TD><TD>protein interactions</TD><TD>1943</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>FAM222A (family with sequence similarity 222 member A)</TD><TD>protein interactions</TD><TD>84915</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>B4GALNT1 (beta-1,4-N-acetyl-galactosaminyltransferase 1)</TD><TD>protein interactions</TD><TD>2583</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>BMP15 (bone morphogenetic protein 15)</TD><TD>protein interactions</TD><TD>9210</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>Fbxo3 (F-box protein 3)</TD><TD>protein interactions</TD><TD>57443</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>BMP5 (bone morphogenetic protein 5)</TD><TD>protein interactions</TD><TD>653</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>FST</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>Ikbip (IKBKB interacting protein)</TD><TD>protein interactions</TD><TD>67454</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>AZGP1</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>RGMB (repulsive guidance molecule BMP co-receptor b)</TD><TD>protein interactions</TD><TD>285704</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>Uhmk1 (U2AF homology motif (UHM) kinase 1)</TD><TD>protein interactions</TD><TD>16589</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>Smad7 (SMAD family member 7)</TD><TD>protein interactions</TD><TD>17131</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.875e-02</TD><TD>-3.98</TD><TD>GO_CELL_CELL_ADHESION</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_ADHESION</TD><TD>582</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,CLDN1,IL7,PCDH20,PCDH11X</TD></TR>
<TR><TD>1.878e-02</TD><TD>-3.97</TD><TD>CHX10_01</TD><TD>MSigDB lists</TD><TD>CHX10_01</TD><TD>212</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,ZFHX4</TD></TR>
<TR><TD>1.878e-02</TD><TD>-3.97</TD><TD>OCT1_03</TD><TD>MSigDB lists</TD><TD>OCT1_03</TD><TD>212</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,PLAG1,MEIS2</TD></TR>
<TR><TD>1.882e-02</TD><TD>-3.97</TD><TD>MORF_FOSL1</TD><TD>MSigDB lists</TD><TD>MORF_FOSL1</TD><TD>384</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,PAX9,GABRB2</TD></TR>
<TR><TD>1.906e-02</TD><TD>-3.96</TD><TD>ConA-like_dom_sf</TD><TD>interpro domains</TD><TD>IPR013320</TD><TD>220</TD><TD>3</TD><TD>18616</TD><TD>48</TD>
<TD>PAPPA,CRB1,NPTX2</TD></TR>
<TR><TD>1.922e-02</TD><TD>-3.95</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY</TD><TD>80</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,EPHA3</TD></TR>
<TR><TD>1.922e-02</TD><TD>-3.95</TD><TD>GLYPICAN</TD><TD>prosite domains</TD><TD>PS01207</TD><TD>6</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.925e-02</TD><TD>-3.95</TD><TD>FOXJ2_02</TD><TD>MSigDB lists</TD><TD>FOXJ2_02</TD><TD>214</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,NPTX2,ZFHX4</TD></TR>
<TR><TD>1.955e-02</TD><TD>-3.93</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.10.20.230</TD><TD>7</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>DCDC2</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>upper_arm</TD><TD>COSMIC cancer mutations</TD><TD>upper_arm</TD><TD>588</TD><TD>5</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH17,PLCH1,CPEB2,CDKN2A,CRB1</TD></TR>
<TR><TD>1.962e-02</TD><TD>-3.93</TD><TD>CDC6 (cell division cycle 6)</TD><TD>protein interactions</TD><TD>990</TD><TD>80</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>1.967e-02</TD><TD>-3.93</TD><TD>CTGYNNCTYTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTGYNNCTYTAA_UNKNOWN</TD><TD>81</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PEX5L</TD></TR>
<TR><TD>1.992e-02</TD><TD>-3.92</TD><TD>ear development</TD><TD>biological process</TD><TD>GO:0043583</TD><TD>217</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>ZIC1,CXCL14,GABRB2</TD></TR>
<TR><TD>2.005e-02</TD><TD>-3.91</TD><TD>9+2 non-motile cilium</TD><TD>cellular component</TD><TD>GO:0097732</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.005e-02</TD><TD>-3.91</TD><TD>kinocilium</TD><TD>cellular component</TD><TD>GO:0060091</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.005e-02</TD><TD>-3.91</TD><TD>HFE-transferrin receptor complex</TD><TD>cellular component</TD><TD>GO:1990712</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.005e-02</TD><TD>-3.91</TD><TD>postsynaptic endocytic zone</TD><TD>cellular component</TD><TD>GO:0098843</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>GRIA2</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0045446</TD><TD>82</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1,HEY1</TD></TR>
<TR><TD>2.013e-02</TD><TD>-3.91</TD><TD>CAMPS_COLON_CANCER_COPY_NUMBER_UP</TD><TD>MSigDB lists</TD><TD>CAMPS_COLON_CANCER_COPY_NUMBER_UP</TD><TD>82</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,PAX9</TD></TR>
<TR><TD>2.013e-02</TD><TD>-3.91</TD><TD>AGGCACT_MIR5153P</TD><TD>MSigDB lists</TD><TD>AGGCACT_MIR5153P</TD><TD>82</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,SLC6A15</TD></TR>
<TR><TD>2.021e-02</TD><TD>-3.90</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1</TD><TD>MSigDB lists</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1</TD><TD>218</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,FST,CLDN1</TD></TR>
<TR><TD>2.021e-02</TD><TD>-3.90</TD><TD>MZF1_01</TD><TD>MSigDB lists</TD><TD>MZF1_01</TD><TD>218</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,MEIS2,PCDH11X</TD></TR>
<TR><TD>2.034e-02</TD><TD>-3.90</TD><TD>trunk</TD><TD>COSMIC cancer mutations</TD><TD>trunk</TD><TD>3603</TD><TD>16</TD><TD>17255</TD><TD>46</TD>
<TD>MEIS2,ZFHX4,GRIA2,PLCH1,EYA4,EPHA3,DCDC2,SLC6A15,CDKN2A,CXCL14,STAC,PAPPA,SPAG6,MTSS1,CRB1,CPEB2</TD></TR>
<TR><TD>2.045e-02</TD><TD>-3.89</TD><TD>Paired_dom</TD><TD>interpro domains</TD><TD>IPR001523</TD><TD>8</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.045e-02</TD><TD>-3.89</TD><TD>Doublecortin_dom</TD><TD>interpro domains</TD><TD>IPR003533</TD><TD>8</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.045e-02</TD><TD>-3.89</TD><TD>OCT1_04</TD><TD>MSigDB lists</TD><TD>OCT1_04</TD><TD>219</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,ZIC1,NPTX2</TD></TR>
<TR><TD>2.048e-02</TD><TD>-3.89</TD><TD>MORF_MAGEA9</TD><TD>MSigDB lists</TD><TD>MORF_MAGEA9</TD><TD>394</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,PAX9,GABRB2</TD></TR>
<TR><TD>2.059e-02</TD><TD>-3.88</TD><TD>chr2q33</TD><TD>MSigDB lists</TD><TD>chr2q33</TD><TD>83</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PLEKHM3,SATB2</TD></TR>
<TR><TD>2.063e-02</TD><TD>-3.88</TD><TD>central</TD><TD>COSMIC cancer mutations</TD><TD>central</TD><TD>83</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,EPHA3</TD></TR>
<TR><TD>2.064e-02</TD><TD>-3.88</TD><TD>GO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE</TD><TD>MSigDB lists</TD><TD>GO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE</TD><TD>1566</TD><TD>9</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,GRIA2,BMPR1B,GPC5,CLDN1,EPHA3,EDA2R,PCDH11X,SLC6A15</TD></TR>
<TR><TD>2.071e-02</TD><TD>-3.88</TD><TD>DNA-binding transcription factor activity</TD><TD>molecular function</TD><TD>GO:0003700</TD><TD>1685</TD><TD>9</TD><TD>17306</TD><TD>43</TD>
<TD>MEIS2,PLAG1,ZFHX4,ALX1,SATB2,ZIC4,ZIC1,HEY1,PAX9</TD></TR>
<TR><TD>2.081e-02</TD><TD>-3.87</TD><TD>soft_tissue</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue</TD><TD>5935</TD><TD>23</TD><TD>17255</TD><TD>46</TD>
<TD>KYNU,GABRB2,GALNT13,CDKN2A,LSR,PEX5L,CRB1,PCDH11X,MTSS1,CLDN1,EDA2R,PAPPA,ZFHX4,EYA4,PLCH1,PCDH20,MEIS2,ZIC1,SATB2,DCDC2,PCDH17,EPHA3,GPC5</TD></TR>
<TR><TD>2.082e-02</TD><TD>-3.87</TD><TD>OTUB1 (OTU deubiquitinase, ubiquitin aldehyde binding 1)</TD><TD>protein interactions</TD><TD>55611</TD><TD>218</TD><TD>3</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B,CPEB2,RNF128</TD></TR>
<TR><TD>2.094e-02</TD><TD>-3.87</TD><TD>DELYS_THYROID_CANCER_DN</TD><TD>MSigDB lists</TD><TD>DELYS_THYROID_CANCER_DN</TD><TD>221</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,PLCH1,EPHA3</TD></TR>
<TR><TD>2.098e-02</TD><TD>-3.86</TD><TD>PAX</TD><TD>pfam domains</TD><TD>PF00292</TD><TD>8</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.106e-02</TD><TD>-3.86</TD><TD>GO_PALATE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_PALATE_DEVELOPMENT</TD><TD>84</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>2.106e-02</TD><TD>-3.86</TD><TD>KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION</TD><TD>MSigDB lists</TD><TD>KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION</TD><TD>84</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ENPP5,PAPPA</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>cellular response to histamine</TD><TD>biological process</TD><TD>GO:0071420</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>glomerulus morphogenesis</TD><TD>biological process</TD><TD>GO:0072102</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>positive regulation of myeloid cell apoptotic process</TD><TD>biological process</TD><TD>GO:0033034</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>blood vessel endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0060837</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>negative regulation of cytoplasmic translation</TD><TD>biological process</TD><TD>GO:2000766</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>protein O-linked glycosylation via threonine</TD><TD>biological process</TD><TD>GO:0018243</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>dorsal aorta morphogenesis</TD><TD>biological process</TD><TD>GO:0035912</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>hyperosmotic salinity response</TD><TD>biological process</TD><TD>GO:0042538</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.108e-02</TD><TD>-3.86</TD><TD>atrioventricular valve formation</TD><TD>biological process</TD><TD>GO:0003190</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.110e-02</TD><TD>-3.86</TD><TD>sinonasal_and_nasal_cavity</TD><TD>COSMIC cancer mutations</TD><TD>sinonasal_and_nasal_cavity</TD><TD>84</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH17,CDKN2A</TD></TR>
<TR><TD>2.111e-02</TD><TD>-3.86</TD><TD>CGCAAAA_MIR450</TD><TD>MSigDB lists</TD><TD>CGCAAAA_MIR450</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>2.111e-02</TD><TD>-3.86</TD><TD>PHONG_TNF_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_TARGETS_DN</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.111e-02</TD><TD>-3.86</TD><TD>OHM_EMBRYONIC_CARCINOMA_DN</TD><TD>MSigDB lists</TD><TD>OHM_EMBRYONIC_CARCINOMA_DN</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.111e-02</TD><TD>-3.86</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX6_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX6_UP</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.111e-02</TD><TD>-3.86</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_UP</TD><TD>MSigDB lists</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_UP</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>central_neurocytoma</TD><TD>COSMIC cancer mutations</TD><TD>central_neurocytoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>eye-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>eye-malignant_melanoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>junctional</TD><TD>COSMIC cancer mutations</TD><TD>junctional</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>cranium</TD><TD>COSMIC cancer mutations</TD><TD>cranium</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>skin-neck-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma-superficial_spreading</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>salivary_gland-retromolar-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-retromolar-carcinoma-adenoid_cystic_carcinoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>bone-coccyx-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-coccyx-chordoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>lichen_sclerosus</TD><TD>COSMIC cancer mutations</TD><TD>lichen_sclerosus</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>central_nervous_system-brain-other-central_neurocytoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-other-central_neurocytoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>skin-neck-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma-nodular</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_III</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>endometrium-carcinoma-mucinous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mucinous_carcinoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>vulva-other-lichen_sclerosus</TD><TD>COSMIC cancer mutations</TD><TD>vulva-other-lichen_sclerosus</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>ovary-germ_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>salivary_gland-parotid-adenoma-pleomorphic</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-adenoma-pleomorphic</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>multihormonal</TD><TD>COSMIC cancer mutations</TD><TD>multihormonal</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>bone-tibia-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>meninges-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>meninges-malignant_melanoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>bone-skull-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-skull-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>actinic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>actinic_keratosis</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>salivary_gland-parotid-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-carcinoma-mucoepidermoid_carcinoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>cervical_intraepithelial_neoplasia_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>cervical_intraepithelial_neoplasia_Grade_I</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>testis-germ_cell_tumour-yolk_sac_tumour</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-yolk_sac_tumour</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>central_nervous_system-basal_ganglia-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-basal_ganglia-glioma-astrocytoma_Grade_IV</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_II</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.113e-02</TD><TD>-3.86</TD><TD>autonomic_ganglia-abdomen-paraganglioma-benign</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-abdomen-paraganglioma-benign</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.114e-02</TD><TD>-3.86</TD><TD>connective tissue development</TD><TD>biological process</TD><TD>GO:0061448</TD><TD>222</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,BMPR1B,ALX1</TD></TR>
<TR><TD>2.119e-02</TD><TD>-3.85</TD><TD>MZF1_02</TD><TD>MSigDB lists</TD><TD>MZF1_02</TD><TD>222</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,CXCL14,PLAG1</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>KLF12 (Kruppel like factor 12)</TD><TD>protein interactions</TD><TD>11278</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>IDO2</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>Rasd2 (RASD family, member 2)</TD><TD>protein interactions</TD><TD>75141</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>GRIP2 (glutamate receptor interacting protein 2)</TD><TD>protein interactions</TD><TD>80852</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GRIA2</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>ARHGEF25 (Rho guanine nucleotide exchange factor 25)</TD><TD>protein interactions</TD><TD>115557</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>USP26 (ubiquitin specific peptidase 26)</TD><TD>protein interactions</TD><TD>83844</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>LRRC3 (leucine rich repeat containing 3)</TD><TD>protein interactions</TD><TD>81543</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>Faap100 (Fanconi anemia core complex associated protein 100)</TD><TD>protein interactions</TD><TD>71885</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>ZNF580 (zinc finger protein 580)</TD><TD>protein interactions</TD><TD>51157</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>NFKB_Q6_01</TD><TD>MSigDB lists</TD><TD>NFKB_Q6_01</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,ZIC4,IL7</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>CHOP_01</TD><TD>MSigDB lists</TD><TD>CHOP_01</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,PCDH17,STAC</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>SOX9_B1</TD><TD>MSigDB lists</TD><TD>SOX9_B1</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,ZIC1,ZIC4</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>RSRFC4_01</TD><TD>MSigDB lists</TD><TD>RSRFC4_01</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,PCDH11X,STAC</TD></TR>
<TR><TD>2.150e-02</TD><TD>-3.84</TD><TD>PIAS2 (protein inhibitor of activated STAT 2)</TD><TD>protein interactions</TD><TD>9063</TD><TD>84</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>PLAG1,CDKN2A</TD></TR>
<TR><TD>2.153e-02</TD><TD>-3.84</TD><TD>KEGG_TGF_BETA_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_TGF_BETA_SIGNALING_PATHWAY</TD><TD>85</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,FST</TD></TR>
<TR><TD>2.153e-02</TD><TD>-3.84</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN</TD><TD>85</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,GALNT13</TD></TR>
<TR><TD>2.168e-02</TD><TD>-3.83</TD><TD>GO_EMBRYONIC_ORGAN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_ORGAN_DEVELOPMENT</TD><TD>401</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,HEY1,ALX1,SATB2</TD></TR>
<TR><TD>2.169e-02</TD><TD>-3.83</TD><TD>POU1F1_Q6</TD><TD>MSigDB lists</TD><TD>POU1F1_Q6</TD><TD>224</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>2.176e-02</TD><TD>-3.83</TD><TD>ACTIVIN2R</TD><TD>prints domains</TD><TD>PR00653</TD><TD>6</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.179e-02</TD><TD>-3.83</TD><TD>human chr10p12.2</TD><TD>chromosome location</TD><TD>human chr10p12.2</TD><TD>12</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>SPAG6</TD></TR>
<TR><TD>2.186e-02</TD><TD>-3.82</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN</TD><TD>402</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L,PCDH20,GABRB2,PAPPA</TD></TR>
<TR><TD>2.194e-02</TD><TD>-3.82</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_PROXIMAL_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_PROXIMAL_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>225</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ZIC1,PLAG1</TD></TR>
<TR><TD>2.194e-02</TD><TD>-3.82</TD><TD>CTTTGCA_MIR527</TD><TD>MSigDB lists</TD><TD>CTTTGCA_MIR527</TD><TD>225</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ENPP5,ZIC1</TD></TR>
<TR><TD>2.203e-02</TD><TD>-3.82</TD><TD>L-tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde</TD><TD>BIOCYC pathways</TD><TD>META_PWY-5651</TD><TD>5</TD><TD>1</TD><TD>902</TD><TD>4</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.215e-02</TD><TD>-3.81</TD><TD>tumor necrosis factor-activated receptor activity</TD><TD>molecular function</TD><TD>GO:0005031</TD><TD>9</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.224e-02</TD><TD>-3.81</TD><TD>positive regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045935</TD><TD>1857</TD><TD>10</TD><TD>18054</TD><TD>48</TD>
<TD>ZFHX4,EYA4,ZIC1,PAX9,MEIS2,PLAG1,HEY1,SATB2,BMPR1B,ALX1</TD></TR>
<TR><TD>2.239e-02</TD><TD>-3.80</TD><TD>CUT</TD><TD>prosite domains</TD><TD>PS51042</TD><TD>7</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>SATB2</TD></TR>
<TR><TD>2.239e-02</TD><TD>-3.80</TD><TD>GS</TD><TD>prosite domains</TD><TD>PS51256</TD><TD>7</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.245e-02</TD><TD>-3.80</TD><TD>NKX62_Q2</TD><TD>MSigDB lists</TD><TD>NKX62_Q2</TD><TD>227</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,PLAG1</TD></TR>
<TR><TD>2.245e-02</TD><TD>-3.80</TD><TD>FOXO1_02</TD><TD>MSigDB lists</TD><TD>FOXO1_02</TD><TD>227</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,MEIS2,SATB2</TD></TR>
<TR><TD>2.248e-02</TD><TD>-3.79</TD><TD>C1</TD><TD>smart domains</TD><TD>SM00109</TD><TD>63</TD><TD>2</TD><TD>9476</TD><TD>35</TD>
<TD>ARHGAP45,STAC</TD></TR>
<TR><TD>2.292e-02</TD><TD>-3.78</TD><TD>regulation of cell junction assembly</TD><TD>biological process</TD><TD>GO:1901888</TD><TD>88</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3,CLDN1</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>MIKKELSEN_MCV6_HCP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_MCV6_HCP_WITH_H3K27ME3</TD><TD>408</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,ZIC1,CXCL14,NPTX2</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>GO_REGULATION_OF_CELL_MATRIX_ADHESION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CELL_MATRIX_ADHESION</TD><TD>88</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,EPHA3</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>CEBPA_01</TD><TD>MSigDB lists</TD><TD>CEBPA_01</TD><TD>229</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,FST,MEIS2</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>NFAT_Q6</TD><TD>MSigDB lists</TD><TD>NFAT_Q6</TD><TD>229</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,ZIC4,ZIC1</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>MHC_I_a_a1/a2</TD><TD>interpro domains</TD><TD>IPR001039</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>AZGP1</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>Doublecortin_dom_sf</TD><TD>interpro domains</TD><TD>IPR036572</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>TB_dom</TD><TD>interpro domains</TD><TD>IPR017878</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>Fol_N</TD><TD>interpro domains</TD><TD>IPR003645</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>Activin_recp</TD><TD>interpro domains</TD><TD>IPR000472</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.297e-02</TD><TD>-3.77</TD><TD>Secretoglobin</TD><TD>interpro domains</TD><TD>IPR016126</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>2.312e-02</TD><TD>-3.77</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP</TD><TD>409</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PLCH1,LSR,AZGP1,ENPP5</TD></TR>
<TR><TD>2.322e-02</TD><TD>-3.76</TD><TD>GO_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS</TD><TD>1081</TD><TD>7</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,PLAG1,BMPR1B,FST,IL7,ALX1,EPHA3</TD></TR>
<TR><TD>2.323e-02</TD><TD>-3.76</TD><TD>HNF1_01</TD><TD>MSigDB lists</TD><TD>HNF1_01</TD><TD>230</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,EPHA3,ZFHX4</TD></TR>
<TR><TD>2.327e-02</TD><TD>-3.76</TD><TD>negative regulation of transcription by RNA polymerase II</TD><TD>biological process</TD><TD>GO:0000122</TD><TD>841</TD><TD>6</TD><TD>18054</TD><TD>48</TD>
<TD>ZFHX4,ALX1,HEY1,MEIS2,SATB2,FST</TD></TR>
<TR><TD>2.340e-02</TD><TD>-3.75</TD><TD>roof of mouth development</TD><TD>biological process</TD><TD>GO:0060021</TD><TD>89</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>2.345e-02</TD><TD>-3.75</TD><TD>HNRNPLL (heterogeneous nuclear ribonucleoprotein L like)</TD><TD>protein interactions</TD><TD>92906</TD><TD>88</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1,ZFHX4</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>HOLLERN_EMT_BREAST_TUMOR_DN</TD><TD>MSigDB lists</TD><TD>HOLLERN_EMT_BREAST_TUMOR_DN</TD><TD>89</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>2.348e-02</TD><TD>-3.75</TD><TD>GO_PATTERN_SPECIFICATION_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PATTERN_SPECIFICATION_PROCESS</TD><TD>411</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ALX1,BMPR1B,ZIC1</TD></TR>
<TR><TD>2.350e-02</TD><TD>-3.75</TD><TD>DBP_Q6</TD><TD>MSigDB lists</TD><TD>DBP_Q6</TD><TD>231</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,PLAG1,PCDH11X</TD></TR>
<TR><TD>2.350e-02</TD><TD>-3.75</TD><TD>HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP</TD><TD>MSigDB lists</TD><TD>HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP</TD><TD>231</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,FST,IL7</TD></TR>
<TR><TD>2.357e-02</TD><TD>-3.75</TD><TD>Activin_recp</TD><TD>pfam domains</TD><TD>PF01064</TD><TD>9</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.357e-02</TD><TD>-3.75</TD><TD>Uteroglobin</TD><TD>pfam domains</TD><TD>PF01099</TD><TD>9</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>2.361e-02</TD><TD>-3.75</TD><TD>TGACATY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGACATY_UNKNOWN</TD><TD>618</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,ZIC1,SPAG6,ZIC4,MEIS2</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>ketone catabolic process</TD><TD>biological process</TD><TD>GO:0042182</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>positive regulation of myoblast proliferation</TD><TD>biological process</TD><TD>GO:2000288</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>MEIS2</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>regulation of synaptic vesicle clustering</TD><TD>biological process</TD><TD>GO:2000807</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH17</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>inhibitory synapse assembly</TD><TD>biological process</TD><TD>GO:1904862</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>dorsal aorta development</TD><TD>biological process</TD><TD>GO:0035907</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>proline transport</TD><TD>biological process</TD><TD>GO:0015824</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>regulation of natural killer cell chemotaxis</TD><TD>biological process</TD><TD>GO:2000501</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CXCL14</TD></TR>
<TR><TD>2.372e-02</TD><TD>-3.74</TD><TD>FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_UP</TD><TD>MSigDB lists</TD><TD>FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_UP</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>2.372e-02</TD><TD>-3.74</TD><TD>MATZUK_CUMULUS_EXPANSION</TD><TD>MSigDB lists</TD><TD>MATZUK_CUMULUS_EXPANSION</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.372e-02</TD><TD>-3.74</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_16</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_16</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1</TD></TR>
<TR><TD>2.372e-02</TD><TD>-3.74</TD><TD>FREDERICK_PRKCI_TARGETS</TD><TD>MSigDB lists</TD><TD>FREDERICK_PRKCI_TARGETS</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.372e-02</TD><TD>-3.74</TD><TD>MARSON_FOXP3_TARGETS_STIMULATED_DN</TD><TD>MSigDB lists</TD><TD>MARSON_FOXP3_TARGETS_STIMULATED_DN</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.372e-02</TD><TD>-3.74</TD><TD>BENPORATH_ES_CORE_NINE</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_CORE_NINE</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>chronic_pancreatitis</TD><TD>COSMIC cancer mutations</TD><TD>chronic_pancreatitis</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_II</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-pleomorphic</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-pleomorphic</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>skin-other-seborrhoeic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>skin-other-seborrhoeic_keratosis</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>ACTH_non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>ACTH_non_functioning</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>sun_exposed_site</TD><TD>COSMIC cancer mutations</TD><TD>sun_exposed_site</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>coccyx</TD><TD>COSMIC cancer mutations</TD><TD>coccyx</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>central_nervous_system-frontal_lobe-glioma-oligodendroglioma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-glioma-oligodendroglioma_Grade_III</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>in_situ_epithelial_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>in_situ_epithelial_neoplasm</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>skin-chest-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-chest-malignant_melanoma-superficial_spreading</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>bone-scapula-chondrosarcoma-central</TD><TD>COSMIC cancer mutations</TD><TD>bone-scapula-chondrosarcoma-central</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>frontotemporal</TD><TD>COSMIC cancer mutations</TD><TD>frontotemporal</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>pancreas-other-chronic_pancreatitis</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-other-chronic_pancreatitis</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>skin-mucosal-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-mucosal-malignant_melanoma-nodular</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>compound</TD><TD>COSMIC cancer mutations</TD><TD>compound</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>peritoneum-mesothelioma-epithelial</TD><TD>COSMIC cancer mutations</TD><TD>peritoneum-mesothelioma-epithelial</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>central_nervous_system-medulla-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-glioma-astrocytoma_Grade_I</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>basal_ganglia</TD><TD>COSMIC cancer mutations</TD><TD>basal_ganglia</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>Bowen_disease</TD><TD>COSMIC cancer mutations</TD><TD>Bowen_disease</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.374e-02</TD><TD>-3.74</TD><TD>upper_aerodigestive_tract-larynx-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>GATA1_03</TD><TD>MSigDB lists</TD><TD>GATA1_03</TD><TD>232</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,MEIS2,ZIC1</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>regulation of epithelial to mesenchymal transition</TD><TD>biological process</TD><TD>GO:0010717</TD><TD>90</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,EPHA3</TD></TR>
<TR><TD>2.395e-02</TD><TD>-3.73</TD><TD>GO_ALPHA_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_ALPHA_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>2.395e-02</TD><TD>-3.73</TD><TD>GAGACTG_MIR452</TD><TD>MSigDB lists</TD><TD>GAGACTG_MIR452</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,ZIC1</TD></TR>
<TR><TD>2.395e-02</TD><TD>-3.73</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,HEY1</TD></TR>
<TR><TD>2.395e-02</TD><TD>-3.73</TD><TD>ACAWYAAAG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ACAWYAAAG_UNKNOWN</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,HEY1</TD></TR>
<TR><TD>2.395e-02</TD><TD>-3.73</TD><TD>CCDC88A (coiled-coil domain containing 88A)</TD><TD>protein interactions</TD><TD>55704</TD><TD>89</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1,EYA4</TD></TR>
<TR><TD>2.398e-02</TD><TD>-3.73</TD><TD>EFNA3 (ephrin A3)</TD><TD>protein interactions</TD><TD>1944</TD><TD>9</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.398e-02</TD><TD>-3.73</TD><TD>RAB38 (RAB38, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>23682</TD><TD>9</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.398e-02</TD><TD>-3.73</TD><TD>PCDH17 (protocadherin 17)</TD><TD>protein interactions</TD><TD>27253</TD><TD>9</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>2.403e-02</TD><TD>-3.73</TD><TD>ICSBP_Q6</TD><TD>MSigDB lists</TD><TD>ICSBP_Q6</TD><TD>233</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,KYNU,SATB2</TD></TR>
<TR><TD>2.403e-02</TD><TD>-3.73</TD><TD>HMGIY_Q6</TD><TD>MSigDB lists</TD><TD>HMGIY_Q6</TD><TD>233</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,PEX5L</TD></TR>
<TR><TD>2.407e-02</TD><TD>-3.73</TD><TD>stomach</TD><TD>COSMIC cancer mutations</TD><TD>stomach</TD><TD>15914</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>LSR,ALX1,GALNT13,GABRB2,CDKN2A,PCDH11X,CRB1,SCGB3A2,CLDN1,SPAG6,EYA4,ZFHX4,PCDH20,ZIC4,SATB2,RBM11,PCDH17,HEY1,FST,IL7,STAC,CXCL14,KYNU,PEX5L,PLEKHM3,SLC6A15,CPEB2,EDA2R,AZGP1,MTSS1,ENPP5,PAPPA,PLAG1,PLCH1,GRIA2,NPTX2,ZIC1,IDO2,PAX9,SAA2,MEIS2,RNF128,DCDC2,GPC5,EPHA3,BMPR1B</TD></TR>
<TR><TD>2.409e-02</TD><TD>-3.73</TD><TD>negative regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051253</TD><TD>1343</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>PAX9,ZFHX4,MEIS2,HEY1,FST,CDKN2A,ALX1,SATB2</TD></TR>
<TR><TD>2.429e-02</TD><TD>-3.72</TD><TD>IPF1_Q4</TD><TD>MSigDB lists</TD><TD>IPF1_Q4</TD><TD>234</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>2.445e-02</TD><TD>-3.71</TD><TD>MACAEVA_PBMC_RESPONSE_TO_IR</TD><TD>MSigDB lists</TD><TD>MACAEVA_PBMC_RESPONSE_TO_IR</TD><TD>91</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EDA2R,PAPPA</TD></TR>
<TR><TD>2.456e-02</TD><TD>-3.71</TD><TD>ISRE_01</TD><TD>MSigDB lists</TD><TD>ISRE_01</TD><TD>235</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,EYA4,PLAG1</TD></TR>
<TR><TD>2.456e-02</TD><TD>-3.71</TD><TD>FREAC2_01</TD><TD>MSigDB lists</TD><TD>FREAC2_01</TD><TD>235</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PAPPA,ZFHX4</TD></TR>
<TR><TD>2.456e-02</TD><TD>-3.71</TD><TD>ZHENG_GLIOBLASTOMA_PLASTICITY_UP</TD><TD>MSigDB lists</TD><TD>ZHENG_GLIOBLASTOMA_PLASTICITY_UP</TD><TD>235</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,BMPR1B,RNF128</TD></TR>
<TR><TD>2.467e-02</TD><TD>-3.70</TD><TD>positive regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903508</TD><TD>1614</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,BMPR1B,ALX1,ZFHX4,ZIC1,PAX9,MEIS2,PLAG1,HEY1</TD></TR>
<TR><TD>2.476e-02</TD><TD>-3.70</TD><TD>positive regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902680</TD><TD>1615</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,BMPR1B,ALX1,PAX9,ZIC1,ZFHX4,MEIS2,PLAG1,HEY1</TD></TR>
<TR><TD>2.478e-02</TD><TD>-3.70</TD><TD>skeletal system morphogenesis</TD><TD>biological process</TD><TD>GO:0048705</TD><TD>236</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,BMPR1B,SATB2</TD></TR>
<TR><TD>2.483e-02</TD><TD>-3.70</TD><TD>MORF_PTPRB</TD><TD>MSigDB lists</TD><TD>MORF_PTPRB</TD><TD>236</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,STAC,IL7</TD></TR>
<TR><TD>2.483e-02</TD><TD>-3.70</TD><TD>STAT6_01</TD><TD>MSigDB lists</TD><TD>STAT6_01</TD><TD>236</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,MTSS1,PCDH17</TD></TR>
<TR><TD>2.492e-02</TD><TD>-3.69</TD><TD>EphrinA-EPHA pathway</TD><TD>Pathway Interaction DB</TD><TD>ephrina_ephapathway</TD><TD>8</TD><TD>1</TD><TD>2226</TD><TD>7</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.495e-02</TD><TD>-3.69</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>92</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>2.495e-02</TD><TD>-3.69</TD><TD>MORF_PTPRR</TD><TD>MSigDB lists</TD><TD>MORF_PTPRR</TD><TD>92</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC</TD></TR>
<TR><TD>2.500e-02</TD><TD>-3.69</TD><TD>messenger ribonucleoprotein complex</TD><TD>cellular component</TD><TD>GO:1990124</TD><TD>10</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.511e-02</TD><TD>-3.68</TD><TD>MORF_MAGEA8</TD><TD>MSigDB lists</TD><TD>MORF_MAGEA8</TD><TD>237</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,GABRB2</TD></TR>
<TR><TD>2.534e-02</TD><TD>-3.68</TD><TD>NAD Biosynthesis II (from tryptophan)</TD><TD>WikiPathways</TD><TD>WP2485</TD><TD>8</TD><TD>1</TD><TD>5311</TD><TD>17</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.537e-02</TD><TD>-3.67</TD><TD>TGCACTT_MIR519C_MIR519B_MIR519A</TD><TD>MSigDB lists</TD><TD>TGCACTT_MIR519C_MIR519B_MIR519A</TD><TD>421</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,ZFHX4,PCDH20,ENPP5</TD></TR>
<TR><TD>2.538e-02</TD><TD>-3.67</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>MSigDB lists</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>238</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,FST,EPHA3</TD></TR>
<TR><TD>2.538e-02</TD><TD>-3.67</TD><TD>TFIIA_Q6</TD><TD>MSigDB lists</TD><TD>TFIIA_Q6</TD><TD>238</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,GABRB2,PLAG1</TD></TR>
<TR><TD>2.538e-02</TD><TD>-3.67</TD><TD>STAT5A_03</TD><TD>MSigDB lists</TD><TD>STAT5A_03</TD><TD>238</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,MTSS1,FST</TD></TR>
<TR><TD>2.538e-02</TD><TD>-3.67</TD><TD>human chr9q33.1</TD><TD>chromosome location</TD><TD>human chr9q33.1</TD><TD>14</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.540e-02</TD><TD>-3.67</TD><TD>synapse assembly</TD><TD>biological process</TD><TD>GO:0007416</TD><TD>93</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH17,GABRB2</TD></TR>
<TR><TD>2.540e-02</TD><TD>-3.67</TD><TD>embryonic skeletal system morphogenesis</TD><TD>biological process</TD><TD>GO:0048704</TD><TD>93</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>2.545e-02</TD><TD>-3.67</TD><TD>TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP</TD><TD>MSigDB lists</TD><TD>TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP</TD><TD>93</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,GRIA2</TD></TR>
<TR><TD>2.547e-02</TD><TD>-3.67</TD><TD>neurogenesis</TD><TD>biological process</TD><TD>GO:0022008</TD><TD>1623</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>CRB1,DCDC2,PLAG1,HEY1,NPTX2,SATB2,GABRB2,BMPR1B,EPHA3</TD></TR>
<TR><TD>2.549e-02</TD><TD>-3.67</TD><TD>TB_dom_sf</TD><TD>interpro domains</TD><TD>IPR036773</TD><TD>10</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>2.549e-02</TD><TD>-3.67</TD><TD>Phosphodiest/P_Trfase</TD><TD>interpro domains</TD><TD>IPR002591</TD><TD>10</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>ENPP5</TD></TR>
<TR><TD>2.555e-02</TD><TD>-3.67</TD><TD>PAIRED_1</TD><TD>prosite domains</TD><TD>PS00034</TD><TD>8</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.555e-02</TD><TD>-3.67</TD><TD>PAIRED_2</TD><TD>prosite domains</TD><TD>PS51057</TD><TD>8</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.555e-02</TD><TD>-3.67</TD><TD>DC</TD><TD>prosite domains</TD><TD>PS50309</TD><TD>8</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.558e-02</TD><TD>-3.67</TD><TD>CUT</TD><TD>smart domains</TD><TD>SM01109</TD><TD>7</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>SATB2</TD></TR>
<TR><TD>2.558e-02</TD><TD>-3.67</TD><TD>GS</TD><TD>smart domains</TD><TD>SM00467</TD><TD>7</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.558e-02</TD><TD>-3.67</TD><TD>NL</TD><TD>smart domains</TD><TD>SM00004</TD><TD>7</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.565e-02</TD><TD>-3.66</TD><TD>PAX2_02</TD><TD>MSigDB lists</TD><TD>PAX2_02</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,ZIC4,MEIS2</TD></TR>
<TR><TD>2.565e-02</TD><TD>-3.66</TD><TD>DR4_Q2</TD><TD>MSigDB lists</TD><TD>DR4_Q2</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,PLAG1,NPTX2</TD></TR>
<TR><TD>2.565e-02</TD><TD>-3.66</TD><TD>AREB6_03</TD><TD>MSigDB lists</TD><TD>AREB6_03</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,FST,LSR</TD></TR>
<TR><TD>2.591e-02</TD><TD>-3.65</TD><TD>regulation of biomineral tissue development</TD><TD>biological process</TD><TD>GO:0070167</TD><TD>94</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,HEY1</TD></TR>
<TR><TD>2.593e-02</TD><TD>-3.65</TD><TD>AP2_Q3</TD><TD>MSigDB lists</TD><TD>AP2_Q3</TD><TD>240</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,EPHA3,HEY1</TD></TR>
<TR><TD>2.602e-02</TD><TD>-3.65</TD><TD>Retrograde endocannabinoid signaling</TD><TD>KEGG pathways</TD><TD>ko04723</TD><TD>101</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>2.602e-02</TD><TD>-3.65</TD><TD>Retrograde endocannabinoid signaling</TD><TD>KEGG pathways</TD><TD>hsa04723</TD><TD>101</TD><TD>2</TD><TD>7161</TD><TD>18</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>2.604e-02</TD><TD>-3.65</TD><TD>large_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_cell_carcinoma</TD><TD>862</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>GALNT13,CDKN2A,CRB1,EPHA3,BMPR1B,SLC6A15</TD></TR>
<TR><TD>2.604e-02</TD><TD>-3.65</TD><TD>lung-carcinoma-large_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-large_cell_carcinoma</TD><TD>862</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>CRB1,GALNT13,CDKN2A,EPHA3,SLC6A15,BMPR1B</TD></TR>
<TR><TD>2.610e-02</TD><TD>-3.65</TD><TD>embryonic organ development</TD><TD>biological process</TD><TD>GO:0048568</TD><TD>425</TD><TD>4</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,ZIC1,ALX1,HEY1</TD></TR>
<TR><TD>2.615e-02</TD><TD>-3.64</TD><TD>Pentaxin</TD><TD>pfam domains</TD><TD>PF00354</TD><TD>10</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.615e-02</TD><TD>-3.64</TD><TD>Phosphodiest</TD><TD>pfam domains</TD><TD>PF01663</TD><TD>10</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>ENPP5</TD></TR>
<TR><TD>2.621e-02</TD><TD>-3.64</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>241</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,SATB2,NPTX2</TD></TR>
<TR><TD>2.621e-02</TD><TD>-3.64</TD><TD>CAGCTTT_MIR320</TD><TD>MSigDB lists</TD><TD>CAGCTTT_MIR320</TD><TD>241</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,EYA4,PLAG1</TD></TR>
<TR><TD>2.621e-02</TD><TD>-3.64</TD><TD>NRF2_Q4</TD><TD>MSigDB lists</TD><TD>NRF2_Q4</TD><TD>241</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,ZIC1,ZIC4</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>negative regulation of activin receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0032926</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>heterochromatin assembly</TD><TD>biological process</TD><TD>GO:0031507</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>protein O-linked glycosylation via serine</TD><TD>biological process</TD><TD>GO:0018242</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>forebrain neuron fate commitment</TD><TD>biological process</TD><TD>GO:0021877</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>regulation of macrophage apoptotic process</TD><TD>biological process</TD><TD>GO:2000109</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>response to interleukin-18</TD><TD>biological process</TD><TD>GO:0070673</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.628e-02</TD><TD>-3.64</TD><TD>regulation of protein catabolic process in the vacuole</TD><TD>biological process</TD><TD>GO:1904350</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>RNF128</TD></TR>
<TR><TD>2.632e-02</TD><TD>-3.64</TD><TD>GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_DN</TD><TD>MSigDB lists</TD><TD>GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_DN</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.632e-02</TD><TD>-3.64</TD><TD>GO_MHC_CLASS_I_PROTEIN_COMPLEX</TD><TD>MSigDB lists</TD><TD>GO_MHC_CLASS_I_PROTEIN_COMPLEX</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1</TD></TR>
<TR><TD>2.632e-02</TD><TD>-3.64</TD><TD>GO_RESPONSE_TO_HISTAMINE</TD><TD>MSigDB lists</TD><TD>GO_RESPONSE_TO_HISTAMINE</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.632e-02</TD><TD>-3.64</TD><TD>MIKKELSEN_PARTIALLY_REPROGRAMMED_TO_PLURIPOTENCY</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_PARTIALLY_REPROGRAMMED_TO_PLURIPOTENCY</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>testis-germ_cell_tumour-teratoma</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-teratoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>large_intestine-left-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-left-carcinoma-adenocarcinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>pancreas-carcinoid-endocrine_tumour-gastrinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour-gastrinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-MALT_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-MALT_lymphoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>skin-back-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-malignant_melanoma-nodular</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>skin-abdomen-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-abdomen-malignant_melanoma-superficial_spreading</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>skin-shoulder-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-shoulder-malignant_melanoma-superficial_spreading</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>cervical_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>cervical_intraepithelial_neoplasia_Grade_III</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>stomach-carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoid-endocrine_tumour</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>intradermal</TD><TD>COSMIC cancer mutations</TD><TD>intradermal</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>kidney-carcinoma-renal_cell_carcinoma_unclassified</TD><TD>COSMIC cancer mutations</TD><TD>kidney-carcinoma-renal_cell_carcinoma_unclassified</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>renal_cell_carcinoma_unclassified</TD><TD>COSMIC cancer mutations</TD><TD>renal_cell_carcinoma_unclassified</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>ovary-adenoma-Brenner_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-adenoma-Brenner_tumour</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-adenocarcinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>osteoblastic</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>central_nervous_system-cerebral_cortex-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebral_cortex-glioma-astrocytoma_Grade_II</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>metaplasia</TD><TD>COSMIC cancer mutations</TD><TD>metaplasia</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>large_intestine-right-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-right-carcinoma-adenocarcinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>elbow</TD><TD>COSMIC cancer mutations</TD><TD>elbow</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_III</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.642e-02</TD><TD>-3.63</TD><TD>plasma membrane organization</TD><TD>biological process</TD><TD>GO:0007009</TD><TD>95</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>CRB1,MTSS1</TD></TR>
<TR><TD>2.642e-02</TD><TD>-3.63</TD><TD>regulation of protein localization to plasma membrane</TD><TD>biological process</TD><TD>GO:1903076</TD><TD>95</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>STAC,EPHA3</TD></TR>
<TR><TD>2.644e-02</TD><TD>-3.63</TD><TD>oesophagus-upper_third-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-upper_third-carcinoma-squamous_cell_carcinoma</TD><TD>636</TD><TD>5</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,CDKN2A,SLC6A15,EPHA3,PEX5L</TD></TR>
<TR><TD>2.644e-02</TD><TD>-3.63</TD><TD>upper_third</TD><TD>COSMIC cancer mutations</TD><TD>upper_third</TD><TD>636</TD><TD>5</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,ZFHX4,PEX5L,EPHA3,SLC6A15</TD></TR>
<TR><TD>2.648e-02</TD><TD>-3.63</TD><TD>GAGCCTG_MIR484</TD><TD>MSigDB lists</TD><TD>GAGCCTG_MIR484</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,ZIC1</TD></TR>
<TR><TD>2.648e-02</TD><TD>-3.63</TD><TD>GSE5589_WT_VS_IL6_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_UP</TD><TD>MSigDB lists</TD><TD>GSE5589_WT_VS_IL6_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_UP</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,RNF128</TD></TR>
<TR><TD>2.648e-02</TD><TD>-3.63</TD><TD>WINZEN_DEGRADED_VIA_KHSRP</TD><TD>MSigDB lists</TD><TD>WINZEN_DEGRADED_VIA_KHSRP</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>FST,PAPPA</TD></TR>
<TR><TD>2.648e-02</TD><TD>-3.63</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_UP</TD><TD>MSigDB lists</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_UP</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,PCDH17</TD></TR>
<TR><TD>2.649e-02</TD><TD>-3.63</TD><TD>PPAR_DR1_Q2</TD><TD>MSigDB lists</TD><TD>PPAR_DR1_Q2</TD><TD>242</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,ZIC4,CXCL14</TD></TR>
<TR><TD>2.649e-02</TD><TD>-3.63</TD><TD>LEF1_Q6</TD><TD>MSigDB lists</TD><TD>LEF1_Q6</TD><TD>242</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,ZIC4,GABRB2</TD></TR>
<TR><TD>2.649e-02</TD><TD>-3.63</TD><TD>STAT6_02</TD><TD>MSigDB lists</TD><TD>STAT6_02</TD><TD>242</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,RNF128,MEIS2</TD></TR>
<TR><TD>2.651e-02</TD><TD>-3.63</TD><TD>SEC24B (SEC24 homolog B, COPII coat complex component)</TD><TD>protein interactions</TD><TD>10427</TD><TD>94</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>EYA4,TMEM255A</TD></TR>
<TR><TD>2.652e-02</TD><TD>-3.63</TD><TD>Defective EXT1 causes exostoses 1, TRPS2 and CHDS</TD><TD>REACTOME pathways</TD><TD>R-HSA-3656253</TD><TD>12</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>2.652e-02</TD><TD>-3.63</TD><TD>Defective EXT2 causes exostoses 2</TD><TD>REACTOME pathways</TD><TD>R-HSA-3656237</TD><TD>12</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>TJP3 (tight junction protein 3)</TD><TD>protein interactions</TD><TD>27134</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>EFNA4 (ephrin A4)</TD><TD>protein interactions</TD><TD>1945</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>CLDN3 (claudin 3)</TD><TD>protein interactions</TD><TD>1365</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>ZNF227 (zinc finger protein 227)</TD><TD>protein interactions</TD><TD>7770</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>BAMBI (BMP and activin membrane bound inhibitor)</TD><TD>protein interactions</TD><TD>25805</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>INHA (inhibin subunit alpha)</TD><TD>protein interactions</TD><TD>3623</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>FST</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>HHV8GK18_gp82 (ORF72)</TD><TD>protein interactions</TD><TD>4961471</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>ERI3 (ERI1 exoribonuclease family member 3)</TD><TD>protein interactions</TD><TD>79033</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>TDRD7 (tudor domain containing 7)</TD><TD>protein interactions</TD><TD>23424</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>URGCP (upregulator of cell proliferation)</TD><TD>protein interactions</TD><TD>55665</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EYA4</TD></TR>
<TR><TD>2.664e-02</TD><TD>-3.63</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>638</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,GRIA2,BMPR1B,EPHA3,AZGP1</TD></TR>
<TR><TD>2.664e-02</TD><TD>-3.63</TD><TD>neuron part</TD><TD>cellular component</TD><TD>GO:0097458</TD><TD>1720</TD><TD>9</TD><TD>18985</TD><TD>48</TD>
<TD>EPHA3,CRB1,PCDH17,GRIA2,NPTX2,DCDC2,GABRB2,CPEB2,BMPR1B</TD></TR>
<TR><TD>2.675e-02</TD><TD>-3.62</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>428</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,SPAG6,EPHA3,NPTX2</TD></TR>
<TR><TD>2.677e-02</TD><TD>-3.62</TD><TD>GR_Q6</TD><TD>MSigDB lists</TD><TD>GR_Q6</TD><TD>243</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,CXCL14,MEIS2</TD></TR>
<TR><TD>2.677e-02</TD><TD>-3.62</TD><TD>RACCACAR_AML_Q6</TD><TD>MSigDB lists</TD><TD>RACCACAR_AML_Q6</TD><TD>243</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,ZIC4,BMPR1B</TD></TR>
<TR><TD>2.693e-02</TD><TD>-3.61</TD><TD>skin-extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-extremity-malignant_melanoma</TD><TD>1914</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>KYNU,CDKN2A,ZFHX4,SLC6A15,RBM11,EDA2R,CPEB2,PAPPA,EPHA3,PCDH17</TD></TR>
<TR><TD>2.694e-02</TD><TD>-3.61</TD><TD>endothelium development</TD><TD>biological process</TD><TD>GO:0003158</TD><TD>96</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1,CLDN1</TD></TR>
<TR><TD>2.700e-02</TD><TD>-3.61</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>96</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,MEIS2</TD></TR>
<TR><TD>2.700e-02</TD><TD>-3.61</TD><TD>death receptor activity</TD><TD>molecular function</TD><TD>GO:0005035</TD><TD>11</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.702e-02</TD><TD>-3.61</TD><TD>extremity</TD><TD>COSMIC cancer mutations</TD><TD>extremity</TD><TD>1915</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>EDA2R,CPEB2,RBM11,EPHA3,PCDH17,PAPPA,KYNU,CDKN2A,ZFHX4,SLC6A15</TD></TR>
<TR><TD>2.705e-02</TD><TD>-3.61</TD><TD>haemangiopericytic</TD><TD>COSMIC cancer mutations</TD><TD>haemangiopericytic</TD><TD>96</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,PLCH1</TD></TR>
<TR><TD>2.705e-02</TD><TD>-3.61</TD><TD>meninges-meningioma-haemangiopericytic</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-haemangiopericytic</TD><TD>96</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>2.717e-02</TD><TD>-3.61</TD><TD>human chr21q11.2</TD><TD>chromosome location</TD><TD>human chr21q11.2</TD><TD>15</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>RBM11</TD></TR>
<TR><TD>2.734e-02</TD><TD>-3.60</TD><TD>JAEGER_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>JAEGER_METASTASIS_DN</TD><TD>245</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>FST,LSR,CXCL14</TD></TR>
<TR><TD>2.734e-02</TD><TD>-3.60</TD><TD>AML_Q6</TD><TD>MSigDB lists</TD><TD>AML_Q6</TD><TD>245</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,PAPPA,HEY1</TD></TR>
<TR><TD>2.752e-02</TD><TD>-3.59</TD><TD>CTGTTAC_MIR194</TD><TD>MSigDB lists</TD><TD>CTGTTAC_MIR194</TD><TD>97</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,MEIS2</TD></TR>
<TR><TD>2.752e-02</TD><TD>-3.59</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_C</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_C</TD><TD>97</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15,RNF128</TD></TR>
<TR><TD>2.763e-02</TD><TD>-3.59</TD><TD>OCT1_Q6</TD><TD>MSigDB lists</TD><TD>OCT1_Q6</TD><TD>246</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH20,SATB2,SLC6A15</TD></TR>
<TR><TD>2.774e-02</TD><TD>-3.58</TD><TD>plasma membrane</TD><TD>cellular component</TD><TD>GO:0005886</TD><TD>5298</TD><TD>20</TD><TD>18985</TD><TD>48</TD>
<TD>BMPR1B,GPC5,ARHGAP45,SLC6A15,PLCH1,ENPP5,CLDN1,LSR,GABRB2,STAC,PLEKHM3,PCDH11X,PCDH20,AZGP1,NPTX2,GRIA2,PCDH17,CRB1,EDA2R,EPHA3</TD></TR>
<TR><TD>2.782e-02</TD><TD>-3.58</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.290.10</TD><TD>10</TD><TD>1</TD><TD>8522</TD><TD>24</TD>
<TD>FST</TD></TR>
<TR><TD>2.792e-02</TD><TD>-3.58</TD><TD>GO_ENDOCYTIC_VESICLE</TD><TD>MSigDB lists</TD><TD>GO_ENDOCYTIC_VESICLE</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,GRIA2,SCGB3A2</TD></TR>
<TR><TD>2.792e-02</TD><TD>-3.58</TD><TD>CEBPB_01</TD><TD>MSigDB lists</TD><TD>CEBPB_01</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,ZIC1,ZIC4</TD></TR>
<TR><TD>2.792e-02</TD><TD>-3.58</TD><TD>TTF1_Q6</TD><TD>MSigDB lists</TD><TD>TTF1_Q6</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,PCDH17,ZIC1</TD></TR>
<TR><TD>2.792e-02</TD><TD>-3.58</TD><TD>MORF_PAX7</TD><TD>MSigDB lists</TD><TD>MORF_PAX7</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,PAX9,GABRB2</TD></TR>
<TR><TD>2.801e-02</TD><TD>-3.58</TD><TD>Pentraxin-related</TD><TD>interpro domains</TD><TD>IPR001759</TD><TD>11</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>HALLMARK_ANDROGEN_RESPONSE</TD><TD>MSigDB lists</TD><TD>HALLMARK_ANDROGEN_RESPONSE</TD><TD>98</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,BMPR1B</TD></TR>
<TR><TD>2.821e-02</TD><TD>-3.57</TD><TD>OCT1_B</TD><TD>MSigDB lists</TD><TD>OCT1_B</TD><TD>248</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,SLC6A15,PCDH20</TD></TR>
<TR><TD>2.839e-02</TD><TD>-3.56</TD><TD>human chr7q22.1</TD><TD>chromosome location</TD><TD>human chr7q22.1</TD><TD>143</TD><TD>2</TD><TD>26169</TD><TD>48</TD>
<TD>AZGP1,NPTX2</TD></TR>
<TR><TD>2.846e-02</TD><TD>-3.56</TD><TD>miR-148a/miR-31/FIH1/HIF1&alpha;-Notch signaling in glioblastoma</TD><TD>WikiPathways</TD><TD>WP3593</TD><TD>9</TD><TD>1</TD><TD>5311</TD><TD>17</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.850e-02</TD><TD>-3.56</TD><TD>SOX5_01</TD><TD>MSigDB lists</TD><TD>SOX5_01</TD><TD>249</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,FST,SATB2</TD></TR>
<TR><TD>2.857e-02</TD><TD>-3.56</TD><TD>TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA</TD><TD>MSigDB lists</TD><TD>TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA</TD><TD>99</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PAX9,EYA4</TD></TR>
<TR><TD>2.870e-02</TD><TD>-3.55</TD><TD>Signaling by Activin</TD><TD>REACTOME pathways</TD><TD>R-HSA-1502540</TD><TD>13</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>FST</TD></TR>
<TR><TD>2.870e-02</TD><TD>-3.55</TD><TD>GABA A receptor activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-977441</TD><TD>13</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.870e-02</TD><TD>-3.55</TD><TD>TB</TD><TD>prosite domains</TD><TD>PS51364</TD><TD>9</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>FST</TD></TR>
<TR><TD>2.873e-02</TD><TD>-3.55</TD><TD>Hairy_orange</TD><TD>pfam domains</TD><TD>PF07527</TD><TD>11</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.879e-02</TD><TD>-3.55</TD><TD>MORF_BRCA1</TD><TD>MSigDB lists</TD><TD>MORF_BRCA1</TD><TD>250</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,PAX9,STAC</TD></TR>
<TR><TD>2.879e-02</TD><TD>-3.55</TD><TD>MYCMAX_02</TD><TD>MSigDB lists</TD><TD>MYCMAX_02</TD><TD>250</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,PLAG1,RNF128</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.55</TD><TD>Notch signaling involved in heart development</TD><TD>biological process</TD><TD>GO:0061314</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.55</TD><TD>regulation of cytoplasmic translational elongation</TD><TD>biological process</TD><TD>GO:1900247</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.55</TD><TD>prostate gland growth</TD><TD>biological process</TD><TD>GO:0060736</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PLAG1</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.55</TD><TD>response to histamine</TD><TD>biological process</TD><TD>GO:0034776</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>PAIREDBOX</TD><TD>prints domains</TD><TD>PR00027</TD><TD>8</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>PENTAXIN</TD><TD>prints domains</TD><TD>PR00895</TD><TD>8</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>GO_POSITIVE_REGULATION_OF_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>GO_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_INVOLVED_IN_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_INVOLVED_IN_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>GO_HETEROCHROMATIN_ORGANIZATION</TD><TD>MSigDB lists</TD><TD>GO_HETEROCHROMATIN_ORGANIZATION</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>GO_POSITIVE_REGULATION_OF_HAIR_CYCLE</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_HAIR_CYCLE</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>REACTOME_IL_7_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_IL_7_SIGNALING</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>IL7</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>GO_PROSTATE_GLAND_GROWTH</TD><TD>MSigDB lists</TD><TD>GO_PROSTATE_GLAND_GROWTH</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>GO_POSITIVE_REGULATION_OF_PROTEIN_SUMOYLATION</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_PROTEIN_SUMOYLATION</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>retromolar</TD><TD>COSMIC cancer mutations</TD><TD>retromolar</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-B_cell_lymphoma_unspecified</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-B_cell_lymphoma_unspecified</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>congenital</TD><TD>COSMIC cancer mutations</TD><TD>congenital</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>skin-back-benign_melanocytic_nevus</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_III</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>frontoparietal</TD><TD>COSMIC cancer mutations</TD><TD>frontoparietal</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_III</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-sarcoma-spindle</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-sarcoma-spindle</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>skin-back-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-malignant_melanoma-superficial_spreading</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>endometrium-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>skin-scalp-malignant_melanoma-lentigo_maligna</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma-lentigo_maligna</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>upper_aerodigestive_tract-mouth-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-other-dysplasia</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>chiasm</TD><TD>COSMIC cancer mutations</TD><TD>chiasm</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_I</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_I</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>gastrinoma</TD><TD>COSMIC cancer mutations</TD><TD>gastrinoma</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>pleura-mesothelioma-sarcomatous-fibrous</TD><TD>COSMIC cancer mutations</TD><TD>pleura-mesothelioma-sarcomatous-fibrous</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>skin-foot-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-malignant_melanoma-nodular</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>pancreas-carcinoid-endocrine_tumour-non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour-non_functioning</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_II</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>seborrhoeic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>seborrhoeic_keratosis</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.895e-02</TD><TD>-3.54</TD><TD>skin-hand-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-hand-malignant_melanoma-acral_lentiginous</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.896e-02</TD><TD>-3.54</TD><TD>human chr3q25.31</TD><TD>chromosome location</TD><TD>human chr3q25.31</TD><TD>16</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>calcium ion binding</TD><TD>molecular function</TD><TD>GO:0005509</TD><TD>701</TD><TD>5</TD><TD>17306</TD><TD>43</TD>
<TD>PCDH11X,PCDH17,PLCH1,CRB1,PCDH20</TD></TR>
<TR><TD>2.909e-02</TD><TD>-3.54</TD><TD>BOQUEST_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>BOQUEST_STEM_CELL_UP</TD><TD>251</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,CXCL14,FST</TD></TR>
<TR><TD>2.909e-02</TD><TD>-3.54</TD><TD>NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>NFAT_Q4_01</TD><TD>251</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,PCDH17,ZIC4</TD></TR>
<TR><TD>2.909e-02</TD><TD>-3.54</TD><TD>HNF4_01</TD><TD>MSigDB lists</TD><TD>HNF4_01</TD><TD>251</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,KYNU,ZIC4</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>GSE11367_CTRL_VS_IL17_TREATED_SMOOTH_MUSCLE_CELL_DN</TD><TD>MSigDB lists</TD><TD>GSE11367_CTRL_VS_IL17_TREATED_SMOOTH_MUSCLE_CELL_DN</TD><TD>100</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,GABRB2</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>100</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH11X,PAPPA</TD></TR>
<TR><TD>2.918e-02</TD><TD>-3.53</TD><TD>DCX</TD><TD>smart domains</TD><TD>SM00537</TD><TD>8</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.918e-02</TD><TD>-3.53</TD><TD>PAX</TD><TD>smart domains</TD><TD>SM00351</TD><TD>8</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>ATP1B2 (ATPase Na+/K+ transporting subunit beta 2)</TD><TD>protein interactions</TD><TD>482</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>PRSS37 (serine protease 37)</TD><TD>protein interactions</TD><TD>136242</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>GPAT3 (glycerol-3-phosphate acyltransferase 3)</TD><TD>protein interactions</TD><TD>84803</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>GRID2 (glutamate ionotropic receptor delta type subunit 2)</TD><TD>protein interactions</TD><TD>2895</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GRIA2</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>NKIRAS1 (NFKB inhibitor interacting Ras like 1)</TD><TD>protein interactions</TD><TD>28512</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>C2orf48 (chromosome 2 open reading frame 48)</TD><TD>protein interactions</TD><TD>348738</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>GALNT1 (polypeptide N-acetylgalactosaminyltransferase 1)</TD><TD>protein interactions</TD><TD>2589</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>PLEKHB1 (pleckstrin homology domain containing B1)</TD><TD>protein interactions</TD><TD>58473</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.923e-02</TD><TD>-3.53</TD><TD>PCDHGA11 (protocadherin gamma subfamily A, 11)</TD><TD>protein interactions</TD><TD>56105</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>2.939e-02</TD><TD>-3.53</TD><TD>MCBRYAN_PUBERTAL_BREAST_4_5WK_UP</TD><TD>MSigDB lists</TD><TD>MCBRYAN_PUBERTAL_BREAST_4_5WK_UP</TD><TD>252</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,CXCL14,HEY1</TD></TR>
<TR><TD>2.939e-02</TD><TD>-3.53</TD><TD>COREBINDINGFACTOR_Q6</TD><TD>MSigDB lists</TD><TD>COREBINDINGFACTOR_Q6</TD><TD>252</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,MEIS2,BMPR1B</TD></TR>
<TR><TD>2.942e-02</TD><TD>-3.53</TD><TD>cyclin-dependent protein serine/threonine kinase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0004861</TD><TD>12</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.962e-02</TD><TD>-3.52</TD><TD>negative regulation of biological process</TD><TD>biological process</TD><TD>GO:0048519</TD><TD>5753</TD><TD>22</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH11X,HEY1,PAX9,ZFHX4,GABRB2,CPEB2,IL7,RNF128,PCDH17,CDKN2A,EPHA3,BMPR1B,PLCH1,CXCL14,FST,MEIS2,PLAG1,EYA4,AZGP1,SATB2,MTSS1,ALX1</TD></TR>
<TR><TD>2.965e-02</TD><TD>-3.52</TD><TD>GHANDHI_DIRECT_IRRADIATION_UP</TD><TD>MSigDB lists</TD><TD>GHANDHI_DIRECT_IRRADIATION_UP</TD><TD>101</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,KYNU</TD></TR>
<TR><TD>2.965e-02</TD><TD>-3.52</TD><TD>GO_REGULATION_OF_B_CELL_ACTIVATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_B_CELL_ACTIVATION</TD><TD>101</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,CDKN2A</TD></TR>
<TR><TD>2.968e-02</TD><TD>-3.52</TD><TD>HOXA4_Q2</TD><TD>MSigDB lists</TD><TD>HOXA4_Q2</TD><TD>253</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,BMPR1B</TD></TR>
<TR><TD>2.968e-02</TD><TD>-3.52</TD><TD>MODULE_112</TD><TD>MSigDB lists</TD><TD>MODULE_112</TD><TD>253</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,AZGP1,CDKN2A</TD></TR>
<TR><TD>2.998e-02</TD><TD>-3.51</TD><TD>GO_MULTICELLULAR_ORGANISMAL_HOMEOSTASIS</TD><TD>MSigDB lists</TD><TD>GO_MULTICELLULAR_ORGANISMAL_HOMEOSTASIS</TD><TD>254</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,CLDN1,AZGP1</TD></TR>
<TR><TD>3.019e-02</TD><TD>-3.50</TD><TD>GO_REGULATION_OF_T_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_T_CELL_DIFFERENTIATION</TD><TD>102</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,CDKN2A</TD></TR>
<TR><TD>3.019e-02</TD><TD>-3.50</TD><TD>LABBE_TGFB1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>LABBE_TGFB1_TARGETS_DN</TD><TD>102</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,NPTX2</TD></TR>
<TR><TD>3.049e-02</TD><TD>-3.49</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>446</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,EPHA3,ENPP5,DCDC2</TD></TR>
<TR><TD>3.051e-02</TD><TD>-3.49</TD><TD>PLC_EF-hand-like</TD><TD>interpro domains</TD><TD>IPR015359</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.051e-02</TD><TD>-3.49</TD><TD>TGFB_receptor</TD><TD>interpro domains</TD><TD>IPR000333</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.051e-02</TD><TD>-3.49</TD><TD>Orange_dom</TD><TD>interpro domains</TD><TD>IPR003650</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.059e-02</TD><TD>-3.49</TD><TD>MORF_FSHR</TD><TD>MSigDB lists</TD><TD>MORF_FSHR</TD><TD>256</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,STAC,IL7</TD></TR>
<TR><TD>3.059e-02</TD><TD>-3.49</TD><TD>AP1FJ_Q2</TD><TD>MSigDB lists</TD><TD>AP1FJ_Q2</TD><TD>256</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,PAX9,MEIS2</TD></TR>
<TR><TD>3.074e-02</TD><TD>-3.48</TD><TD>human chr1q31.3</TD><TD>chromosome location</TD><TD>human chr1q31.3</TD><TD>17</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>CRB1</TD></TR>
<TR><TD>3.076e-02</TD><TD>-3.48</TD><TD>GO_CALCIUM_ION_BINDING</TD><TD>MSigDB lists</TD><TD>GO_CALCIUM_ION_BINDING</TD><TD>663</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,PCDH11X,PCDH20,PCDH17,PLCH1</TD></TR>
<TR><TD>3.076e-02</TD><TD>-3.48</TD><TD>Selenium Micronutrient Network</TD><TD>WikiPathways</TD><TD>WP15</TD><TD>87</TD><TD>2</TD><TD>5311</TD><TD>17</TD>
<TD>SAA2,KYNU</TD></TR>
<TR><TD>3.080e-02</TD><TD>-3.48</TD><TD>eye-uveal_tract-malignant_melanoma-mixed</TD><TD>COSMIC cancer mutations</TD><TD>eye-uveal_tract-malignant_melanoma-mixed</TD><TD>103</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,RBM11</TD></TR>
<TR><TD>3.122e-02</TD><TD>-3.47</TD><TD>alpha-amino acid catabolic process</TD><TD>biological process</TD><TD>GO:1901606</TD><TD>104</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.122e-02</TD><TD>-3.47</TD><TD>negative regulation of extrinsic apoptotic signaling pathway</TD><TD>biological process</TD><TD>GO:2001237</TD><TD>104</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>3.122e-02</TD><TD>-3.47</TD><TD>cell-cell junction assembly</TD><TD>biological process</TD><TD>GO:0007043</TD><TD>104</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1,LSR</TD></TR>
<TR><TD>3.129e-02</TD><TD>-3.46</TD><TD>GSE5589_WT_VS_IL10_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_DN</TD><TD>MSigDB lists</TD><TD>GSE5589_WT_VS_IL10_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_DN</TD><TD>104</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2,GPC5</TD></TR>
<TR><TD>3.130e-02</TD><TD>-3.46</TD><TD>EF-hand_like</TD><TD>pfam domains</TD><TD>PF09279</TD><TD>12</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.130e-02</TD><TD>-3.46</TD><TD>Ephrin_rec_like</TD><TD>pfam domains</TD><TD>PF07699</TD><TD>12</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.145e-02</TD><TD>-3.46</TD><TD>positive regulation of voltage-gated calcium channel activity</TD><TD>biological process</TD><TD>GO:1901387</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>STAC</TD></TR>
<TR><TD>3.145e-02</TD><TD>-3.46</TD><TD>positive regulation of B cell differentiation</TD><TD>biological process</TD><TD>GO:0045579</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>IL7</TD></TR>
<TR><TD>3.145e-02</TD><TD>-3.46</TD><TD>replicative senescence</TD><TD>biological process</TD><TD>GO:0090399</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.145e-02</TD><TD>-3.46</TD><TD>positive regulation of hair follicle development</TD><TD>biological process</TD><TD>GO:0051798</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>3.145e-02</TD><TD>-3.46</TD><TD>regulation of postsynaptic neurotransmitter receptor activity</TD><TD>biological process</TD><TD>GO:0098962</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_FOREBRAIN_NEURON_FATE_COMMITMENT</TD><TD>MSigDB lists</TD><TD>GO_FOREBRAIN_NEURON_FATE_COMMITMENT</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_REGULATION_OF_CYTOPLASMIC_TRANSLATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CYTOPLASMIC_TRANSLATION</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_SODIUM_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_SODIUM_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_RIBOSOMAL_SMALL_SUBUNIT_BINDING</TD><TD>MSigDB lists</TD><TD>GO_RIBOSOMAL_SMALL_SUBUNIT_BINDING</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_REPLICATIVE_SENESCENCE</TD><TD>MSigDB lists</TD><TD>GO_REPLICATIVE_SENESCENCE</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>REACTOME_GABA_A_RECEPTOR_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_GABA_A_RECEPTOR_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>SA_REG_CASCADE_OF_CYCLIN_EXPR</TD><TD>MSigDB lists</TD><TD>SA_REG_CASCADE_OF_CYCLIN_EXPR</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_HEART_VALVE_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_HEART_VALVE_FORMATION</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_ACTIVIN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_ACTIVIN_BINDING</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>ITO_PTTG1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ITO_PTTG1_TARGETS_UP</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_CYCLIN_DEPENDENT_PROTEIN_SERINE_THREONINE_KINASE_INHIBITOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_CYCLIN_DEPENDENT_PROTEIN_SERINE_THREONINE_KINASE_INHIBITOR_ACTIVITY</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>GO_NAD_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_NAD_BIOSYNTHETIC_PROCESS</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP</TD><TD>MSigDB lists</TD><TD>SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>haematopoietic_and_lymphoid_tissue-mediastinum-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-mediastinum-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-desmoid_tumour-fibromatosis</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-desmoid_tumour-fibromatosis</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>ovary-low_malignant_potential_(borderline)_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-low_malignant_potential_(borderline)_tumour</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>GH-PRL</TD><TD>COSMIC cancer mutations</TD><TD>GH-PRL</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>left</TD><TD>COSMIC cancer mutations</TD><TD>left</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>desmoid_tumour-fibromatosis</TD><TD>COSMIC cancer mutations</TD><TD>desmoid_tumour-fibromatosis</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>cervix-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>cervix-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>skin-abdomen-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-abdomen-malignant_melanoma-nodular</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>bone-sacrum-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-sacrum-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>clear_cell</TD><TD>COSMIC cancer mutations</TD><TD>clear_cell</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>pituitary-adenoma-GH-PRL</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-GH-PRL</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>trachea</TD><TD>COSMIC cancer mutations</TD><TD>trachea</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>lymphoplasmacytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>lymphoplasmacytic_lymphoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.154e-02</TD><TD>-3.46</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.180e-02</TD><TD>-3.45</TD><TD>GAPDH (glyceraldehyde-3-phosphate dehydrogenase)</TD><TD>protein interactions</TD><TD>2597</TD><TD>257</TD><TD>3</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1,CDKN2A,GRIA2</TD></TR>
<TR><TD>3.181e-02</TD><TD>-3.45</TD><TD>TGCCAAR_NF1_Q6</TD><TD>MSigDB lists</TD><TD>TGCCAAR_NF1_Q6</TD><TD>669</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,CXCL14,MEIS2,PEX5L,EPHA3</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>amino acid:sodium symporter activity</TD><TD>molecular function</TD><TD>GO:0005283</TD><TD>13</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>ribosomal large subunit binding</TD><TD>molecular function</TD><TD>GO:0043023</TD><TD>13</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>GABA-gated chloride ion channel activity</TD><TD>molecular function</TD><TD>GO:0022851</TD><TD>13</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.184e-02</TD><TD>-3.45</TD><TD>GCTTGAA_MIR498</TD><TD>MSigDB lists</TD><TD>GCTTGAA_MIR498</TD><TD>105</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,GRIA2</TD></TR>
<TR><TD>3.184e-02</TD><TD>-3.45</TD><TD>SENESE_HDAC2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC2_TARGETS_UP</TD><TD>105</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,SLC6A15</TD></TR>
<TR><TD>3.184e-02</TD><TD>-3.45</TD><TD>LE_EGR2_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>LE_EGR2_TARGETS_DN</TD><TD>105</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2,SLC6A15</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>SDR9C7 (short chain dehydrogenase/reductase family 9C member 7)</TD><TD>protein interactions</TD><TD>121214</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>RBM18 (RNA binding motif protein 18)</TD><TD>protein interactions</TD><TD>92400</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>SRGAP1 (SLIT-ROBO Rho GTPase activating protein 1)</TD><TD>protein interactions</TD><TD>57522</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>SIX4 (SIX homeobox 4)</TD><TD>protein interactions</TD><TD>51804</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EYA4</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>TUBA3D (tubulin alpha 3d)</TD><TD>protein interactions</TD><TD>113457</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>GABRB3 (gamma-aminobutyric acid type A receptor beta3 subunit)</TD><TD>protein interactions</TD><TD>2562</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>MAB21L1 (mab-21 like 1)</TD><TD>protein interactions</TD><TD>4081</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>VAMP1 (vesicle associated membrane protein 1)</TD><TD>protein interactions</TD><TD>6843</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>CAPN15 (calpain 15)</TD><TD>protein interactions</TD><TD>6650</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>DCDC2B (doublecortin domain containing 2B)</TD><TD>protein interactions</TD><TD>149069</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>CD40LG (CD40 ligand)</TD><TD>protein interactions</TD><TD>959</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>RNF128</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>RASL12 (RAS like family 12)</TD><TD>protein interactions</TD><TD>51285</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.185e-02</TD><TD>-3.45</TD><TD>ZP3 (zona pellucida glycoprotein 3)</TD><TD>protein interactions</TD><TD>7784</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH17</TD></TR>
<TR><TD>3.199e-02</TD><TD>-3.44</TD><TD>NS-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>NS-malignant_melanoma</TD><TD>3475</TD><TD>15</TD><TD>17255</TD><TD>46</TD>
<TD>PAPPA,EPHA3,GPC5,SATB2,CRB1,AZGP1,MTSS1,SAA2,MEIS2,IDO2,ZFHX4,GALNT13,CDKN2A,NPTX2,PLCH1</TD></TR>
<TR><TD>3.213e-02</TD><TD>-3.44</TD><TD>YKACATTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YKACATTT_UNKNOWN</TD><TD>261</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH11X,ZFHX4,PLAG1</TD></TR>
<TR><TD>3.222e-02</TD><TD>-3.44</TD><TD>skin-leg-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-malignant_melanoma-nodular</TD><TD>261</TD><TD>3</TD><TD>17255</TD><TD>46</TD>
<TD>SATB2,CDKN2A,MTSS1</TD></TR>
<TR><TD>3.238e-02</TD><TD>-3.43</TD><TD>chylomicron</TD><TD>cellular component</TD><TD>GO:0042627</TD><TD>13</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>3.240e-02</TD><TD>-3.43</TD><TD>GO_NEURON_MIGRATION</TD><TD>MSigDB lists</TD><TD>GO_NEURON_MIGRATION</TD><TD>106</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>DCDC2,SATB2</TD></TR>
<TR><TD>3.240e-02</TD><TD>-3.43</TD><TD>ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN</TD><TD>106</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,KYNU</TD></TR>
<TR><TD>3.247e-02</TD><TD>-3.43</TD><TD>MHCCLASSI</TD><TD>prints domains</TD><TD>PR01638</TD><TD>9</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>AZGP1</TD></TR>
<TR><TD>3.277e-02</TD><TD>-3.42</TD><TD>ORANGE</TD><TD>smart domains</TD><TD>SM00511</TD><TD>9</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.277e-02</TD><TD>-3.42</TD><TD>FOLN</TD><TD>smart domains</TD><TD>SM00274</TD><TD>9</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>FST</TD></TR>
<TR><TD>3.296e-02</TD><TD>-3.41</TD><TD>GO_CELLULAR_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>107</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.296e-02</TD><TD>-3.41</TD><TD>DOANE_BREAST_CANCER_ESR1_UP</TD><TD>MSigDB lists</TD><TD>DOANE_BREAST_CANCER_ESR1_UP</TD><TD>107</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,AZGP1</TD></TR>
<TR><TD>3.302e-02</TD><TD>-3.41</TD><TD>positive regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051254</TD><TD>1699</TD><TD>9</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,ALX1,SATB2,ZFHX4,ZIC1,PAX9,HEY1,PLAG1,MEIS2</TD></TR>
<TR><TD>3.303e-02</TD><TD>-3.41</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I</TD><TD>107</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>GPC5,CDKN2A</TD></TR>
<TR><TD>3.312e-02</TD><TD>-3.41</TD><TD>neurotransmitter receptor activity</TD><TD>molecular function</TD><TD>GO:0030594</TD><TD>115</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>3.338e-02</TD><TD>-3.40</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>459</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,CPEB2,SLC6A15,KYNU</TD></TR>
<TR><TD>3.353e-02</TD><TD>-3.40</TD><TD>ATAAGCT_MIR21</TD><TD>MSigDB lists</TD><TD>ATAAGCT_MIR21</TD><TD>108</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PCDH17</TD></TR>
<TR><TD>3.403e-02</TD><TD>-3.38</TD><TD>positive regulation of hair cycle</TD><TD>biological process</TD><TD>GO:0042635</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>FST</TD></TR>
<TR><TD>3.403e-02</TD><TD>-3.38</TD><TD>heart valve formation</TD><TD>biological process</TD><TD>GO:0003188</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.403e-02</TD><TD>-3.38</TD><TD>protein import into peroxisome matrix</TD><TD>biological process</TD><TD>GO:0016558</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PEX5L</TD></TR>
<TR><TD>3.403e-02</TD><TD>-3.38</TD><TD>heart trabecula formation</TD><TD>biological process</TD><TD>GO:0060347</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_LOW_DENSITY_LIPOPROTEIN_PARTICLE</TD><TD>MSigDB lists</TD><TD>GO_LOW_DENSITY_LIPOPROTEIN_PARTICLE</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>LSR</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_REGULATION_OF_VASCULOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_VASCULOGENESIS</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_POSITIVE_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_DICARBOXYLIC_ACID_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_DICARBOXYLIC_ACID_BIOSYNTHETIC_PROCESS</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_PROTEIN_IMPORT_INTO_PEROXISOME_MATRIX</TD><TD>MSigDB lists</TD><TD>GO_PROTEIN_IMPORT_INTO_PEROXISOME_MATRIX</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>chr21q11</TD><TD>MSigDB lists</TD><TD>chr21q11</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>RBM11</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>LEE_SP4_THYMOCYTE</TD><TD>MSigDB lists</TD><TD>LEE_SP4_THYMOCYTE</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_CHYLOMICRON</TD><TD>MSigDB lists</TD><TD>GO_CHYLOMICRON</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>LSR</TD></TR>
<TR><TD>3.408e-02</TD><TD>-3.38</TD><TD>GO_REGULATION_OF_SMOOTH_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_SMOOTH_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.410e-02</TD><TD>-3.38</TD><TD>GO_REGULATION_OF_STEM_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_STEM_CELL_DIFFERENTIATION</TD><TD>109</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,EPHA3</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>stomach-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-adenoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>pituitary-adenoma-PRL</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-PRL</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>cervix-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>cervix-carcinoma-adenocarcinoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>skin-vulva-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-vulva-malignant_melanoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>soft_tissue-fat-lipoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fat-lipoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>radius</TD><TD>COSMIC cancer mutations</TD><TD>radius</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>Brenner_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Brenner_tumour</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>ovary-adenoma-mucinous</TD><TD>COSMIC cancer mutations</TD><TD>ovary-adenoma-mucinous</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>skin-malignant_melanoma-lentigo_maligna</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-lentigo_maligna</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Hodgkin_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Hodgkin_lymphoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>sarcomatous-fibrous</TD><TD>COSMIC cancer mutations</TD><TD>sarcomatous-fibrous</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>chest_wall</TD><TD>COSMIC cancer mutations</TD><TD>chest_wall</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>PRL</TD><TD>COSMIC cancer mutations</TD><TD>PRL</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>intraventricular</TD><TD>COSMIC cancer mutations</TD><TD>intraventricular</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>anus</TD><TD>COSMIC cancer mutations</TD><TD>anus</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.412e-02</TD><TD>-3.38</TD><TD>skin-scalp-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma-nodular</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.422e-02</TD><TD>-3.37</TD><TD>SKIL (SKI like proto-oncogene)</TD><TD>protein interactions</TD><TD>6498</TD><TD>108</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>PAPPA,HEY1</TD></TR>
<TR><TD>3.424e-02</TD><TD>-3.37</TD><TD>activin binding</TD><TD>molecular function</TD><TD>GO:0048185</TD><TD>14</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>FST</TD></TR>
<TR><TD>3.424e-02</TD><TD>-3.37</TD><TD>translation repressor activity, mRNA regulatory element binding</TD><TD>molecular function</TD><TD>GO:0000900</TD><TD>14</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.424e-02</TD><TD>-3.37</TD><TD>GTPase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0005095</TD><TD>14</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.429e-02</TD><TD>-3.37</TD><TD>human chr4p15.32</TD><TD>chromosome location</TD><TD>human chr4p15.32</TD><TD>19</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>breast-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma</TD><TD>15396</TD><TD>45</TD><TD>17255</TD><TD>46</TD>
<TD>CLDN1,PCDH11X,CRB1,SCGB3A2,SPAG6,GABRB2,CDKN2A,GALNT13,ALX1,LSR,RBM11,SATB2,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20,MTSS1,AZGP1,EDA2R,CPEB2,PLAG1,PAPPA,ENPP5,KYNU,STAC,FST,IL7,SLC6A15,PLEKHM3,PEX5L,DCDC2,BMPR1B,EPHA3,GPC5,NPTX2,GRIA2,PLCH1,MEIS2,RNF128,SAA2,PAX9,IDO2,ZIC1</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>GLIS1 (GLIS family zinc finger 1)</TD><TD>protein interactions</TD><TD>148979</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>ATP8B2 (ATPase phospholipid transporting 8B2)</TD><TD>protein interactions</TD><TD>57198</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>BMP6 (bone morphogenetic protein 6)</TD><TD>protein interactions</TD><TD>654</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>KIAA1958 (KIAA1958)</TD><TD>protein interactions</TD><TD>158405</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>STAC</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>PLBD1 (phospholipase B domain containing 1)</TD><TD>protein interactions</TD><TD>79887</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>RUFY2 (RUN and FYVE domain containing 2)</TD><TD>protein interactions</TD><TD>55680</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>RIN2 (Ras and Rab interactor 2)</TD><TD>protein interactions</TD><TD>54453</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>Sept7 (septin 7)</TD><TD>protein interactions</TD><TD>235072</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>IGFBP4 (insulin like growth factor binding protein 4)</TD><TD>protein interactions</TD><TD>3487</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PAPPA</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>IGSF1 (immunoglobulin superfamily member 1)</TD><TD>protein interactions</TD><TD>3547</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.445e-02</TD><TD>-3.37</TD><TD>AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2)</TD><TD>protein interactions</TD><TD>10555</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.467e-02</TD><TD>-3.36</TD><TD>GSE37532_VISCERAL_ADIPOSE_TISSUE_VS_LN_DERIVED_TCONV_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE37532_VISCERAL_ADIPOSE_TISSUE_VS_LN_DERIVED_TCONV_CD4_TCELL_UP</TD><TD>110</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,ZIC1</TD></TR>
<TR><TD>3.467e-02</TD><TD>-3.36</TD><TD>DAIRKEE_TERT_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>DAIRKEE_TERT_TARGETS_DN</TD><TD>110</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,PLEKHM3</TD></TR>
<TR><TD>3.481e-02</TD><TD>-3.36</TD><TD>extraskeletal</TD><TD>COSMIC cancer mutations</TD><TD>extraskeletal</TD><TD>923</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>ZFHX4,CDKN2A,MTSS1,EYA4,HEY1,PLEKHM3</TD></TR>
<TR><TD>3.496e-02</TD><TD>-3.35</TD><TD>PTX_2</TD><TD>prosite domains</TD><TD>PS51828</TD><TD>11</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.504e-02</TD><TD>-3.35</TD><TD>negative regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045934</TD><TD>1443</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1,MEIS2,ZFHX4,PAX9,FST,ALX1,CDKN2A,SATB2</TD></TR>
<TR><TD>3.505e-02</TD><TD>-3.35</TD><TD>positive regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010628</TD><TD>2000</TD><TD>10</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B,ALX1,SATB2,IL7,ZIC1,PAX9,ZFHX4,MEIS2,HEY1,PLAG1</TD></TR>
<TR><TD>3.507e-02</TD><TD>-3.35</TD><TD>L-tryptophan degradation III (eukaryotic)</TD><TD>BIOCYC pathways</TD><TD>META_TRYPTOPHAN-DEGRADATION-1</TD><TD>8</TD><TD>1</TD><TD>902</TD><TD>4</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.525e-02</TD><TD>-3.35</TD><TD>aging</TD><TD>biological process</TD><TD>GO:0007568</TD><TD>271</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,CLDN1,CDKN2A</TD></TR>
<TR><TD>3.533e-02</TD><TD>-3.34</TD><TD>integral component of postsynaptic membrane</TD><TD>cellular component</TD><TD>GO:0099055</TD><TD>117</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>PCDH17,GABRB2</TD></TR>
<TR><TD>3.551e-02</TD><TD>-3.34</TD><TD>Tyr_kinase_rcpt_V_CS</TD><TD>interpro domains</TD><TD>IPR001426</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.551e-02</TD><TD>-3.34</TD><TD>Tyr_kinase_ephrin_rcpt</TD><TD>interpro domains</TD><TD>IPR016257</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.551e-02</TD><TD>-3.34</TD><TD>Eph_TM</TD><TD>interpro domains</TD><TD>IPR027936</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.551e-02</TD><TD>-3.34</TD><TD>Ephrin_rcpt_lig-bd_dom</TD><TD>interpro domains</TD><TD>IPR001090</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.552e-02</TD><TD>-3.34</TD><TD>GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METABOLIC_PROCESS</TD><TD>1447</TD><TD>8</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,MEIS2,HEY1,ALX1,FST,PAX9,CPEB2,CDKN2A</TD></TR>
<TR><TD>3.566e-02</TD><TD>-3.33</TD><TD>TATTATA_MIR374</TD><TD>MSigDB lists</TD><TD>TATTATA_MIR374</TD><TD>272</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,PAPPA,PLAG1</TD></TR>
<TR><TD>3.583e-02</TD><TD>-3.33</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>112</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,CXCL14</TD></TR>
<TR><TD>3.583e-02</TD><TD>-3.33</TD><TD>GSE36095_WT_VS_HDAC9_KO_TREG_DN</TD><TD>MSigDB lists</TD><TD>GSE36095_WT_VS_HDAC9_KO_TREG_DN</TD><TD>112</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,NPTX2</TD></TR>
<TR><TD>3.634e-02</TD><TD>-3.31</TD><TD>PTX</TD><TD>smart domains</TD><TD>SM00159</TD><TD>10</TD><TD>1</TD><TD>9476</TD><TD>35</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.641e-02</TD><TD>-3.31</TD><TD>GSE1925_CTRL_VS_IFNG_PRIMED_MACROPHAGE_3H_IFNG_STIM_DN</TD><TD>MSigDB lists</TD><TD>GSE1925_CTRL_VS_IFNG_PRIMED_MACROPHAGE_3H_IFNG_STIM_DN</TD><TD>113</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IDO2,EDA2R</TD></TR>
<TR><TD>3.643e-02</TD><TD>-3.31</TD><TD>WH2</TD><TD>pfam domains</TD><TD>PF02205</TD><TD>14</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>3.643e-02</TD><TD>-3.31</TD><TD>EphA2_TM</TD><TD>pfam domains</TD><TD>PF14575</TD><TD>14</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.643e-02</TD><TD>-3.31</TD><TD>Ephrin_lbd</TD><TD>pfam domains</TD><TD>PF01404</TD><TD>14</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.660e-02</TD><TD>-3.31</TD><TD>regulation of vasculogenesis</TD><TD>biological process</TD><TD>GO:2001212</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.660e-02</TD><TD>-3.31</TD><TD>dicarboxylic acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0043650</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.660e-02</TD><TD>-3.31</TD><TD>synaptic transmission, GABAergic</TD><TD>biological process</TD><TD>GO:0051932</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.660e-02</TD><TD>-3.31</TD><TD>establishment of endothelial intestinal barrier</TD><TD>biological process</TD><TD>GO:0090557</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.660e-02</TD><TD>-3.31</TD><TD>positive regulation of extrinsic apoptotic signaling pathway via death domain receptors</TD><TD>biological process</TD><TD>GO:1902043</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.660e-02</TD><TD>-3.31</TD><TD>GO_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>695</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,MEIS2,PAX9,PLAG1,ALX1</TD></TR>
<TR><TD>3.664e-02</TD><TD>-3.31</TD><TD>transforming growth factor beta-activated receptor activity</TD><TD>molecular function</TD><TD>GO:0005024</TD><TD>15</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>AHRARNT_02</TD><TD>MSigDB lists</TD><TD>AHRARNT_02</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>GO_HEART_TRABECULA_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_HEART_TRABECULA_FORMATION</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>GO_PYRIDINE_NUCLEOTIDE_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PYRIDINE_NUCLEOTIDE_BIOSYNTHETIC_PROCESS</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>chr13q21</TD><TD>MSigDB lists</TD><TD>chr13q21</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>GO_CELLULAR_RESPONSE_TO_ARSENIC_CONTAINING_SUBSTANCE</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_RESPONSE_TO_ARSENIC_CONTAINING_SUBSTANCE</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>CASTELLANO_NRAS_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>CASTELLANO_NRAS_TARGETS_DN</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>SA_G1_AND_S_PHASES</TD><TD>MSigDB lists</TD><TD>SA_G1_AND_S_PHASES</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>BIOCARTA_STEM_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_STEM_PATHWAY</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>IL7</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>GO_TRANSCRIPTION_FACTOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_SEQUENCE_SPECIFIC</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTION_FACTOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_SEQUENCE_SPECIFIC</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>GO_GTPASE_INHIBITOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_GTPASE_INHIBITOR_ACTIVITY</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.665e-02</TD><TD>-3.31</TD><TD>GO_LIGASE_REGULATOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_LIGASE_REGULATOR_ACTIVITY</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.669e-02</TD><TD>-3.31</TD><TD>acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>acinar_carcinoma</TD><TD>2014</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,ZFHX4,MTSS1,AZGP1,PCDH11X,DCDC2,ZIC4,BMPR1B,PLAG1,PAPPA</TD></TR>
<TR><TD>3.669e-02</TD><TD>-3.31</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>2014</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>ZIC4,DCDC2,AZGP1,PCDH11X,MTSS1,PAPPA,PLAG1,BMPR1B,ZFHX4,CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>pituitary-adenoma-ACTH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-ACTH</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>chondroid</TD><TD>COSMIC cancer mutations</TD><TD>chondroid</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>pituitary-adenoma-non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-non_functioning</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>in_situ_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>in_situ_neoplasm</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>ACTH</TD><TD>COSMIC cancer mutations</TD><TD>ACTH</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>ovary-sex_cord-stromal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-sex_cord-stromal_tumour</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>penis</TD><TD>COSMIC cancer mutations</TD><TD>penis</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>autonomic_ganglia-paraganglioma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-paraganglioma</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>bone-vertebrae-chordoma-chondroid</TD><TD>COSMIC cancer mutations</TD><TD>bone-vertebrae-chordoma-chondroid</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_II</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.31</TD><TD>bone-calcaneus-chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-calcaneus-chondrosarcoma</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.700e-02</TD><TD>-3.30</TD><TD>KIM_WT1_TARGETS_8HR_DN</TD><TD>MSigDB lists</TD><TD>KIM_WT1_TARGETS_8HR_DN</TD><TD>114</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,FST</TD></TR>
<TR><TD>3.706e-02</TD><TD>-3.30</TD><TD>MTSS1 (MTSS I-BAR domain containing 1)</TD><TD>protein interactions</TD><TD>9788</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MTSS1</TD></TR>
<TR><TD>3.706e-02</TD><TD>-3.30</TD><TD>Sqstm1 (sequestosome 1)</TD><TD>protein interactions</TD><TD>18412</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.706e-02</TD><TD>-3.30</TD><TD>RHEBL1 (RHEB like 1)</TD><TD>protein interactions</TD><TD>121268</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.706e-02</TD><TD>-3.30</TD><TD>SLC25A15 (solute carrier family 25 member 15)</TD><TD>protein interactions</TD><TD>10166</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EYA4</TD></TR>
<TR><TD>3.706e-02</TD><TD>-3.30</TD><TD>AMHR2 (anti-Mullerian hormone receptor type 2)</TD><TD>protein interactions</TD><TD>269</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.706e-02</TD><TD>-3.30</TD><TD>SOX3 (SRY-box transcription factor 3)</TD><TD>protein interactions</TD><TD>6658</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.708e-02</TD><TD>-3.29</TD><TD>skin-chest-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-chest-malignant_melanoma</TD><TD>114</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>3.719e-02</TD><TD>-3.29</TD><TD>movement of cell or subcellular component</TD><TD>biological process</TD><TD>GO:0006928</TD><TD>1460</TD><TD>8</TD><TD>18054</TD><TD>48</TD>
<TD>GPC5,SATB2,ALX1,EPHA3,BMPR1B,SAA2,CXCL14,DCDC2</TD></TR>
<TR><TD>3.727e-02</TD><TD>-3.29</TD><TD>low-density lipoprotein particle</TD><TD>cellular component</TD><TD>GO:0034362</TD><TD>15</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>3.733e-02</TD><TD>-3.29</TD><TD>GO_EMBRYONIC_ORGAN_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_ORGAN_MORPHOGENESIS</TD><TD>277</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ALX1,ZIC1</TD></TR>
<TR><TD>3.737e-02</TD><TD>-3.29</TD><TD>Unblocking of NMDA receptor, glutamate binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-438066</TD><TD>17</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GRIA2</TD></TR>
<TR><TD>3.737e-02</TD><TD>-3.29</TD><TD>Trafficking of GluR2-containing AMPA receptors</TD><TD>REACTOME pathways</TD><TD>R-HSA-416993</TD><TD>17</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GRIA2</TD></TR>
<TR><TD>3.737e-02</TD><TD>-3.29</TD><TD>SUMOylation of transcription factors</TD><TD>REACTOME pathways</TD><TD>R-HSA-3232118</TD><TD>17</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.751e-02</TD><TD>-3.28</TD><TD>regulation of protein localization to cell periphery</TD><TD>biological process</TD><TD>GO:1904375</TD><TD>115</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3,STAC</TD></TR>
<TR><TD>3.760e-02</TD><TD>-3.28</TD><TD>AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP</TD><TD>MSigDB lists</TD><TD>AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,FST</TD></TR>
<TR><TD>3.760e-02</TD><TD>-3.28</TD><TD>GSE32901_NAIVE_VS_TH1_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE32901_NAIVE_VS_TH1_CD4_TCELL_UP</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128,PCDH20</TD></TR>
<TR><TD>3.760e-02</TD><TD>-3.28</TD><TD>GSE12707_AT16L1_HYPOMORPH_VS_WT_THYMUS_UP</TD><TD>MSigDB lists</TD><TD>GSE12707_AT16L1_HYPOMORPH_VS_WT_THYMUS_UP</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,CLDN1</TD></TR>
<TR><TD>3.760e-02</TD><TD>-3.28</TD><TD>GSE25677_MPL_VS_MPL_AND_R848_STIM_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE25677_MPL_VS_MPL_AND_R848_STIM_BCELL_DN</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CRB1,KYNU</TD></TR>
<TR><TD>3.778e-02</TD><TD>-3.28</TD><TD>Bone Morphogenic Protein (BMP) Signalling and Regulation</TD><TD>WikiPathways</TD><TD>WP1425</TD><TD>12</TD><TD>1</TD><TD>5311</TD><TD>17</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>human chr13q31.3</TD><TD>chromosome location</TD><TD>human chr13q31.3</TD><TD>21</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>GPC5</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>human chr3q26.33</TD><TD>chromosome location</TD><TD>human chr3q26.33</TD><TD>21</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>PEX5L</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>human chr3q28</TD><TD>chromosome location</TD><TD>human chr3q28</TD><TD>21</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.788e-02</TD><TD>-3.27</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>478</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,CPEB2,KYNU,CLDN1</TD></TR>
<TR><TD>3.800e-02</TD><TD>-3.27</TD><TD>PI-PLC_fam</TD><TD>interpro domains</TD><TD>IPR001192</TD><TD>15</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.800e-02</TD><TD>-3.27</TD><TD>PLipase_C_Pinositol-sp_Y</TD><TD>interpro domains</TD><TD>IPR001711</TD><TD>15</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.808e-02</TD><TD>-3.27</TD><TD>ORANGE</TD><TD>prosite domains</TD><TD>PS51054</TD><TD>12</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.813e-02</TD><TD>-3.27</TD><TD>intrinsic component of postsynaptic membrane</TD><TD>cellular component</TD><TD>GO:0098936</TD><TD>122</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>PCDH17,GABRB2</TD></TR>
<TR><TD>3.813e-02</TD><TD>-3.27</TD><TD>axoneme</TD><TD>cellular component</TD><TD>GO:0005930</TD><TD>122</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>DCDC2,SPAG6</TD></TR>
<TR><TD>3.819e-02</TD><TD>-3.27</TD><TD>GGCACTT_MIR519E</TD><TD>MSigDB lists</TD><TD>GGCACTT_MIR519E</TD><TD>116</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,ZIC4</TD></TR>
<TR><TD>3.835e-02</TD><TD>-3.26</TD><TD>HORIUCHI_WTAP_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HORIUCHI_WTAP_TARGETS_UP</TD><TD>280</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,PAPPA,HEY1</TD></TR>
<TR><TD>3.835e-02</TD><TD>-3.26</TD><TD>CHANDRAN_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>CHANDRAN_METASTASIS_DN</TD><TD>280</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1,EPHA3,EYA4</TD></TR>
<TR><TD>3.845e-02</TD><TD>-3.26</TD><TD>chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>chondrosarcoma</TD><TD>1201</TD><TD>7</TD><TD>17255</TD><TD>46</TD>
<TD>HEY1,PCDH20,EPHA3,CDKN2A,ZFHX4,ALX1,EYA4</TD></TR>
<TR><TD>3.864e-02</TD><TD>-3.25</TD><TD>serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>serous_carcinoma</TD><TD>11226</TD><TD>36</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,AZGP1,ENPP5,PLAG1,PAPPA,FST,IL7,KYNU,STAC,PEX5L,PLEKHM3,SLC6A15,DCDC2,GPC5,EPHA3,BMPR1B,GRIA2,PLCH1,IDO2,ZIC1,RNF128,MEIS2,PAX9,SCGB3A2,PCDH11X,CRB1,SPAG6,LSR,CDKN2A,GALNT13,ALX1,SATB2,PCDH17,EYA4,ZFHX4,PCDH20</TD></TR>
<TR><TD>3.870e-02</TD><TD>-3.25</TD><TD>ciliary plasm</TD><TD>cellular component</TD><TD>GO:0097014</TD><TD>123</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>SPAG6,DCDC2</TD></TR>
<TR><TD>3.879e-02</TD><TD>-3.25</TD><TD>KAN_RESPONSE_TO_ARSENIC_TRIOXIDE</TD><TD>MSigDB lists</TD><TD>KAN_RESPONSE_TO_ARSENIC_TRIOXIDE</TD><TD>117</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,CXCL14</TD></TR>
<TR><TD>3.879e-02</TD><TD>-3.25</TD><TD>AAAGGAT_MIR501</TD><TD>MSigDB lists</TD><TD>AAAGGAT_MIR501</TD><TD>117</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,SATB2</TD></TR>
<TR><TD>3.879e-02</TD><TD>-3.25</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>MSigDB lists</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>117</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,AZGP1</TD></TR>
<TR><TD>3.880e-02</TD><TD>-3.25</TD><TD>skin-back-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-malignant_melanoma</TD><TD>281</TD><TD>3</TD><TD>17255</TD><TD>46</TD>
<TD>PLAG1,PLCH1,CDKN2A</TD></TR>
<TR><TD>3.898e-02</TD><TD>-3.24</TD><TD>PI-PLC-Y</TD><TD>pfam domains</TD><TD>PF00387</TD><TD>15</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.898e-02</TD><TD>-3.24</TD><TD>OAR</TD><TD>pfam domains</TD><TD>PF03826</TD><TD>15</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>ALX1</TD></TR>
<TR><TD>3.904e-02</TD><TD>-3.24</TD><TD>heparan sulfate proteoglycan binding</TD><TD>molecular function</TD><TD>GO:0043395</TD><TD>16</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>FST</TD></TR>
<TR><TD>3.904e-02</TD><TD>-3.24</TD><TD>inhibitory extracellular ligand-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0005237</TD><TD>16</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_T_CELL_LINEAGE_COMMITMENT</TD><TD>MSigDB lists</TD><TD>GO_T_CELL_LINEAGE_COMMITMENT</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>IL7</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>MODULE_215</TD><TD>MSigDB lists</TD><TD>MODULE_215</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_POLYPEPTIDE_N_ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_POLYPEPTIDE_N_ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GALNT13</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>ZHANG_GATA6_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ZHANG_GATA6_TARGETS_UP</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GALNT13</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>chr2q22</TD><TD>MSigDB lists</TD><TD>chr2q22</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>RODRIGUES_NTN1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>RODRIGUES_NTN1_TARGETS_UP</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_ATRIOVENTRICULAR_VALVE_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_ATRIOVENTRICULAR_VALVE_MORPHOGENESIS</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_REGULATION_OF_HAIR_FOLLICLE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_HAIR_FOLLICLE_DEVELOPMENT</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_NEGATIVE_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>GO_SUMO_TRANSFERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_SUMO_TRANSFERASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>CAIRO_PML_TARGETS_BOUND_BY_MYC_DN</TD><TD>MSigDB lists</TD><TD>CAIRO_PML_TARGETS_BOUND_BY_MYC_DN</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.922e-02</TD><TD>-3.24</TD><TD>REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS</TD><TD>MSigDB lists</TD><TD>REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>lipoma</TD><TD>COSMIC cancer mutations</TD><TD>lipoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>testis-germ_cell_tumour-mixed</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-mixed</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>soft_tissue-nerve_sheath-neurofibroma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-nerve_sheath-neurofibroma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>pituitary-adenoma-GH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-GH</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>GH</TD><TD>COSMIC cancer mutations</TD><TD>GH</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>transitional</TD><TD>COSMIC cancer mutations</TD><TD>transitional</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>right</TD><TD>COSMIC cancer mutations</TD><TD>right</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>thymus-thymic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thymus-thymic_carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>choriocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>choriocarcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-gastrointestinal_stromal_tumour-epithelioid</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-gastrointestinal_stromal_tumour-epithelioid</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>adrenal_gland-adrenal_gland-pheochromocytoma</TD><TD>COSMIC cancer mutations</TD><TD>adrenal_gland-adrenal_gland-pheochromocytoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>salivary_gland-parotid-carcinoma-acinic_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-carcinoma-acinic_cell_carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>ureter</TD><TD>COSMIC cancer mutations</TD><TD>ureter</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>pituitary-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>meninges-meningioma-anaplastic</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-anaplastic</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>autonomic_ganglia-head_neck-paraganglioma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-head_neck-paraganglioma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>biliary_tract-bile_duct-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>biliary_tract-bile_duct-carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>meninges-meningioma-atypical</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-atypical</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>meninges-meningioma-transitional</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-transitional</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>meninges-meningioma-fibroblastic</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-fibroblastic</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>central_nervous_system-brain-other-ganglioglioma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-other-ganglioglioma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.927e-02</TD><TD>-3.24</TD><TD>testis-germ_cell_tumour-embryonal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-embryonal_carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>GCTNWTTGK_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GCTNWTTGK_UNKNOWN</TD><TD>283</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,ZIC4,EPHA3</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>L-tryptophan degradation XI (mammalian, via kynurenine)</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6309</TD><TD>9</TD><TD>1</TD><TD>902</TD><TD>4</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>NAD biosynthesis II (from tryptophan)</TD><TD>BIOCYC pathways</TD><TD>META_NADSYN-PWY</TD><TD>9</TD><TD>1</TD><TD>902</TD><TD>4</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.939e-02</TD><TD>-3.23</TD><TD>NKX25_01</TD><TD>MSigDB lists</TD><TD>NKX25_01</TD><TD>118</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC4,PCDH17</TD></TR>
<TR><TD>3.948e-02</TD><TD>-3.23</TD><TD>central_nervous_system-brain-glioma-oligoastrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-oligoastrocytoma_Grade_III</TD><TD>118</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH20,CDKN2A</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>side of membrane</TD><TD>cellular component</TD><TD>GO:0098552</TD><TD>510</TD><TD>4</TD><TD>18985</TD><TD>48</TD>
<TD>STAC,GRIA2,AZGP1,NPTX2</TD></TR>
<TR><TD>3.957e-02</TD><TD>-3.23</TD><TD>CACGTG_MYC_Q2</TD><TD>MSigDB lists</TD><TD>CACGTG_MYC_Q2</TD><TD>953</TD><TD>6</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,RNF128,PLAG1,SLC6A15,SATB2,EYA4</TD></TR>
<TR><TD>3.959e-02</TD><TD>-3.23</TD><TD>TLE1 (TLE family member 1, transcriptional corepressor)</TD><TD>protein interactions</TD><TD>7088</TD><TD>117</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1,PAX9</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>CLDN1 (claudin 1)</TD><TD>protein interactions</TD><TD>9076</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>CYB5D2 (cytochrome b5 domain containing 2)</TD><TD>protein interactions</TD><TD>124936</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>MAB21L2 (mab-21 like 2)</TD><TD>protein interactions</TD><TD>10586</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>ZNF440 (zinc finger protein 440)</TD><TD>protein interactions</TD><TD>126070</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PAX9</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>AGAP2 (ArfGAP with GTPase domain, ankyrin repeat and PH domain 2)</TD><TD>protein interactions</TD><TD>116986</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GRIA2</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>PAPPA (pappalysin 1)</TD><TD>protein interactions</TD><TD>5069</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PAPPA</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>WNK4 (WNK lysine deficient protein kinase 4)</TD><TD>protein interactions</TD><TD>65266</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>MMRN1 (multimerin 1)</TD><TD>protein interactions</TD><TD>22915</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>CRELD2 (cysteine rich with EGF like domains 2)</TD><TD>protein interactions</TD><TD>79174</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>GABBR1 (gamma-aminobutyric acid type B receptor subunit 1)</TD><TD>protein interactions</TD><TD>2550</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>EFNA5 (ephrin A5)</TD><TD>protein interactions</TD><TD>1946</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>ASPRV1 (aspartic peptidase retroviral like 1)</TD><TD>protein interactions</TD><TD>151516</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>Tubb5 (tubulin, beta 5 class I)</TD><TD>protein interactions</TD><TD>22154</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>GSDMA (gasdermin A)</TD><TD>protein interactions</TD><TD>284110</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>3.965e-02</TD><TD>-3.23</TD><TD>RNF128 (ring finger protein 128)</TD><TD>protein interactions</TD><TD>79589</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>RNF128</TD></TR>
<TR><TD>3.973e-02</TD><TD>-3.23</TD><TD>MORF_ARL3</TD><TD>MSigDB lists</TD><TD>MORF_ARL3</TD><TD>284</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,GABRB2,PAX9</TD></TR>
<TR><TD>3.991e-02</TD><TD>-3.22</TD><TD>neuron migration</TD><TD>biological process</TD><TD>GO:0001764</TD><TD>119</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,DCDC2</TD></TR>
<TR><TD>3.991e-02</TD><TD>-3.22</TD><TD>regulation of cell-matrix adhesion</TD><TD>biological process</TD><TD>GO:0001952</TD><TD>119</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>4.000e-02</TD><TD>-3.22</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT</TD><TD>119</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2,ALX1</TD></TR>
<TR><TD>4.000e-02</TD><TD>-3.22</TD><TD>PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP</TD><TD>MSigDB lists</TD><TD>PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP</TD><TD>119</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EYA4,MEIS2</TD></TR>
<TR><TD>4.002e-02</TD><TD>-3.22</TD><TD>parathyroid</TD><TD>COSMIC cancer mutations</TD><TD>parathyroid</TD><TD>486</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,CDKN2A,ZIC1,GPC5</TD></TR>
<TR><TD>4.016e-02</TD><TD>-3.21</TD><TD>TUBA1A (tubulin alpha 1a)</TD><TD>protein interactions</TD><TD>7846</TD><TD>282</TD><TD>3</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2,HEY1,CDKN2A</TD></TR>
<TR><TD>4.017e-02</TD><TD>-3.21</TD><TD>HER-positive_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>HER-positive_carcinoma</TD><TD>2045</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,FST,PLCH1,PLEKHM3,DCDC2,BMPR1B,PLAG1,HEY1,EPHA3,GPC5</TD></TR>
<TR><TD>4.017e-02</TD><TD>-3.21</TD><TD>breast-carcinoma-HER-positive_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-HER-positive_carcinoma</TD><TD>2045</TD><TD>10</TD><TD>17255</TD><TD>46</TD>
<TD>DCDC2,HEY1,PLAG1,BMPR1B,EPHA3,GPC5,CDKN2A,FST,PLCH1,PLEKHM3</TD></TR>
<TR><TD>4.020e-02</TD><TD>-3.21</TD><TD>BMPR1A (bone morphogenetic protein receptor type 1A)</TD><TD>protein interactions</TD><TD>657</TD><TD>118</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B,FST</TD></TR>
<TR><TD>4.033e-02</TD><TD>-3.21</TD><TD>embryonic organ morphogenesis</TD><TD>biological process</TD><TD>GO:0048562</TD><TD>286</TD><TD>3</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2,ALX1,ZIC1</TD></TR>
<TR><TD>4.048e-02</TD><TD>-3.21</TD><TD>OAR_dom</TD><TD>interpro domains</TD><TD>IPR003654</TD><TD>16</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>ALX1</TD></TR>
<TR><TD>4.065e-02</TD><TD>-3.20</TD><TD>skin-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma</TD><TD>16096</TD><TD>46</TD><TD>17255</TD><TD>46</TD>
<TD>GRIA2,PLCH1,NPTX2,ZIC1,IDO2,SAA2,PAX9,RNF128,MEIS2,DCDC2,EPHA3,GPC5,BMPR1B,FST,IL7,CXCL14,STAC,KYNU,PEX5L,SLC6A15,PLEKHM3,CPEB2,EDA2R,AZGP1,MTSS1,ENPP5,PAPPA,PLAG1,EYA4,ZFHX4,PCDH20,ZIC4,SATB2,RBM11,PCDH17,HEY1,LSR,ALX1,GALNT13,CDKN2A,GABRB2,SCGB3A2,PCDH11X,CRB1,CLDN1,SPAG6</TD></TR>
<TR><TD>4.071e-02</TD><TD>-3.20</TD><TD>receptor regulator activity</TD><TD>molecular function</TD><TD>GO:0030545</TD><TD>525</TD><TD>4</TD><TD>17306</TD><TD>43</TD>
<TD>SAA2,IL7,FST,CXCL14</TD></TR>
<TR><TD>4.076e-02</TD><TD>-3.20</TD><TD>endocytic vesicle</TD><TD>cellular component</TD><TD>GO:0030139</TD><TD>302</TD><TD>3</TD><TD>18985</TD><TD>48</TD>
<TD>GRIA2,SCGB3A2,MTSS1</TD></TR>
<TR><TD>4.078e-02</TD><TD>-3.20</TD><TD>RNGTGGGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RNGTGGGC_UNKNOWN</TD><TD>716</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,FST,SATB2,PAX9,MEIS2</TD></TR>
<TR><TD>4.120e-02</TD><TD>-3.19</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>718</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,SATB2,FST,HEY1,ALX1</TD></TR>
<TR><TD>4.143e-02</TD><TD>-3.18</TD><TD>transmembrane receptor protein serine/threonine kinase activity</TD><TD>molecular function</TD><TD>GO:0004675</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.143e-02</TD><TD>-3.18</TD><TD>ribosomal small subunit binding</TD><TD>molecular function</TD><TD>GO:0043024</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.143e-02</TD><TD>-3.18</TD><TD>transmembrane-ephrin receptor activity</TD><TD>molecular function</TD><TD>GO:0005005</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.143e-02</TD><TD>-3.18</TD><TD>amino acid:cation symporter activity</TD><TD>molecular function</TD><TD>GO:0005416</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.152e-02</TD><TD>-3.18</TD><TD>PI-PLC-X</TD><TD>pfam domains</TD><TD>PF00388</TD><TD>16</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>tight junction</TD><TD>cellular component</TD><TD>GO:0070160</TD><TD>128</TD><TD>2</TD><TD>18985</TD><TD>48</TD>
<TD>CLDN1,LSR</TD></TR>
<TR><TD>4.166e-02</TD><TD>-3.18</TD><TD>Neurotransmitter Receptor Binding And Downstream Transmission In The  Postsynaptic Cell</TD><TD>REACTOME pathways</TD><TD>R-HSA-112314</TD><TD>146</TD><TD>2</TD><TD>10287</TD><TD>23</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>4.167e-02</TD><TD>-3.18</TD><TD>Defective B4GALT7 causes EDS, progeroid type</TD><TD>REACTOME pathways</TD><TD>R-HSA-3560783</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.167e-02</TD><TD>-3.18</TD><TD>Na+/Cl- dependent neurotransmitter transporters</TD><TD>REACTOME pathways</TD><TD>R-HSA-442660</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.167e-02</TD><TD>-3.18</TD><TD>Miscellaneous transport and binding events</TD><TD>REACTOME pathways</TD><TD>R-HSA-5223345</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.167e-02</TD><TD>-3.18</TD><TD>Defective B3GAT3 causes JDSSDHD</TD><TD>REACTOME pathways</TD><TD>R-HSA-3560801</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.167e-02</TD><TD>-3.18</TD><TD>Defective B3GALT6 causes EDSP2 and SEMDJL1</TD><TD>REACTOME pathways</TD><TD>R-HSA-4420332</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.172e-02</TD><TD>-3.18</TD><TD>response to follicle-stimulating hormone</TD><TD>biological process</TD><TD>GO:0032354</TD><TD>16</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PAPPA</TD></TR>
<TR><TD>4.172e-02</TD><TD>-3.18</TD><TD>inositol trisphosphate biosynthetic process</TD><TD>biological process</TD><TD>GO:0032959</TD><TD>16</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.175e-02</TD><TD>-3.18</TD><TD>positive regulation of protein localization to membrane</TD><TD>biological process</TD><TD>GO:1905477</TD><TD>122</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>EPHA3,STAC</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>GO_CELLULAR_MODIFIED_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_MODIFIED_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>FUKUSHIMA_TNFSF11_TARGETS</TD><TD>MSigDB lists</TD><TD>FUKUSHIMA_TNFSF11_TARGETS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>PID_HIF1A_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_HIF1A_PATHWAY</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>chr4q23</TD><TD>MSigDB lists</TD><TD>chr4q23</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS</TD><TD>MSigDB lists</TD><TD>REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>GO_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_INVOLVED_IN_HEART_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_INVOLVED_IN_HEART_DEVELOPMENT</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>GO_POSITIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_VIA_DEATH_DOMAIN_RECEPTORS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_VIA_DEATH_DOMAIN_RECEPTORS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>GO_CATION_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_CATION_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_III-IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_III-IV</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-precursor_T_cell_lymphoblastic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-precursor_T_cell_lymphoblastic_lymphoma</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>embryonal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>embryonal_carcinoma</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>normal</TD><TD>COSMIC cancer mutations</TD><TD>normal</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>skin-leg-adnexal_tumour-malignant_adnexal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-adnexal_tumour-malignant_adnexal_tumour</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>renal_pelvis</TD><TD>COSMIC cancer mutations</TD><TD>renal_pelvis</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>urinary_tract-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-carcinoma</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>flank</TD><TD>COSMIC cancer mutations</TD><TD>flank</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>eye-uveal_tract-malignant_melanoma-epithelioid</TD><TD>COSMIC cancer mutations</TD><TD>eye-uveal_tract-malignant_melanoma-epithelioid</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.186e-02</TD><TD>-3.17</TD><TD>urinary_tract</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract</TD><TD>14410</TD><TD>43</TD><TD>17255</TD><TD>46</TD>
<TD>CLDN1,PCDH11X,CRB1,SPAG6,GALNT13,GABRB2,CDKN2A,ALX1,LSR,RBM11,SATB2,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20,MTSS1,EDA2R,PLAG1,PAPPA,ENPP5,KYNU,CXCL14,STAC,IL7,FST,PLEKHM3,SLC6A15,PEX5L,DCDC2,BMPR1B,GPC5,EPHA3,NPTX2,PLCH1,GRIA2,MEIS2,RNF128,PAX9,SAA2,IDO2,ZIC1</TD></TR>
<TR><TD>4.186e-02</TD><TD>-3.17</TD><TD>bladder</TD><TD>COSMIC cancer mutations</TD><TD>bladder</TD><TD>14410</TD><TD>43</TD><TD>17255</TD><TD>46</TD>
<TD>RBM11,SATB2,ZIC4,HEY1,PCDH17,ZFHX4,EYA4,PCDH20,CLDN1,PCDH11X,CRB1,SPAG6,GABRB2,GALNT13,CDKN2A,ALX1,LSR,DCDC2,BMPR1B,EPHA3,GPC5,NPTX2,PLCH1,GRIA2,RNF128,MEIS2,PAX9,SAA2,IDO2,ZIC1,MTSS1,EDA2R,PLAG1,PAPPA,ENPP5,KYNU,STAC,CXCL14,IL7,FST,SLC6A15,PLEKHM3,PEX5L</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>NMU (neuromedin U)</TD><TD>protein interactions</TD><TD>10874</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>INHBA (inhibin subunit beta A)</TD><TD>protein interactions</TD><TD>3624</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>FST</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>FLRT1 (fibronectin leucine rich transmembrane protein 1)</TD><TD>protein interactions</TD><TD>23769</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH17</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>CHN1 (chimerin 1)</TD><TD>protein interactions</TD><TD>1123</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>ULBP2 (UL16 binding protein 2)</TD><TD>protein interactions</TD><TD>80328</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>IDO2</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>CAPNS2 (calpain small subunit 2)</TD><TD>protein interactions</TD><TD>84290</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>FRG1 (FSHD region gene 1)</TD><TD>protein interactions</TD><TD>2483</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>MTMR11 (myotubularin related protein 11)</TD><TD>protein interactions</TD><TD>10903</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>INHBE (inhibin subunit beta E)</TD><TD>protein interactions</TD><TD>83729</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>FST</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>Stub1 (STIP1 homology and U-Box containing protein 1)</TD><TD>protein interactions</TD><TD>56424</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.235e-02</TD><TD>-3.16</TD><TD>skin-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-carcinoma-squamous_cell_carcinoma</TD><TD>495</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>EPHA3,ZIC1,ZIC4,CDKN2A</TD></TR>
<TR><TD>4.237e-02</TD><TD>-3.16</TD><TD>cellular amino acid catabolic process</TD><TD>biological process</TD><TD>GO:0009063</TD><TD>123</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.248e-02</TD><TD>-3.16</TD><TD>Growth_fac_rcpt_cys_sf</TD><TD>interpro domains</TD><TD>IPR009030</TD><TD>127</TD><TD>2</TD><TD>18616</TD><TD>48</TD>
<TD>CRB1,EPHA3</TD></TR>
<TR><TD>4.296e-02</TD><TD>-3.15</TD><TD>PA_domain</TD><TD>interpro domains</TD><TD>IPR003137</TD><TD>17</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.299e-02</TD><TD>-3.15</TD><TD>GO_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_BEHAVIOR</TD><TD>498</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2,MEIS2,PCDH17,ZIC1</TD></TR>
<TR><TD>4.318e-02</TD><TD>-3.14</TD><TD>skin-ear-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-malignant_melanoma</TD><TD>124</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>4.330e-02</TD><TD>-3.14</TD><TD>CAGTGTT_MIR141_MIR200A</TD><TD>MSigDB lists</TD><TD>CAGTGTT_MIR141_MIR200A</TD><TD>294</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1,PAPPA,MTSS1</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>liver development</TD><TD>biological process</TD><TD>GO:0001889</TD><TD>125</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1,LSR</TD></TR>
<TR><TD>4.372e-02</TD><TD>-3.13</TD><TD>GO_NEGATIVE_REGULATION_OF_HEMOPOIESIS</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_HEMOPOIESIS</TD><TD>125</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,MEIS2</TD></TR>
<TR><TD>4.372e-02</TD><TD>-3.13</TD><TD>GO_CELL_JUNCTION_ASSEMBLY</TD><TD>MSigDB lists</TD><TD>GO_CELL_JUNCTION_ASSEMBLY</TD><TD>125</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>4.372e-02</TD><TD>-3.13</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP</TD><TD>125</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,NPTX2</TD></TR>
<TR><TD>4.372e-02</TD><TD>-3.13</TD><TD>GO_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_NUCLEUS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_NUCLEUS</TD><TD>125</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,CDKN2A</TD></TR>
<TR><TD>4.381e-02</TD><TD>-3.13</TD><TD>knee</TD><TD>COSMIC cancer mutations</TD><TD>knee</TD><TD>125</TD><TD>2</TD><TD>17255</TD><TD>46</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>4.406e-02</TD><TD>-3.12</TD><TD>PA</TD><TD>pfam domains</TD><TD>PF02225</TD><TD>17</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.416e-02</TD><TD>-3.12</TD><TD>Senescence and Autophagy in Cancer</TD><TD>WikiPathways</TD><TD>WP615</TD><TD>106</TD><TD>2</TD><TD>5311</TD><TD>17</TD>
<TD>CDKN2A,CXCL14</TD></TR>
<TR><TD>4.425e-02</TD><TD>-3.12</TD><TD>embryonic skeletal system development</TD><TD>biological process</TD><TD>GO:0048706</TD><TD>126</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>4.427e-02</TD><TD>-3.12</TD><TD>pulmonary valve morphogenesis</TD><TD>biological process</TD><TD>GO:0003184</TD><TD>17</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.429e-02</TD><TD>-3.12</TD><TD>RECEPTOR_TYR_KIN_V_1</TD><TD>prosite domains</TD><TD>PS00790</TD><TD>14</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.429e-02</TD><TD>-3.12</TD><TD>EPH_LBD</TD><TD>prosite domains</TD><TD>PS51550</TD><TD>14</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.429e-02</TD><TD>-3.12</TD><TD>RECEPTOR_TYR_KIN_V_2</TD><TD>prosite domains</TD><TD>PS00791</TD><TD>14</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_PROTEIN_LOCALIZATION_TO_LYSOSOME</TD><TD>MSigDB lists</TD><TD>GO_PROTEIN_LOCALIZATION_TO_LYSOSOME</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_LABYRINTHINE_LAYER_BLOOD_VESSEL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_LABYRINTHINE_LAYER_BLOOD_VESSEL_DEVELOPMENT</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>TGCACGA_MIR517A_MIR517C</TD><TD>MSigDB lists</TD><TD>TGCACGA_MIR517A_MIR517C</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>BIOCARTA_ARF_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_ARF_PATHWAY</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_ENDOCYTIC_VESICLE_LUMEN</TD><TD>MSigDB lists</TD><TD>GO_ENDOCYTIC_VESICLE_LUMEN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_REGULATORY_REGION_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_REGULATORY_REGION_DNA_BINDING</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>BIOCARTA_IL7_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_IL7_PATHWAY</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>IL7</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>YAO_HOXA10_TARGETS_VIA_PROGESTERONE_DN</TD><TD>MSigDB lists</TD><TD>YAO_HOXA10_TARGETS_VIA_PROGESTERONE_DN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>PLASARI_NFIC_TARGETS_BASAL_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_NFIC_TARGETS_BASAL_DN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS</TD><TD>MSigDB lists</TD><TD>REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_POLY_PYRIMIDINE_TRACT_BINDING</TD><TD>MSigDB lists</TD><TD>GO_POLY_PYRIMIDINE_TRACT_BINDING</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>RBM11</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP</TD><TD>MSigDB lists</TD><TD>GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>GO_REGULATION_OF_WATER_LOSS_VIA_SKIN</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_WATER_LOSS_VIA_SKIN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.435e-02</TD><TD>-3.12</TD><TD>GO_AMINE_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AMINE_METABOLIC_PROCESS</TD><TD>126</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.435e-02</TD><TD>-3.12</TD><TD>GSE21033_3H_VS_12H_POLYIC_STIM_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE21033_3H_VS_12H_POLYIC_STIM_DC_DN</TD><TD>126</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ALX1,STAC</TD></TR>
<TR><TD>4.435e-02</TD><TD>-3.12</TD><TD>GSE38696_LIGHT_ZONE_VS_DARK_ZONE_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE38696_LIGHT_ZONE_VS_DARK_ZONE_BCELL_DN</TD><TD>126</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,PCDH11X</TD></TR>
<TR><TD>4.435e-02</TD><TD>-3.12</TD><TD>GO_LEARNING</TD><TD>MSigDB lists</TD><TD>GO_LEARNING</TD><TD>126</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,NPTX2</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>thymoma</TD><TD>COSMIC cancer mutations</TD><TD>thymoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>extranodal</TD><TD>COSMIC cancer mutations</TD><TD>extranodal</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>neurofibroma</TD><TD>COSMIC cancer mutations</TD><TD>neurofibroma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>thymic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thymic_carcinoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>pineal_gland</TD><TD>COSMIC cancer mutations</TD><TD>pineal_gland</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>optic_nerve</TD><TD>COSMIC cancer mutations</TD><TD>optic_nerve</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>anaplastic</TD><TD>COSMIC cancer mutations</TD><TD>anaplastic</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>liver-other-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>liver-other-adenoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-adult_T_cell_lymphoma-leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-adult_T_cell_lymphoma-leukaemia</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>upper_extremity</TD><TD>COSMIC cancer mutations</TD><TD>upper_extremity</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>hypothalamus</TD><TD>COSMIC cancer mutations</TD><TD>hypothalamus</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>small_intestine-jejunum-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_intestine-jejunum-carcinoma-adenocarcinoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>adult_T_cell_lymphoma-leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>adult_T_cell_lymphoma-leukaemia</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>jejunum</TD><TD>COSMIC cancer mutations</TD><TD>jejunum</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>thymus-thymoma</TD><TD>COSMIC cancer mutations</TD><TD>thymus-thymoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.439e-02</TD><TD>-3.11</TD><TD>lower_extremity</TD><TD>COSMIC cancer mutations</TD><TD>lower_extremity</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.457e-02</TD><TD>-3.11</TD><TD>neuron projection</TD><TD>cellular component</TD><TD>GO:0043005</TD><TD>1306</TD><TD>7</TD><TD>18985</TD><TD>48</TD>
<TD>BMPR1B,GABRB2,GRIA2,CPEB2,NPTX2,EPHA3,DCDC2</TD></TR>
<TR><TD>4.458e-02</TD><TD>-3.11</TD><TD>leg</TD><TD>COSMIC cancer mutations</TD><TD>leg</TD><TD>980</TD><TD>6</TD><TD>17255</TD><TD>46</TD>
<TD>PLAG1,PLCH1,GRIA2,CDKN2A,MTSS1,SATB2</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>ANKRD12 (ankyrin repeat domain 12)</TD><TD>protein interactions</TD><TD>23253</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>SLC4A1 (solute carrier family 4 member 1 (Diego blood group))</TD><TD>protein interactions</TD><TD>6521</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>SPPL3 (signal peptide peptidase like 3)</TD><TD>protein interactions</TD><TD>121665</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>PCDH12 (protocadherin 12)</TD><TD>protein interactions</TD><TD>51294</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH17</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>ATG2A (autophagy related 2A)</TD><TD>protein interactions</TD><TD>23130</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>ALX4 (ALX homeobox 4)</TD><TD>protein interactions</TD><TD>60529</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ALX1</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>GLI2 (GLI family zinc finger 2)</TD><TD>protein interactions</TD><TD>2736</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>ZIC1</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>AZIN1 (antizyme inhibitor 1)</TD><TD>protein interactions</TD><TD>51582</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>CNTNAP3B (contactin associated protein like 3B)</TD><TD>protein interactions</TD><TD>728577</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>TTC33 (tetratricopeptide repeat domain 33)</TD><TD>protein interactions</TD><TD>23548</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>RBM11</TD></TR>
<TR><TD>4.482e-02</TD><TD>-3.11</TD><TD>Shcbp1 (Shc SH2-domain binding protein 1)</TD><TD>protein interactions</TD><TD>20419</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>human chr5q34</TD><TD>chromosome location</TD><TD>human chr5q34</TD><TD>25</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.498e-02</TD><TD>-3.10</TD><TD>SABATES_COLORECTAL_ADENOMA_UP</TD><TD>MSigDB lists</TD><TD>SABATES_COLORECTAL_ADENOMA_UP</TD><TD>127</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,AZGP1</TD></TR>
<TR><TD>4.498e-02</TD><TD>-3.10</TD><TD>GO_REGULATION_OF_LYMPHOCYTE_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_LYMPHOCYTE_DIFFERENTIATION</TD><TD>127</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A,IL7</TD></TR>
<TR><TD>4.514e-02</TD><TD>-3.10</TD><TD>MORF_ERCC4</TD><TD>MSigDB lists</TD><TD>MORF_ERCC4</TD><TD>299</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,GABRB2,PAX9</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>FOXL1 (forkhead box L1)</TD><TD>protein interactions</TD><TD>2300</TD><TD>126</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>ZFHX4,SATB2</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>NABA_MATRISOME_ASSOCIATED</TD><TD>MSigDB lists</TD><TD>NABA_MATRISOME_ASSOCIATED</TD><TD>737</TD><TD>5</TD><TD>17275</TD><TD>46</TD>
<TD>CXCL14,GPC5,PAPPA,FST,IL7</TD></TR>
<TR><TD>4.543e-02</TD><TD>-3.09</TD><TD>Iono_rcpt_met</TD><TD>interpro domains</TD><TD>IPR001508</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.543e-02</TD><TD>-3.09</TD><TD>PLipase_C_PInositol-sp_X_dom</TD><TD>interpro domains</TD><TD>IPR000909</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.543e-02</TD><TD>-3.09</TD><TD>Iontro_rcpt</TD><TD>interpro domains</TD><TD>IPR001320</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.543e-02</TD><TD>-3.09</TD><TD>Glu/Gly-bd</TD><TD>interpro domains</TD><TD>IPR019594</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.552e-02</TD><TD>-3.09</TD><TD>hepaticobiliary system development</TD><TD>biological process</TD><TD>GO:0061008</TD><TD>128</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1,LSR</TD></TR>
<TR><TD>4.562e-02</TD><TD>-3.09</TD><TD>GSE37605_C57BL6_VS_NOD_FOXP3_IRES_GFP_TCONV_UP</TD><TD>MSigDB lists</TD><TD>GSE37605_C57BL6_VS_NOD_FOXP3_IRES_GFP_TCONV_UP</TD><TD>128</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PAPPA,HEY1</TD></TR>
<TR><TD>4.562e-02</TD><TD>-3.09</TD><TD>PR_02</TD><TD>MSigDB lists</TD><TD>PR_02</TD><TD>128</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>ZFHX4,CXCL14</TD></TR>
<TR><TD>4.589e-02</TD><TD>-3.08</TD><TD>CCCNNGGGAR_OLF1_01</TD><TD>MSigDB lists</TD><TD>CCCNNGGGAR_OLF1_01</TD><TD>301</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,MEIS2,PLAG1</TD></TR>
<TR><TD>4.596e-02</TD><TD>-3.08</TD><TD>Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)</TD><TD>REACTOME pathways</TD><TD>R-HSA-381426</TD><TD>21</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>PAPPA</TD></TR>
<TR><TD>4.596e-02</TD><TD>-3.08</TD><TD>Scavenging by Class A Receptors</TD><TD>REACTOME pathways</TD><TD>R-HSA-3000480</TD><TD>21</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>4.596e-02</TD><TD>-3.08</TD><TD>HS-GAG degradation</TD><TD>REACTOME pathways</TD><TD>R-HSA-2024096</TD><TD>21</TD><TD>1</TD><TD>10287</TD><TD>23</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.608e-02</TD><TD>-3.08</TD><TD>ligand-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0015276</TD><TD>138</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>4.608e-02</TD><TD>-3.08</TD><TD>ligand-gated channel activity</TD><TD>molecular function</TD><TD>GO:0022834</TD><TD>138</TD><TD>2</TD><TD>17306</TD><TD>43</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>4.619e-02</TD><TD>-3.07</TD><TD>polypeptide N-acetylgalactosaminyltransferase activity</TD><TD>molecular function</TD><TD>GO:0004653</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GALNT13</TD></TR>
<TR><TD>4.619e-02</TD><TD>-3.07</TD><TD>ionotropic glutamate receptor activity</TD><TD>molecular function</TD><TD>GO:0004970</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.619e-02</TD><TD>-3.07</TD><TD>ephrin receptor activity</TD><TD>molecular function</TD><TD>GO:0005003</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.619e-02</TD><TD>-3.07</TD><TD>GABA-A receptor activity</TD><TD>molecular function</TD><TD>GO:0004890</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.626e-02</TD><TD>-3.07</TD><TD>GSE11818_WT_VS_DICER_KO_TREG_UP</TD><TD>MSigDB lists</TD><TD>GSE11818_WT_VS_DICER_KO_TREG_UP</TD><TD>129</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GPC5,SATB2</TD></TR>
<TR><TD>4.626e-02</TD><TD>-3.07</TD><TD>POOLA_INVASIVE_BREAST_CANCER_DN</TD><TD>MSigDB lists</TD><TD>POOLA_INVASIVE_BREAST_CANCER_DN</TD><TD>129</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,AZGP1</TD></TR>
<TR><TD>4.626e-02</TD><TD>-3.07</TD><TD>JOHNSTONE_PARVB_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>JOHNSTONE_PARVB_TARGETS_2_UP</TD><TD>129</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>FST,LSR</TD></TR>
<TR><TD>4.626e-02</TD><TD>-3.07</TD><TD>GO_REGULATION_OF_HEMOPOIESIS</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_HEMOPOIESIS</TD><TD>302</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2,CDKN2A,IL7</TD></TR>
<TR><TD>4.659e-02</TD><TD>-3.07</TD><TD>Lig_chan</TD><TD>pfam domains</TD><TD>PF00060</TD><TD>18</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.659e-02</TD><TD>-3.07</TD><TD>MHC_I</TD><TD>pfam domains</TD><TD>PF00129</TD><TD>18</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.659e-02</TD><TD>-3.07</TD><TD>Lig_chan-Glu_bd</TD><TD>pfam domains</TD><TD>PF10613</TD><TD>18</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.663e-02</TD><TD>-3.07</TD><TD>human chr4q32.1</TD><TD>chromosome location</TD><TD>human chr4q32.1</TD><TD>26</TD><TD>1</TD><TD>26169</TD><TD>48</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.664e-02</TD><TD>-3.07</TD><TD>MODULE_48</TD><TD>MSigDB lists</TD><TD>MODULE_48</TD><TD>303</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B,GALNT13,GPC5</TD></TR>
<TR><TD>4.678e-02</TD><TD>-3.06</TD><TD>Ser-Thr/Tyr_kinase_cat_dom</TD><TD>interpro domains</TD><TD>IPR001245</TD><TD>134</TD><TD>2</TD><TD>18616</TD><TD>48</TD>
<TD>EPHA3,BMPR1B</TD></TR>
<TR><TD>4.681e-02</TD><TD>-3.06</TD><TD>peroxisomal membrane transport</TD><TD>biological process</TD><TD>GO:0015919</TD><TD>18</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PEX5L</TD></TR>
<TR><TD>4.681e-02</TD><TD>-3.06</TD><TD>heterochromatin organization</TD><TD>biological process</TD><TD>GO:0070828</TD><TD>18</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>NIELSEN_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_SYNOVIAL_SARCOMA_UP</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>NPTX2</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_OSTEOBLAST_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_OSTEOBLAST_DEVELOPMENT</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SATB2</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>NADERI_BREAST_CANCER_PROGNOSIS_DN</TD><TD>MSigDB lists</TD><TD>NADERI_BREAST_CANCER_PROGNOSIS_DN</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_TRIGLYCERIDE_RICH_LIPOPROTEIN_PARTICLE</TD><TD>MSigDB lists</TD><TD>GO_TRIGLYCERIDE_RICH_LIPOPROTEIN_PARTICLE</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>LSR</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2</TD><TD>MSigDB lists</TD><TD>HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>chr3q28</TD><TD>MSigDB lists</TD><TD>chr3q28</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_PEROXISOMAL_TRANSPORT</TD><TD>MSigDB lists</TD><TD>GO_PEROXISOMAL_TRANSPORT</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PEX5L</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_GABA_RECEPTOR_COMPLEX</TD><TD>MSigDB lists</TD><TD>GO_GABA_RECEPTOR_COMPLEX</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN</TD><TD>MSigDB lists</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>LSR</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_PYRIDINE_CONTAINING_COMPOUND_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PYRIDINE_CONTAINING_COMPOUND_BIOSYNTHETIC_PROCESS</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_ATRIOVENTRICULAR_VALVE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_ATRIOVENTRICULAR_VALVE_DEVELOPMENT</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>GO_RETINAL_GANGLION_CELL_AXON_GUIDANCE</TD><TD>MSigDB lists</TD><TD>GO_RETINAL_GANGLION_CELL_AXON_GUIDANCE</TD><TD>18</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-anaplastic_large_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-anaplastic_large_cell_lymphoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>dysplasia</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>endometrium-carcinoma-clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-clear_cell_carcinoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>salivary_duct_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_duct_carcinoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>fibroblastic</TD><TD>COSMIC cancer mutations</TD><TD>fibroblastic</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>meninges-meningioma-meningothelial</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-meningothelial</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>meningothelial</TD><TD>COSMIC cancer mutations</TD><TD>meningothelial</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>calcaneus</TD><TD>COSMIC cancer mutations</TD><TD>calcaneus</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.698e-02</TD><TD>-3.06</TD><TD>GABA-A receptor complex</TD><TD>cellular component</TD><TD>GO:1902711</TD><TD>19</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.702e-02</TD><TD>-3.06</TD><TD>Pkinase_Tyr</TD><TD>pfam domains</TD><TD>PF07714</TD><TD>131</TD><TD>2</TD><TD>17385</TD><TD>46</TD>
<TD>BMPR1B,EPHA3</TD></TR>
<TR><TD>4.702e-02</TD><TD>-3.06</TD><TD>MORF_SUPT3H</TD><TD>MSigDB lists</TD><TD>MORF_SUPT3H</TD><TD>304</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>STAC,GABRB2,IL7</TD></TR>
<TR><TD>4.720e-02</TD><TD>-3.05</TD><TD>SMAD9 (SMAD family member 9)</TD><TD>protein interactions</TD><TD>4093</TD><TD>129</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>PAPPA,HEY1</TD></TR>
<TR><TD>4.734e-02</TD><TD>-3.05</TD><TD>MODULE_100</TD><TD>MSigDB lists</TD><TD>MODULE_100</TD><TD>514</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,ZIC1,MTSS1,MEIS2</TD></TR>
<TR><TD>4.738e-02</TD><TD>-3.05</TD><TD>PIPLC_Y_DOMAIN</TD><TD>prosite domains</TD><TD>PS50008</TD><TD>15</TD><TD>1</TD><TD>12079</TD><TD>39</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>EOGT (EGF domain specific O-linked N-acetylglucosamine transferase)</TD><TD>protein interactions</TD><TD>285203</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EYA4</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>FOXD3 (forkhead box D3)</TD><TD>protein interactions</TD><TD>27022</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SATB2</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>STK35 (serine/threonine kinase 35)</TD><TD>protein interactions</TD><TD>140901</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>KDELR3 (KDEL endoplasmic reticulum protein retention receptor 3)</TD><TD>protein interactions</TD><TD>11015</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>RPS26P11 (ribosomal protein S26 pseudogene 11)</TD><TD>protein interactions</TD><TD>441502</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>ADK (adenosine kinase)</TD><TD>protein interactions</TD><TD>132</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>PPIAL4G (peptidylprolyl isomerase A like 4G)</TD><TD>protein interactions</TD><TD>644591</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>EFNA1 (ephrin A1)</TD><TD>protein interactions</TD><TD>1942</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>Tgfbr1 (transforming growth factor, beta receptor I)</TD><TD>protein interactions</TD><TD>21812</TD><TD>18</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.740e-02</TD><TD>-3.05</TD><TD>MORF_ATF2</TD><TD>MSigDB lists</TD><TD>MORF_ATF2</TD><TD>305</TD><TD>3</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,STAC,GABRB2</TD></TR>
<TR><TD>4.753e-02</TD><TD>-3.05</TD><TD>parathyroid-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>parathyroid-carcinoma</TD><TD>305</TD><TD>3</TD><TD>17255</TD><TD>46</TD>
<TD>MTSS1,GPC5,ZIC1</TD></TR>
<TR><TD>4.755e-02</TD><TD>-3.05</TD><TD>ALK_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>ALK_DN.V1_UP</TD><TD>131</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>KYNU,BMPR1B</TD></TR>
<TR><TD>4.789e-02</TD><TD>-3.04</TD><TD>Na/ntran_symport</TD><TD>interpro domains</TD><TD>IPR000175</TD><TD>19</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.789e-02</TD><TD>-3.04</TD><TD>WH2_dom</TD><TD>interpro domains</TD><TD>IPR003124</TD><TD>19</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>MTSS1</TD></TR>
<TR><TD>4.789e-02</TD><TD>-3.04</TD><TD>SNS_sf</TD><TD>interpro domains</TD><TD>IPR037272</TD><TD>19</TD><TD>1</TD><TD>18616</TD><TD>48</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.797e-02</TD><TD>-3.04</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>10941</TD><TD>35</TD><TD>17255</TD><TD>46</TD>
<TD>IL7,FST,STAC,KYNU,PEX5L,SLC6A15,PLEKHM3,AZGP1,MTSS1,ENPP5,PAPPA,PLCH1,GRIA2,ZIC1,IDO2,PAX9,MEIS2,RNF128,DCDC2,EPHA3,GPC5,BMPR1B,LSR,ALX1,GALNT13,CDKN2A,SCGB3A2,PCDH11X,CRB1,SPAG6,EYA4,ZFHX4,PCDH20,SATB2,PCDH17</TD></TR>
<TR><TD>4.812e-02</TD><TD>-3.03</TD><TD>postsynaptic membrane</TD><TD>cellular component</TD><TD>GO:0045211</TD><TD>323</TD><TD>3</TD><TD>18985</TD><TD>48</TD>
<TD>PCDH17,GABRB2,GRIA2</TD></TR>
<TR><TD>4.818e-02</TD><TD>-3.03</TD><TD>MODULE_137</TD><TD>MSigDB lists</TD><TD>MODULE_137</TD><TD>517</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1,MEIS2,GRIA2,ZIC1</TD></TR>
<TR><TD>4.821e-02</TD><TD>-3.03</TD><TD>GO_ADULT_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_ADULT_BEHAVIOR</TD><TD>132</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>PCDH17,ZIC1</TD></TR>
<TR><TD>4.821e-02</TD><TD>-3.03</TD><TD>GO_MESENCHYMAL_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_MESENCHYMAL_CELL_DIFFERENTIATION</TD><TD>132</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,ALX1</TD></TR>
<TR><TD>4.821e-02</TD><TD>-3.03</TD><TD>AHRARNT_01</TD><TD>MSigDB lists</TD><TD>AHRARNT_01</TD><TD>132</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>IL7,PCDH17</TD></TR>
<TR><TD>4.856e-02</TD><TD>-3.02</TD><TD>protein transporter activity</TD><TD>molecular function</TD><TD>GO:0140318</TD><TD>20</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.856e-02</TD><TD>-3.02</TD><TD>ligand-gated anion channel activity</TD><TD>molecular function</TD><TD>GO:0099095</TD><TD>20</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.856e-02</TD><TD>-3.02</TD><TD>protein transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0008320</TD><TD>20</TD><TD>1</TD><TD>17306</TD><TD>43</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.875e-02</TD><TD>-3.02</TD><TD>coenzyme biosynthetic process</TD><TD>biological process</TD><TD>GO:0009108</TD><TD>133</TD><TD>2</TD><TD>18054</TD><TD>48</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>4.912e-02</TD><TD>-3.01</TD><TD>SNF</TD><TD>pfam domains</TD><TD>PF00209</TD><TD>19</TD><TD>1</TD><TD>17385</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.915e-02</TD><TD>-3.01</TD><TD>BMP signaling</TD><TD>KEGG pathways</TD><TD>M00679</TD><TD>20</TD><TD>1</TD><TD>7161</TD><TD>18</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.915e-02</TD><TD>-3.01</TD><TD>BMP signaling</TD><TD>KEGG pathways</TD><TD>hsa_M00679</TD><TD>20</TD><TD>1</TD><TD>7161</TD><TD>18</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>retinal ganglion cell axon guidance</TD><TD>biological process</TD><TD>GO:0031290</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>presynapse assembly</TD><TD>biological process</TD><TD>GO:0099054</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PCDH17</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>regulation of translational elongation</TD><TD>biological process</TD><TD>GO:0006448</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>xenobiotic transport</TD><TD>biological process</TD><TD>GO:0042908</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>osteoblast development</TD><TD>biological process</TD><TD>GO:0002076</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>SATB2</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>inositol trisphosphate metabolic process</TD><TD>biological process</TD><TD>GO:0032957</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>cellular response to arsenic-containing substance</TD><TD>biological process</TD><TD>GO:0071243</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>positive regulation of glial cell proliferation</TD><TD>biological process</TD><TD>GO:0060252</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>PLAG1</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>labyrinthine layer blood vessel development</TD><TD>biological process</TD><TD>GO:0060716</TD><TD>19</TD><TD>1</TD><TD>18054</TD><TD>48</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.939e-02</TD><TD>-3.01</TD><TD>very-low-density lipoprotein particle</TD><TD>cellular component</TD><TD>GO:0034361</TD><TD>20</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>4.939e-02</TD><TD>-3.01</TD><TD>triglyceride-rich plasma lipoprotein particle</TD><TD>cellular component</TD><TD>GO:0034385</TD><TD>20</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>LSR</TD></TR>
<TR><TD>4.939e-02</TD><TD>-3.01</TD><TD>GABA receptor complex</TD><TD>cellular component</TD><TD>GO:1902710</TD><TD>20</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.939e-02</TD><TD>-3.01</TD><TD>endocytic vesicle lumen</TD><TD>cellular component</TD><TD>GO:0071682</TD><TD>20</TD><TD>1</TD><TD>18985</TD><TD>48</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_TRANSLATION_REGULATOR_ACTIVITY_NUCLEIC_ACID_BINDING</TD><TD>MSigDB lists</TD><TD>GO_TRANSLATION_REGULATOR_ACTIVITY_NUCLEIC_ACID_BINDING</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_MACROMOLECULE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_MACROMOLECULE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_EPHRIN_RECEPTOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_EPHRIN_RECEPTOR_ACTIVITY</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>ATGCACG_MIR517B</TD><TD>MSigDB lists</TD><TD>ATGCACG_MIR517B</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MEIS2</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>DUNNE_TARGETS_OF_AML1_MTG8_FUSION_DN</TD><TD>MSigDB lists</TD><TD>DUNNE_TARGETS_OF_AML1_MTG8_FUSION_DN</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_ACTIN_MONOMER_BINDING</TD><TD>MSigDB lists</TD><TD>GO_ACTIN_MONOMER_BINDING</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_ECTODERM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_ECTODERM_DEVELOPMENT</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>EDA2R</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>STREICHER_LSM1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>STREICHER_LSM1_TARGETS_DN</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>DE_YY1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>DE_YY1_TARGETS_UP</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>ZHAN_MULTIPLE_MYELOMA_SPIKED</TD><TD>MSigDB lists</TD><TD>ZHAN_MULTIPLE_MYELOMA_SPIKED</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_POSITIVE_REGULATION_OF_CHONDROCYTE_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_CHONDROCYTE_DIFFERENTIATION</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_CELLULAR_RESPONSE_TO_FLUID_SHEAR_STRESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_RESPONSE_TO_FLUID_SHEAR_STRESS</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>MTSS1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GRANDVAUX_IRF3_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GRANDVAUX_IRF3_TARGETS_DN</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GTCAACC_MIR3805P</TD><TD>MSigDB lists</TD><TD>GTCAACC_MIR3805P</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>PLAG1</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>GO_NEUROTRANSMITTER_SODIUM_SYMPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_NEUROTRANSMITTER_SODIUM_SYMPORTER_ACTIVITY</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>MATZUK_EMBRYONIC_GERM_CELL</TD><TD>MSigDB lists</TD><TD>MATZUK_EMBRYONIC_GERM_CELL</TD><TD>19</TD><TD>1</TD><TD>17275</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-solitary_fibrous_tumour</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-solitary_fibrous_tumour</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-chest-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-chest-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>gliosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>gliosarcoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-sole-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-sole-malignant_melanoma-nodular</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-leg-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-carcinoma-squamous_cell_carcinoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-upper_leg-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-scalp-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma-superficial_spreading</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-gastrointestinal_stromal_tumour-spindle_and_epithelioid</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-gastrointestinal_stromal_tumour-spindle_and_epithelioid</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-lower_leg-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_leg-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-back-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-genital-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-genital-carcinoma-squamous_cell_carcinoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>bone-sacrum-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-sacrum-chordoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>ependymoma_Grade_III-IV</TD><TD>COSMIC cancer mutations</TD><TD>ependymoma_Grade_III-IV</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-chest-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-chest-carcinoma-squamous_cell_carcinoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-lip-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-lip-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-upper_arm-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_arm-carcinoma-squamous_cell_carcinoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-arm-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>supratentorial</TD><TD>COSMIC cancer mutations</TD><TD>supratentorial</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>small_intestine-ileum-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_intestine-ileum-carcinoma-adenocarcinoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>cerebral_cortex</TD><TD>COSMIC cancer mutations</TD><TD>cerebral_cortex</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>genital</TD><TD>COSMIC cancer mutations</TD><TD>genital</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>skin-face-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-other-keratoacanthoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>spindle_and_epithelioid</TD><TD>COSMIC cancer mutations</TD><TD>spindle_and_epithelioid</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>malignant_adnexal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>malignant_adnexal_tumour</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>precursor_T_cell_lymphoblastic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>precursor_T_cell_lymphoblastic_lymphoma</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>ependymoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>ependymoma_Grade_II</TD><TD>19</TD><TD>1</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.949e-02</TD><TD>-3.01</TD><TD>meningioma</TD><TD>COSMIC cancer mutations</TD><TD>meningioma</TD><TD>521</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>EDA2R,PLCH1,CDKN2A,PLAG1</TD></TR>
<TR><TD>4.949e-02</TD><TD>-3.01</TD><TD>meninges</TD><TD>COSMIC cancer mutations</TD><TD>meninges</TD><TD>521</TD><TD>4</TD><TD>17255</TD><TD>46</TD>
<TD>EDA2R,PLCH1,CDKN2A,PLAG1</TD></TR>
<TR><TD>4.952e-02</TD><TD>-3.01</TD><TD>REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL</TD><TD>MSigDB lists</TD><TD>REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL</TD><TD>134</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>4.952e-02</TD><TD>-3.01</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP</TD><TD>MSigDB lists</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP</TD><TD>134</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,GRIA2</TD></TR>
<TR><TD>4.952e-02</TD><TD>-3.01</TD><TD>MEL18_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>MEL18_DN.V1_UP</TD><TD>134</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>CLDN1,PAPPA</TD></TR>
<TR><TD>4.952e-02</TD><TD>-3.01</TD><TD>KRAS.300_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.300_UP.V1_UP</TD><TD>134</TD><TD>2</TD><TD>17275</TD><TD>46</TD>
<TD>HEY1,SLC6A15</TD></TR>
<TR><TD>4.960e-02</TD><TD>-3.00</TD><TD>MODULE_66</TD><TD>MSigDB lists</TD><TD>MODULE_66</TD><TD>522</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>ZIC1,GRIA2,MTSS1,MEIS2</TD></TR>
<TR><TD>4.985e-02</TD><TD>-3.00</TD><TD>FOXB1 (forkhead box B1)</TD><TD>protein interactions</TD><TD>27023</TD><TD>133</TD><TD>2</TD><TD>17456</TD><TD>47</TD>
<TD>ZFHX4,SATB2</TD></TR>
<TR><TD>4.986e-02</TD><TD>-3.00</TD><TD>back</TD><TD>COSMIC cancer mutations</TD><TD>back</TD><TD>311</TD><TD>3</TD><TD>17255</TD><TD>46</TD>
<TD>CDKN2A,PLCH1,PLAG1</TD></TR>
<TR><TD>4.989e-02</TD><TD>-3.00</TD><TD>TGCCTTA_MIR124A</TD><TD>MSigDB lists</TD><TD>TGCCTTA_MIR124A</TD><TD>523</TD><TD>4</TD><TD>17275</TD><TD>46</TD>
<TD>EPHA3,EYA4,GRIA2,RNF128</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>KLHL36 (kelch like family member 36)</TD><TD>protein interactions</TD><TD>79786</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>TEX29 (testis expressed 29)</TD><TD>protein interactions</TD><TD>121793</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>CREBZF (CREB/ATF bZIP transcription factor)</TD><TD>protein interactions</TD><TD>58487</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>MAF1 (MAF1 homolog, negative regulator of RNA polymerase III)</TD><TD>protein interactions</TD><TD>84232</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>ZNF420 (zinc finger protein 420)</TD><TD>protein interactions</TD><TD>147923</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>MEST (mesoderm specific transcript)</TD><TD>protein interactions</TD><TD>4232</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>FST</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>LMX1B (LIM homeobox transcription factor 1 beta)</TD><TD>protein interactions</TD><TD>4010</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>MEIS2</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>ZNF410 (zinc finger protein 410)</TD><TD>protein interactions</TD><TD>57862</TD><TD>19</TD><TD>1</TD><TD>17456</TD><TD>47</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.999e-02</TD><TD>-3.00</TD><TD>prostate-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma-adenocarcinoma</TD><TD>12652</TD><TD>39</TD><TD>17255</TD><TD>46</TD>
<TD>PCDH11X,CRB1,SPAG6,LSR,CDKN2A,GALNT13,GABRB2,ALX1,ZIC4,SATB2,PCDH17,HEY1,EYA4,ZFHX4,PCDH20,MTSS1,AZGP1,ENPP5,PAPPA,FST,IL7,KYNU,CXCL14,STAC,PEX5L,PLEKHM3,SLC6A15,DCDC2,EPHA3,GPC5,BMPR1B,GRIA2,PLCH1,NPTX2,ZIC1,RNF128,MEIS2,SAA2,PAX9</TD></TR>
</TABLE>
</BODY></HTML>
